WO1997003973A1 - 4,5-diaryl oxazole derivatives - Google Patents

4,5-diaryl oxazole derivatives Download PDF

Info

Publication number
WO1997003973A1
WO1997003973A1 PCT/JP1996/001996 JP9601996W WO9703973A1 WO 1997003973 A1 WO1997003973 A1 WO 1997003973A1 JP 9601996 W JP9601996 W JP 9601996W WO 9703973 A1 WO9703973 A1 WO 9703973A1
Authority
WO
WIPO (PCT)
Prior art keywords
diphenyloxazol
compound
nmr
salt
solution
Prior art date
Application number
PCT/JP1996/001996
Other languages
French (fr)
Inventor
Kiyoshi Taniguchi
Kouji Hattori
Kazunori Tsubaki
Osamu Okitsu
Seiichiro Tabuchi
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515085.0A external-priority patent/GB9515085D0/en
Priority claimed from AUPN9002A external-priority patent/AUPN900296A0/en
Priority to AT96924137T priority Critical patent/ATE224380T1/en
Priority to AU64697/96A priority patent/AU716304B2/en
Priority to MX9800577A priority patent/MX9800577A/en
Priority to DE69623785T priority patent/DE69623785T2/en
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to CA002227442A priority patent/CA2227442A1/en
Priority to DK96924137T priority patent/DK0842161T3/en
Priority to US08/983,139 priority patent/US5972965A/en
Priority to JP9504319A priority patent/JPH11509191A/en
Priority to EP96924137A priority patent/EP0842161B1/en
Priority to EA199800141A priority patent/EA002156B1/en
Publication of WO1997003973A1 publication Critical patent/WO1997003973A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.
  • This invention relates to new heterocyclic compounds.
  • this invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof which have pharmacological activities such as an inhibitory activity on platelet aggregation, vasodilating activity, antihypertensive activity or the like and are prostaglandin I 2 agonists, to processes for their production, to a
  • one object of this invention is to provide new and useful heterocyclic compounds and pharmaceutically acceptable salts thereof.
  • Another object of this invention is to provide processes for production of the heterocyclic compounds and salts thereof.
  • a further object of this invention is to provide a pharmaceutical composition containing, as an active
  • Still further object of this invention is to provide use of the heterocyclic compounds and pharmaceutically acceptable salts thereof for manufacture of medicaments for the therapeutic and/or prophylactic treatment of arterial obstruction, cerebrovascular disease, hepatic cirrhosis, arteriosclerosis, ischemic heart disease, restenosis after percutaneous transluminal coronary angioplasty, hypertension or the like.
  • heterocyclic compounds of this invention can be represented by the following formula (I) :
  • R 1 is carboxy or protected carboxy
  • R 2 is aryl which may have suitable substituent (s)
  • R 3 is aryl which may have suitable substituent (s)
  • R 4 is hydrogen, lower alkyl, hydroxy or aryl
  • a 1 is lower alkylene
  • bicycloheptane bicycloheptene, tetrahydrofuran, tetrahydrothiophene,
  • azetidine, pyrrolidine or piperidine each of which may have suitable substituent (s) ) or -X-A 6 - [in which -X- is -O-, -S- or
  • a 6 is lower alkylene which may have suitable substituent (s)], and
  • n 0 or 1.
  • the new heterocyclic compounds (I) can be prepared by the processes which are illustrated in the following scheme.
  • Y 1 is acid residue
  • R a 1 is protected carboxy
  • R 6 is imino protective group, is cyclo (C 7 -C 8 ) alkene
  • Y 2 is halogen
  • the starting compounds (II), (V) and (VI) are novel and can be prepared by the following process.
  • R 1 , R 2 , R 3 , R 4 , n, A 1 , , -A 3 -, -A 4 - and Y 2 are each as defined above,
  • R 7 is hydroxy protective group
  • R 8 is acyl
  • Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g. acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate,
  • a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g
  • an inorganic acid salt e.g.
  • hydrochloride hydrobromide, sulfate, phosphate, etc.
  • a salt with an amino acid e.g. arginine, aspartic acid, glutamic acid, etc.
  • Suitable "aryl” and “aryl moiety” in the term “mono (or di or tri) aryl (lower) alkyl” may include phenyl, naphthyl and the like.
  • Suitable "lower alkylene” may include straight one having 1 to 6 carbon atom(s), such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene and
  • hexamethylene preferably one having 1 to 3 carbon atom(s).
  • Suitable "lower alkyl” and “lower alkyl moiety" in the term “mono (or di or tri) aryl (lower) alkyl” may include
  • Suitable "protected carboxy” may include esterified carboxy and the like.
  • ester moiety of an esterified carboxy may be the ones such as lower alkyl ester (e.g.
  • methyl ester ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, etc.
  • suitable substituent for example, lower alkanoyloxy(lower) alkyl ester [e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester,
  • pivaloyloxymethyl ester pivaloyloxymethyl ester, hexanoyloxymethyl ester, 1(or 2)-acetoxyethyl ester, 1(or 2 or 3)-acetoxypropyl ester, 1(or 2 or 3 or 4) -acetoxybutyl ester, 1(or 2)-propionyloxyethyl ester, 1(or 2 or 3)-propionyloxypropyl ester, 1(or 2)-butyryloxyethyl ester, 1(or 2)-isobutyryloxyethyl ester, (1 or 2)-pivaloyloxyethyl ester, 1(or 2)-hexanoyloxyethyl ester, isobutyryloxymethyl ester, 2-ethylbutyryloxymethyl ester, 3,3-dimethylbutyryloxymethyl ester, 1 (or 2)-pentanoyloxyethyl ester, etc.], lower alkyls
  • 2-mesylethyl ester, etc. mono (or di or tri)-halo(lower)alkyl ester (e.g. 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.), lower alkoxycarbonyloxy(lower)alkyl ester (e.g.
  • lower alkenyl ester e.g. vinyl ester, allyl ester, etc.
  • lower alkynyl ester e.g. ethynyl ester, propynyl ester, etc.
  • ar (lower) alkyl ester which may have at least one suitable substituent (s) such as mono (or di or tri)phenyl (lower) alkyl ester which may have at least one suitable substituent (s) (e.g. benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis (methoxyphenyl) methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-tert-butylbenzyl ester, etc.);
  • suitable substituent e.g. benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis (methoxyphenyl) methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-
  • substituent (s) e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.
  • substituent (s) e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.
  • phthalidyl ester e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.
  • Suitable "substituent" in the term “aryl which may have suitable substituent (s) " may include halogen, amino,
  • Suitable "halogen” may include chlorine, bromine, iodine and the like.
  • Suitable "lower alkoxy” may include methoxy, ethoxy propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like.
  • Suitable "cyclo(C 5 -C 8 )alkene” may include cyclopentene, cyclohexene, cycloheptene and cyclooctene.
  • Suitable "cyclo(C 7 -C 8 )alkene” may include cycloheptene and cyclooctene.
  • Suitable "cyclo(C 7 -C 8 )alkane” may include cycloheptane and cyclooctane.
  • Suitable "bicycloheptane” may include
  • Suitable "bicycloheptene” may include
  • bicyclo[2.2.1]heptene e.g., bicyclo[2.2.1]hept-2-en, etc.
  • bicyclo[2.2.1]hept-2-en e.g., bicyclo[2.2.1]hept-2-en, etc.
  • substituent (s) may include imino, hydroxy, oxo, acyl, imino protective group, and the like.
  • Suitable “acyl” may include lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, oxalyl, succinyl, pivaloyl, etc.);
  • lower alkanoyl e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, oxalyl, succinyl, pivaloyl, etc.
  • lower alkoxycarbonyl e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.
  • lower alkanesulfonyl e.g. mesyl, ethanesulfonyl
  • aroyl e.g. benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl, indancarbonyl, etc.
  • ar (lower)alkanoyl e.g. phenylacetvl, phenylpropionyl, etc.
  • ar (lower)alkoxycarbonyl e.g. benzyloxycarbonyl
  • Suitable “imino protective group” may include mono(or di or tri)aryl(lower)alkyl and the like.
  • Suitable "hydroxy protective group” may include lower alkyl as exemplified above, silyl which may have one to three suitable substituent (s), and the like.
  • Suitable "substituent” in the term “silyl which may have one to three suitable substituent (s)” may include lower alkyl as exemplified above, aryl as exemplified above, and the like.
  • Suitable "substituent" in the term “lower alkylene which may have suitable substituent (s)” may include lower alkyl as exemplified above, hydroxy(lower)alkyl (e.g. hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, etc.) and the like.
  • Suitable "acid residue” may include halogen as
  • lower alkanoyloxy e.g. acetyloxy, etc.
  • sulfonyloxy e.g. methylsulfonyloxy, phenylsulfonyloxy, tolylsulfonyloxy, etc.
  • R 1 is carboxy or protected carboxy (more preferably
  • esterified carboxy most preferably lower
  • R 2 is aryl which may have lower alkyl (more preferably phenyl or lower alkylphenyl, most preferably phenyl or C 1 -C 4 alkylphenyl),
  • R 3 is aryl which may have lower alkyl (more preferably phenyl or lower alkylphenyl, most preferably phenyl or C 1 -C 4 alkylphenyl),
  • R 4 is hydrogen, lower alkyl (more preferably C 1 -C 4 alkyl, most preferably methyl), hydroxy or aryl (more
  • a 1 is lower alkylene (more preferably C 1 -C 4 alkylene, most preferably methylene or ethylene),
  • -A 3 - is ⁇ [in which -A 4 - is bond, -CH 2 - or -CO-,
  • bicyclo[2.2.1]heptane bicycloheptene (more preferably bicyclo[2.2.1]heptane, most preferably bicyclo[2.2.1]hept-2-ene), tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have one to three (more preferably one or two) suitable
  • substituent (s) selected from the group consisting of imino, oxo, acyl (more preferably lower alkanoyl, most preferably C 1 -C 4 alkanoyl) and imino protective group (more preferably mono (or di or tri)phenyl(lower)alkyl, most preferably
  • R 5 is hydrogen, lower alkyl (more preferably C 1 -C 4 alkyl) or acyl (more preferably lower
  • alkanoyl most preferably C 1 -C 4 alkanoyl
  • a 6 is lower alkylene (more preferably C 1 -C 4 alkylene, most preferably methylene or ethylene) which may have one to three (more preferably one) suitable substituent (s) selected from the group consisting of lower alkyl (more preferably C 1 -C 4 alkyl) and hydroxy (lower)alkyl (more preferably
  • n 0 or 1.
  • More preferred compounds of the object compound (I) are the compounds of the following formulae (I-A) and (I-B) :
  • R 1 is carboxy, or protected carboxy (more preferably esterified carboxy, most preferably lower alkoxycarbonyl),
  • R 2 is phenyl, or lower alkylphenyl (more preferably
  • R 3 is phenyl, or lower alkylphenyl (more preferably
  • a 1 is lower alkylene (more preferably C 1 -C 4 alkylene, most preferably methylene).
  • R 1 is carboxy, or protected carboxy (more preferably esterified carboxy, most preferably lower alkoxycarbonyl),
  • R 2 is phenyl
  • R 3 is phenyl
  • a 1 is lower alkylene (more preferably C 1 -C 4 alkylene, most preferably methylene).
  • the object compound (I) may include one or more stereoisomers due to asymmetric carbon atom(s) and double bond, and all of such isomers and a mixture thereof are included within the scope of the present invention.
  • isomerization or rearrangement of the object compound (I) may occur due to the effect of the light, acid, base or the like, and the compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention.
  • the compound (Ii) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the
  • This reaction is usually carried out in a solvent such as acetonitrile, benzene, N,N-dimethylformamide,
  • the reaction temperature is not critical and the
  • reaction is usually carried out under cooling to warming.
  • the reaction is usually carried out in the presence of a base.
  • Suitable base may include the inorganic base such as alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.g.
  • magnesium hydroxide, calcium hydroxide, etc. alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g. magnesium carbonate, calcium carbonate, etc.) or- the like, and the organic base such as tri(lower)alkylamino (e.g., trimethylamine,
  • di(lower)alkylaniline e.g. dimethylaniline, etc.
  • pyridine e.g. pyridine
  • the compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to elimination reaction of the carboxy protective group.
  • Suitable method of this reaction may include
  • the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
  • Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene,
  • an alkali metal e.g. sodium, potassium, etc.
  • the hydroxide or carbonate or bicarbonate thereof e.g. trimethylamine, triethylamine, etc.
  • trialkylamine e.g. trimethylamine, triethylamine, etc.
  • picoline 1,5-diazabicyclo[4.3.0]non-5-ene
  • Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g.
  • hydrochloric acid hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.
  • Lewis acid such as trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].
  • the reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, 1,2-dimethoxyethane, a mixture thereof or any other solvent which does not adversely influence the reaction.
  • a liquid base or acid can be also used as the solvent.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
  • Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.
  • a metal e.g. tin, zinc, iron, etc.
  • metallic compound e.g. chromium chloride, chromium acetate, etc.
  • organic or inorganic acid e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g. reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g. reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g. reduced iron, Raney iron, etc.), copper catalysts (e.g.
  • platinum catalysts e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
  • palladium catalysts e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon
  • the reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, ethyl acetate, N,N-dimethylformamide,
  • reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.
  • the compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof to oxidation reaction.
  • Oxidation is carried out in a conventional manner and suitable oxidizing reagent may include per acid (e.g., perbenzoic acid, m-chloroperbenzoic acid, performic acid, peracetic acid, perphthalic acid, etc.), and the like.
  • per acid e.g., perbenzoic acid, m-chloroperbenzoic acid, performic acid, peracetic acid, perphthalic acid, etc.
  • the reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
  • a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
  • N,N-dimethylformamide N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction.
  • the reaction temperature is not critical and the
  • the compound (If) or a salt thereof can be prepared by subjecting the compound (Ie) or a salt thereof to elimination reaction of the imino protective group.
  • This reaction can be carried out in a similar manner to that of the aforementioned Process 2 , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 2.
  • the reaction conditions e.g., solvent, reaction temperature, etc.
  • the compound (Ih) or a salt thereof can be prepared by subjecting the compound (Ig) or a salt thereof to reduction reaction.
  • the compound (Ij) or a salt thereof can be prepared by reacting the compound (V) or a salt thereof with the compound (VI) or a salt thereof.
  • This reaction can be carried out in a similar manner to that of the aforementioned Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 1.
  • the reaction conditions e.g., solvent, reaction temperature, etc.
  • the compound (II) or a salt thereof can be prepared by subjecting the compound (IV) or a salt thereof to elimination reaction of the hydroxy protective group.
  • the reagent to be used in this reaction may include halotrialkylsilane (e.g., iodotrimethylsilane, etc.), alkali metal thioalkoxide (e.g., sodium thioethoxide, etc.), alkali metal sulfide (e.g., sodium sulfide, etc.), alkali metal diphenylphosphide (e.g., lithium diphenylphosphide, etc.), aluminum halide (e.g., aluminum chloride, aluminum bromide, etc.), boron trihalide (e.g., boron trichloride, boron tribromide, etc.), pyridine hydrochloride, alkylmagnesium halide (e.g., methylmagnesium iodide, etc.), lithium halide (e.g., lithium chloride, etc.), tetraalkylammonium halide (e.g., t
  • the reaction is usually carried out in a conventional solvent such as water, alcohol, (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
  • a conventional solvent such as water, alcohol, (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
  • dichloromethane ethylene dichloride, chloroform, N,N- dimethylformamide, N,N-dimethylacetamide, or any other
  • the reaction temperature is not critical and the
  • reaction is usually carried out under cooling to heating.
  • the compound (IV) or a salt thereof can be prepared by the methods disclosed in the Preparations described later or similar manners thereto.
  • the compound (V) or a salt thereof can be prepared by subjecting the compound (VII) or a salt thereof to halogenation reaction.
  • This reaction can be carried out by the method disclosed in the Preparation 21 or similar manners thereto.
  • the compound (VII) or a salt thereof can be prepared by the methods disclosed in the Preparations described later or similar manners thereto.
  • the compound (VI) or a salt thereof can be prepared by subjecting the compound (VIII) or a salt thereof to elimination reaction of the acyl group.
  • This reaction can be carried out in a similar manner to that of the aforementioned Process 2. and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 2.
  • the reaction conditions e.g., solvent, reaction temperature, etc.
  • the compound (VIII) or a salt thereof can be prepared by the methods disclosed in the Preparations described later or similar manners thereto.
  • pharmaceutically acceptable salt thereof have pharmacological activities such as an inhibitory activity on platelet
  • vasodilating activity aggregation, vasodilating activity, antihypertensive activity or the like and are prostaglandin I 2 agonists, and therefore can be used for treating and/or preventing thrombosis, arterial obstruction (e.g., chronic arterial obstruction, etc.),
  • ischemic heart disease CAD
  • restenosis or ischemic complications after coronary angioplasty e.g., PTCA, coronary stenting, etc.
  • hypertension inflammation, autoimmune disease, heart failure, renal disease (e.g., renal failure, nephritis, etc.), diabetic complication (e.g., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, etc.), peripheral circulatory disturbance, baldness, bedsore, and the like, and can be also used for protecting organs after transplantation or surgery.
  • object compound (I) and pharmaceutically acceptable salt thereof can be also used as a component for organ preserving fluids and as an agent for inhibiting
  • the pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form (e.g. tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, solution, emulsion, suspension etc.), which contains the object compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient, suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.
  • a pharmaceutical preparation for example, in solid, semisolid or liquid form (e.g. tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, solution, emulsion, suspension etc.), which contains the object compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient, suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, o
  • the pharmaceutical composition of this invention can contain various organic or inorganic carrier materials, which are conventionally used for pharmaceutical purpose, such as excipient (e.g. sucrose, starch, mannit, sorbit, lactose. glucose, cellulose, talc, calcium phosphate, calcium
  • excipient e.g. sucrose, starch, mannit, sorbit, lactose. glucose, cellulose, talc, calcium phosphate, calcium
  • binding agent e.g. cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch, etc.
  • disintegrator e.g. starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch, sodium glycol-starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc.
  • lubricant e.g. magnesium stearate, talc, sodium laurylsulfate, etc.
  • flavoring agent e.g.
  • citric acid citric acid, mentol, glycine, orange powders, etc.
  • preservative e.g. sodium benzoate, sodium bisulfite, methylparaben, propylparaben, etc.
  • stabilizer e.g. citric acid, sodium citrate, acetic acid, etc.
  • suspending agent e.g. methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc.
  • dispersing agent e.g. water
  • base wax e.g. cacao butter
  • the effective ingredient may usually be administered with a unit dose of 0.01 mg/kg to 50 mg/kg, 1 to 4 times a day. However, the above dosage may be increased or decreased according to age, weight, conditions of the patient .or the administering method.
  • the obtained oil was dissolved into DMF (10 ml) and then K 2 CO 3 (1.0 g) and ethyl bromoacetate (0.3 ml) were added at room temperature. The mixture was stirred for 2 hours at the same temperature and then partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO 3 and brine. The dried solvent was
  • dimethylaminopyridine (0.21 g) were added to the solution at room temperature under N 2 . After being stirred for 12 hours at room temperature, the solvent was evaporated in vacuo, and the residue was partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat.
  • AD-mix- ⁇ (trade name, Aldrich) (114 g) in a mixture of t-butyl alcohol (400 ml) and water (400 ml) was stirred for 1 hour, and then methanesulfonamide (7.6 g) and 2-vinyl-4,5-diphenyloxazole (20 g) was added to the solution at 0°C. After being stirred for 8 hours at the same
  • Triethylamine (3.36 ml) was added to a stirred solution of 3-benzyloxybenzoic acid (5.0 g) and isobutyl chloroformate (3.13 ml) in THF (67 ml) under ice-cooling and the resulting mixture was stirred at the same temperature for 1 hour.
  • 2-Oxo-1,2-diphenylethyl 1-(3-methoxybenzyl)-2- piperidinecarboxylate was prepared from 1-(3-methoxybenzyl)-2-piperidinecarboxylic acid and desyl bromide in a similar manner to that of Preparation 65.
  • 2-(4,5-Diphenyl-2-oxazolyl)-1-(3-methoxybenzyl)-piperidine was prepared from 2-oxo-1,2-diphenylethyl 1-(3-methoxybenzyl)-2-piperidinecarboxylate in a similar manner to that of Preparation 66.
  • 2-Oxo-1,2-diphenylethyl 2-oxo-5-pyrrolidinecarboxylate was prepared from 2-oxo-5-pyrrolidinecarboxylic acid in a similar manner to that of Preparation 65.
  • 2-(5-Imino-2-pyrrolidinyl)-4,5-diphenyloxazole was prepared from 2-oxo-1,2-diphenylethyl 2-oxo-5-pyrrolidine- carboxylate in a similar manner to that of Preparation 66.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Heterocyclic compounds of formula (I), wherein R1 is carboxy or protected carboxy, R2 is aryl which may have suitable substituent(s), R3 is aryl which may have suitable substituent(s), R4 is hydrogen, lower alkyl, hydroxy or aryl, A1 is lower alkylene, (a) is (b), etc., -A3- is (c), etc. and n is 0 or 1, and pharmaceutically acceptable salts thereof which are useful as a medicament.

Description

DESCRIPTION 4,5-DIARYL OXAZOLE DERIVATIVES TECHNICAL FIELD
This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof which are useful as a medicament. BACKGROUND ART
Some heterocyclic compounds have been known as
described, for example, in WO 95/17393.
DISCLOSURE OF INVENTION
This invention relates to new heterocyclic compounds.
More particularly, this invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof which have pharmacological activities such as an inhibitory activity on platelet aggregation, vasodilating activity, antihypertensive activity or the like and are prostaglandin I2 agonists, to processes for their production, to a
pharmaceutical composition containing the same and to a use thereof for manufacture of medicaments.
Accordingly, one object of this invention is to provide new and useful heterocyclic compounds and pharmaceutically acceptable salts thereof.
Another object of this invention is to provide processes for production of the heterocyclic compounds and salts thereof.
A further object of this invention is to provide a pharmaceutical composition containing, as an active
ingredient, said heterocyclic compounds or pharmaceutically acceptable salts thereof.
Still further object of this invention is to provide use of the heterocyclic compounds and pharmaceutically acceptable salts thereof for manufacture of medicaments for the therapeutic and/or prophylactic treatment of arterial obstruction, cerebrovascular disease, hepatic cirrhosis, arteriosclerosis, ischemic heart disease, restenosis after percutaneous transluminal coronary angioplasty, hypertension or the like.
The heterocyclic compounds of this invention can be represented by the following formula (I) :
Figure imgf000004_0001
wherein R1 is carboxy or protected carboxy,
R2 is aryl which may have suitable substituent (s), R3 is aryl which may have suitable substituent (s), R4 is hydrogen, lower alkyl, hydroxy or aryl,
A1 is lower alkylene,
Figure imgf000004_0002
-A3- is (in which -A4- is bond,
Figure imgf000004_0003
-CH2- or -CO-, and is cyclo-
Figure imgf000005_0001
(C5-C8) alkene, cyclo(C7-C8) alkane,
bicycloheptane, bicycloheptene, tetrahydrofuran, tetrahydrothiophene,
azetidine, pyrrolidine or piperidine, each of which may have suitable substituent (s) ) or -X-A6- [in which -X- is -O-, -S- or
Figure imgf000005_0003
(in which R5 is hydrogen, lower
alkyl or acyl) and
A6 is lower alkylene which may have suitable substituent (s)], and
n is 0 or 1.
According to the present invention, the new heterocyclic compounds (I) can be prepared by the processes which are illustrated in the following scheme.
Process 1
Figure imgf000005_0002
Figure imgf000006_0001
Process 2
Figure imgf000006_0002
Figure imgf000007_0001
Process 3
Figure imgf000007_0002
Figure imgf000008_0001
Process 4
Figure imgf000008_0002
Figure imgf000009_0001
Process 5
Figure imgf000009_0002
Figure imgf000010_0001
Process 6
Figure imgf000010_0002
wherein R1, R2, R3, R4, n, A1, , -A3- and -A4- are each
Figure imgf000011_0001
as defined above,
Y1 is acid residue,
Ra 1 is protected carboxy,
R6 is imino protective group, is cyclo (C7-C8) alkene,
Figure imgf000011_0002
is cyclo (C7-C8) alkane, and
Figure imgf000011_0003
Y2 is halogen.
The starting compounds (II), (V) and (VI) are novel and can be prepared by the following process.
Process A
Figure imgf000011_0004
Figure imgf000012_0001
Process B
Figure imgf000012_0002
Figure imgf000013_0001
Process C
Figure imgf000013_0002
Figure imgf000014_0002
wherein R1, R2, R3, R4, n, A1, , -A3-, -A4- and Y2
Figure imgf000014_0001
are each as defined above,
R7 is hydroxy protective group, and
R8 is acyl.
Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g. acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate,
trifluoroacetate, etc.), an inorganic acid salt (e.g.
hydrochloride, hydrobromide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), and the like.
In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention include within the scope thereof are explained in detail as follows.
The term "lower" is intended to mean 1 to 6 carbon atom(s), unless otherwise indicated.
Suitable "aryl" and "aryl moiety" in the term "mono (or di or tri) aryl (lower) alkyl" may include phenyl, naphthyl and the like.
Suitable "lower alkylene" may include straight one having 1 to 6 carbon atom(s), such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene and
hexamethylene, preferably one having 1 to 3 carbon atom(s).
Suitable "lower alkyl" and "lower alkyl moiety" in the term "mono (or di or tri) aryl (lower) alkyl" may include
straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, t-pentyl, hexyl or the like,
preferably one having 1 to 4 carbon atom(s).
Suitable "protected carboxy" may include esterified carboxy and the like.
Suitable example of the ester moiety of an esterified carboxy may be the ones such as lower alkyl ester (e.g.
methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, etc.) which may have at least one suitable substituent (s), for example, lower alkanoyloxy(lower) alkyl ester [e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester,
pivaloyloxymethyl ester, hexanoyloxymethyl ester, 1(or 2)-acetoxyethyl ester, 1(or 2 or 3)-acetoxypropyl ester, 1(or 2 or 3 or 4) -acetoxybutyl ester, 1(or 2)-propionyloxyethyl ester, 1(or 2 or 3)-propionyloxypropyl ester, 1(or 2)-butyryloxyethyl ester, 1(or 2)-isobutyryloxyethyl ester, (1 or 2)-pivaloyloxyethyl ester, 1(or 2)-hexanoyloxyethyl ester, isobutyryloxymethyl ester, 2-ethylbutyryloxymethyl ester, 3,3-dimethylbutyryloxymethyl ester, 1 (or 2)-pentanoyloxyethyl ester, etc.], lower alkylsulfonyl (lower)alkyl ester (e.g. 2-mesylethyl ester, etc.), mono (or di or tri)-halo(lower)alkyl ester (e.g. 2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.), lower alkoxycarbonyloxy(lower)alkyl ester (e.g.
methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, 2-methoxycarbonyloxyethyl ester,
1-ethoxycarbonyloxyethyl ester, 1-isopropoxycarbonyloxyethyl ester, etc.), phthalidylidene (lower)alkyl ester, or (5-lower alkyl-2-oxo-1,3-dioxol-4-yl) (lower)alkyl ester [e.g. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5-propyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, etc.];
lower alkenyl ester (e.g. vinyl ester, allyl ester, etc.); lower alkynyl ester (e.g. ethynyl ester, propynyl ester, etc.);
ar (lower) alkyl ester which may have at least one suitable substituent (s) such as mono (or di or tri)phenyl (lower) alkyl ester which may have at least one suitable substituent (s) (e.g. benzyl ester, 4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester, bis (methoxyphenyl) methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-tert-butylbenzyl ester, etc.);
aryl ester which may have at least one suitable
substituent (s) (e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.); phthalidyl ester; and the like.
Suitable "substituent" in the term "aryl which may have suitable substituent (s) " may include halogen, amino,
hydroxy, lower alkoxy, lower alkyl as exemplified above, and the like.
Suitable "halogen" may include chlorine, bromine, iodine and the like.
Suitable "lower alkoxy" may include methoxy, ethoxy propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like.
Suitable "cyclo(C5-C8)alkene" may include cyclopentene, cyclohexene, cycloheptene and cyclooctene.
Suitable "cyclo(C7-C8)alkene" may include cycloheptene and cyclooctene.
Suitable "cyclo(C7-C8)alkane" may include cycloheptane and cyclooctane.
Suitable "bicycloheptane" may include
bicyclo[2.2.1]heptane and the like.
Suitable "bicycloheptene" may include
bicyclo[2.2.1]heptene (e.g., bicyclo[2.2.1]hept-2-en, etc.) and the like.
Suitable "substituent" in the term "cyclo(C5-C8)alkene, cyclo(C7-C8)alkane, bicycloheptane, bicycloheptene,
tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have suitable
substituent (s)" may include imino, hydroxy, oxo, acyl, imino protective group, and the like.
Suitable "acyl" may include lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, oxalyl, succinyl, pivaloyl, etc.);
lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.); lower alkanesulfonyl (e.g. mesyl, ethanesulfonyl,
propanesulfonyl, isopropanesulfonyl, butanesulfonyl, etc.); arenesulfonyl (e.g. benzenesulfonyl, tosyl, etc.);
aroyl (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl, indancarbonyl, etc.);
ar (lower)alkanoyl (e.g. phenylacetvl, phenylpropionyl, etc.); ar (lower)alkoxycarbonyl (e.g. benzyloxycarbonyl,
phenethyloxycarbqnyl, etc.), and the like.
Suitable "imino protective group" may include mono(or di or tri)aryl(lower)alkyl and the like.
Suitable "hydroxy protective group" may include lower alkyl as exemplified above, silyl which may have one to three suitable substituent (s), and the like.
Suitable "substituent" in the term "silyl which may have one to three suitable substituent (s)" may include lower alkyl as exemplified above, aryl as exemplified above, and the like.
Suitable "substituent" in the term "lower alkylene which may have suitable substituent (s)" may include lower alkyl as exemplified above, hydroxy(lower)alkyl (e.g. hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, etc.) and the like.
Suitable "acid residue" may include halogen as
exemplified above, lower alkanoyloxy (e.g. acetyloxy, etc.), sulfonyloxy (e.g. methylsulfonyloxy, phenylsulfonyloxy, tolylsulfonyloxy, etc.), and the like.
Preferred embodiments of the object compound (I) are as follows : R1 is carboxy or protected carboxy (more preferably
esterified carboxy, most preferably lower
alkoxycarbonyl),
R2 is aryl which may have lower alkyl (more preferably phenyl or lower alkylphenyl, most preferably phenyl or C1-C4 alkylphenyl),
R3 is aryl which may have lower alkyl (more preferably phenyl or lower alkylphenyl, most preferably phenyl or C1-C4 alkylphenyl),
R4 is hydrogen, lower alkyl (more preferably C1-C4 alkyl, most preferably methyl), hydroxy or aryl (more
preferably phenyl),
A1 is lower alkylene (more preferably C1-C4 alkylene, most preferably methylene or ethylene),
Figure imgf000019_0001
-A3- is ~ [in which -A4- is bond, -CH2 - or -CO-,
Figure imgf000019_0003
and is cyclo (C5-C8)alkene, cyclo(C7-C8)-
Figure imgf000019_0004
alkane, bicycloheptane (more preferably
bicyclo[2.2.1]heptane), bicycloheptene (more preferably bicyclo[2.2.1]heptane, most preferably bicyclo[2.2.1]hept-2-ene), tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have one to three (more preferably one or two) suitable
substituent (s) selected from the group consisting of imino, oxo, acyl (more preferably lower alkanoyl, most preferably C1-C4 alkanoyl) and imino protective group (more preferably mono (or di or tri)phenyl(lower)alkyl, most preferably
phenyl(lower)alkyl)] or
-X-A6- [in which -X- is -O-, -S- or
Figure imgf000019_0002
(in which R5 is hydrogen, lower alkyl (more preferably C1-C4 alkyl) or acyl (more preferably lower
alkanoyl, most preferably C1-C4 alkanoyl) and
A6 is lower alkylene (more preferably C1-C4 alkylene, most preferably methylene or ethylene) which may have one to three (more preferably one) suitable substituent (s) selected from the group consisting of lower alkyl (more preferably C1-C4 alkyl) and hydroxy (lower)alkyl (more preferably
hydroxy (C1-C4)alkyl)], and
n is 0 or 1.
More preferred compounds of the object compound (I) are the compounds of the following formulae (I-A) and (I-B) :
Figure imgf000020_0001
Figure imgf000020_0002
wherein R1 is carboxy, or protected carboxy (more preferably esterified carboxy, most preferably lower alkoxycarbonyl),
R2 is phenyl, or lower alkylphenyl (more preferably
C1-C4 alkylphenyl),
R3 is phenyl, or lower alkylphenyl (more preferably
C1-C4 alkylphenyl) and
A1 is lower alkylene (more preferably C1-C4 alkylene, most preferably methylene).
Most preferred compounds of the object compound (I) are the compounds of the following formulae (I-C) and (I-D) :
Figure imgf000021_0001
Figure imgf000021_0002
wherein R1 is carboxy, or protected carboxy (more preferably esterified carboxy, most preferably lower alkoxycarbonyl),
R2 is phenyl,
R3 is phenyl, and
A1 is lower alkylene (more preferably C1-C4 alkylene, most preferably methylene).
It is to be noted the object compound (I) may include one or more stereoisomers due to asymmetric carbon atom(s) and double bond, and all of such isomers and a mixture thereof are included within the scope of the present invention.
It is further to be noted isomerization or rearrangement of the object compound (I) may occur due to the effect of the light, acid, base or the like, and the compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention.
It is also to be noted that the solvating form of the compound (I) (e.g. hydrate, etc.) and any form of the crystal of the compound (I) are included within the scope of the present invention.
The processes for preparing the object and starting compounds of the present invention are explained in detail in the following.
Process 1
The compound (Ii) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the
compound (III) or a salt thereof.
This reaction is usually carried out in a solvent such as acetonitrile, benzene, N,N-dimethylformamide,
tetrahydrofuran, methylene chloride, ethylene chloride, chloroform, diethyl ether or any other solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the
reaction is usually carried out under cooling to warming.
The reaction is usually carried out in the presence of a base.
Suitable base may include the inorganic base such as alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.g.
magnesium hydroxide, calcium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g. magnesium carbonate, calcium carbonate, etc.) or- the like, and the organic base such as tri(lower)alkylamino (e.g., trimethylamine,
triethylamine, diisopropylethylamine, etc.),
di(lower)alkylaniline (e.g. dimethylaniline, etc.), pyridine or the like.
Process 2
The compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to elimination reaction of the carboxy protective group.
Suitable method of this reaction may include
conventional one such as hydrolysis, reduction and the like.
(i) For Hydrolysis :
The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene,
1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.
Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g.
hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.]. The elimination using Lewis acid such as trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].
The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, 1,2-dimethoxyethane, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
(ii) For reduction :
Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.
Suitable reducing agents to be used in chemical
reduction are a combination of a metal (e.g. tin, zinc, iron, etc.) or metallic compound (e.g. chromium chloride, chromium acetate, etc.) and an organic or inorganic acid (e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g. reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g. reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g. reduced iron, Raney iron, etc.), copper catalysts (e.g. reduced copper, Raney copper, Ullman copper, etc.) and the like. The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, ethyl acetate, N,N-dimethylformamide,
tetrahydrofuran, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.
The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.
Process 3
The compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof to oxidation reaction.
Oxidation is carried out in a conventional manner and suitable oxidizing reagent may include per acid (e.g., perbenzoic acid, m-chloroperbenzoic acid, performic acid, peracetic acid, perphthalic acid, etc.), and the like.
The reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
dichloromethane, ethylene dichloride, chloroform,
N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the
reaction is usually carried out under cooling to heating. Process 4
The compound (If) or a salt thereof can be prepared by subjecting the compound (Ie) or a salt thereof to elimination reaction of the imino protective group.
This reaction can be carried out in a similar manner to that of the aforementioned Process 2 , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 2. Process 5
The compound (Ih) or a salt thereof can be prepared by subjecting the compound (Ig) or a salt thereof to reduction reaction.
This reduction can be carried out in a similar manner to that of the aforementioned Process 2 , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 2. Process 6
The compound (Ij) or a salt thereof can be prepared by reacting the compound (V) or a salt thereof with the compound (VI) or a salt thereof.
This reaction can be carried out in a similar manner to that of the aforementioned Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 1. Process A
The compound (II) or a salt thereof can be prepared by subjecting the compound (IV) or a salt thereof to elimination reaction of the hydroxy protective group.
The reagent to be used in this reaction may include halotrialkylsilane (e.g., iodotrimethylsilane, etc.), alkali metal thioalkoxide (e.g., sodium thioethoxide, etc.), alkali metal sulfide (e.g., sodium sulfide, etc.), alkali metal diphenylphosphide (e.g., lithium diphenylphosphide, etc.), aluminum halide (e.g., aluminum chloride, aluminum bromide, etc.), boron trihalide (e.g., boron trichloride, boron tribromide, etc.), pyridine hydrochloride, alkylmagnesium halide (e.g., methylmagnesium iodide, etc.), lithium halide (e.g., lithium chloride, etc.), tetraalkylammonium halide (e.g., tetrabutylammonium fluoride, etc.), a combination of methionine and sulfonic acid (e.g., methanesulfonic acid, etc.), and the like.
The reaction is usually carried out in a conventional solvent such as water, alcohol, (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
dichloromethane, ethylene dichloride, chloroform, N,N- dimethylformamide, N,N-dimethylacetamide, or any other
organic solvent which does not adversely affect the reaction.
The reaction temperature is not critical and the
reaction is usually carried out under cooling to heating.
The compound (IV) or a salt thereof can be prepared by the methods disclosed in the Preparations described later or similar manners thereto.
Process B
The compound (V) or a salt thereof can be prepared by subjecting the compound (VII) or a salt thereof to halogenation reaction.
This reaction can be carried out by the method disclosed in the Preparation 21 or similar manners thereto.
The compound (VII) or a salt thereof can be prepared by the methods disclosed in the Preparations described later or similar manners thereto.
Process C
The compound (VI) or a salt thereof can be prepared by subjecting the compound (VIII) or a salt thereof to elimination reaction of the acyl group.
This reaction can be carried out in a similar manner to that of the aforementioned Process 2. and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 2.
The compound (VIII) or a salt thereof can be prepared by the methods disclosed in the Preparations described later or similar manners thereto.
The object compound (I) of this invention and
pharmaceutically acceptable salt thereof have pharmacological activities such as an inhibitory activity on platelet
aggregation, vasodilating activity, antihypertensive activity or the like and are prostaglandin I2 agonists, and therefore can be used for treating and/or preventing thrombosis, arterial obstruction (e.g., chronic arterial obstruction, etc.),
cerebrovascular disease, gastric ulcer, hepatitis, hepatic insufficiency, hepatic cirrhosis, arteriosclerosis, ischemic heart disease, restenosis or ischemic complications after coronary angioplasty (e.g., PTCA, coronary stenting, etc.), hypertension, inflammation, autoimmune disease, heart failure, renal disease (e.g., renal failure, nephritis, etc.), diabetic complication (e.g., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, etc.), peripheral circulatory disturbance, baldness, bedsore, and the like, and can be also used for protecting organs after transplantation or surgery.
Further, the object compound (I) and pharmaceutically acceptable salt thereof can be also used as a component for organ preserving fluids and as an agent for inhibiting
metastasis of cancer.
In order to show the utility of the object compound (I), pharmacological data of the representative compounds thereof are shown in the following.
Inhibition of human platelet aggregation induced
by ADP [I] Test Compound :
(1) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohepten-1- yl]methyl]phenoxy]acetate (2) Sodium salt of (IR)-1-[(2R)-2-(4,5-diphenyloxazol-2- yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
[II] Test Method Human blood was obtained from healthy volunteers and mixed with 1/10 volume of 3.8% sodium citrate, pH 7.4. The citrate blood was centrifuged at 150 × g for 10 minutes and the platelet rich plasma (PRP) was removed. The remaining blood was centrifuged for a further 10 minutes at 1500 × g to prepare the platelet poor plasma (PPP), which was used as a reference for platelet aggregation. Aggregation studies were carried out using HEMATRACER 801 (NBS, Japan), a 8 channel aggregometer. 25 μl of sample solution and 225 μl of PRP were mixed and stirred at 1000 rpm for 2 minutes at 37°C. Aggregation was induced by ADP solution at the final
concentration of 2.5 μM.
[III] Test result :
Figure imgf000029_0001
The pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form (e.g. tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, solution, emulsion, suspension etc.), which contains the object compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient, suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.
The pharmaceutical composition of this invention can contain various organic or inorganic carrier materials, which are conventionally used for pharmaceutical purpose, such as excipient (e.g. sucrose, starch, mannit, sorbit, lactose. glucose, cellulose, talc, calcium phosphate, calcium
carbonate, etc.), binding agent (e.g. cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch, etc.), disintegrator (e.g. starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch, sodium glycol-starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc.), lubricant (e.g. magnesium stearate, talc, sodium laurylsulfate, etc.), flavoring agent (e.g.
citric acid, mentol, glycine, orange powders, etc.),
preservative (e.g. sodium benzoate, sodium bisulfite, methylparaben, propylparaben, etc.), stabilizer (e.g. citric acid, sodium citrate, acetic acid, etc.), suspending agent (e.g. methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc.), dispersing agent, aqueous diluting agent (e.g. water), base wax (e.g. cacao butter,
polyethyleneglycol, white petrolatum, etc.).
The effective ingredient may usually be administered with a unit dose of 0.01 mg/kg to 50 mg/kg, 1 to 4 times a day. However, the above dosage may be increased or decreased according to age, weight, conditions of the patient .or the administering method.
The following Preparations and Examples are given only for the purpose of illustrating the present invention in more detail.
Preparation 1
(1) To a solution of γ-butyrolactone (3.0 g) in
tetrahydrofuran (THF) (30 ml) was added lithium
diisopropylamide (LDA) (28 ml, 1.5 M solution in cyclohexane) at -78°C under N2, and then after 30 minutes, a solution of m-anisaldehyde (4.7 g) in THF (10 ml) was added in the solution. After being stirred for 2 hours at the same temperature, the solution was poured into the mixture of ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by
chromatography on silica gel to afford 3-[hydroxy(3-methoxyphenyl)methyl)-2-oxotetrahydrofuran (7.4 g).
MS (m/z) : 205 (M+-17)
IR (Neat) : 3400, 1725 cm-1
NMR (CDCl3, δ) : 2.2-2.8 (4H, m), 3.81 (3H, s), 4.1- 4.4 (2H, m), 4.80 (1H, d, J=8.0Hz), 6.8-7.1 (3H, m), 7.27 (1H, t, J=8.0Hz)
(2) A mixture of 3-[hydroxy(3-methoxyphenyl)methyl]-2-oxotetrahydrofuran (1.0 g) and 10% Pd/C (0.5 g) in ethanol (20 ml) was stirred under H2 for 10 hours. The catalyst was filtered off and the filtrate was evaporated in vacuo to give 3-(3-methoxybenzyl)-2-oxotetrahydrofuran (0.8 g).
MS (m/z) : 207 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 2.0-2.6 (4H, m), 2.7-3.2 (3H, m),
3.79 (3H, s), 4.1-4.4 (2H, m), 6.7-7.1 (3H, m),
7.2-7.4 (1H, m)
(3) To a solution of 3-(3-methoxybenzyl)-2-oxotetrahydrofuran (4.7 g) in dichloromethane (60 ml) was added BBr3 (46 ml, 1M solution in dichloromethane) at 0°C. After being stirred for 2 hours, the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, and the mixture was washed with water and brine. The dried solvent was evaporated and the residue was dissolved in N,N-dimethylformamide (DMF) (30 ml). To the solution were added imidazole (3.1 g) and t-butyldiphenylsilyl chloride (8.9 g) and stirred for 2 hours at room temperature. The solution was poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 3-(3-t-butyldiphenylsilyloxybenzyl)-2-oxotetrahydrofuran (8.6 g).
MS (m/z) : 429 (M+-1)
IR (Neat) : 1760 cm-1
NMR (CDCl3, δ) : 1.05 (9H, s), 1.4-2.0 (2H, m), 2.3- 2.6 (2H, m), 3.01-3.06 (1H, m), 3.8-4.2 (2H, m), 6.47 (1H, m), 6.6-6.8 (2H, m), 7.05 (1H, t, J=8Hz), 7.2-7.5 (6H, m), 7.6-7.8 (4H, m) (4) To a solution of 4,5-diphenyloxazole (5.3 g) in THF (50 ml) at -78°C under N2 was added n-butyllithium (1.6 M in hexane, 9.2 ml). After 30 minutes, a solution of 3-(3-t-butyldiphenylsilyloxybenzyl)-2-oxotetrahydrofuran (3.3 g) in THF (30 ml) was added thereto and stirred for 1 hour at the same temperature. The reaction mixture was poured into the mixture of ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The oily residue was dissolved in THF (100 ml) and LiAlH4 was added to the solution at 0°C. After being stirred for 2 hours, the mixture was poured into a mixture of ethyl acetate and 1N-HCl solution. The organic layer was washed with sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 3-[3-(4,5-diphenyloxazol-2-yl)-3-hydroxy-2-(2-hydroxyethyl)propyl]-1-(t-butyldiphenylsilyloxy)benzene (4.3 g).
MS (m/z) : 654 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.09 (9H, s), 1.4-1.8 (2H, m), 2.2- 2.7 (3H, m), 3.3-3.8 (2H, m), 4.6-4.8 (1H, m), 6.5- 6.8 (3H, m), 6.99 (1H, t, J=8Hz), 7.2-7.8 (20H, m)
(5) A mixture of 3-[3-(4,5-diphenyloxazol-2-yl)-3-hydroxy-2- (2-hydroxyethyl)propyl]-1-(t-butyldiphenylsilyloxy)benzene (1.3 g) and p-toluenesulfonic acid (100 mg) in toluene (20 ml) was stirred under reflux for 6 hours. The solution was washed with sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo to afford crude 2-(4,5-diphenyloxazol-2-yl)-3-(3-t-butyldiphenylsilyloxybenzyl)tetrahydrofuran (1.5 g).
Preparation 2
A mixture of 3-[3-(4,5-diphenyloxazol-2-yl)-3-hydroxy-2- (2-hydroxyethyl)propyl]-1-(t-butyldiphenylsilyloxy)benzene (3.0 g) and methanesulfonyl chloride (1.1 ml) and
triethylamine (2.6 ml) in THF (50 ml) was stirred at room temperature for 1 hour. The solution was diluted with ethyl acetate and washed with sat. NaHCO3 and brine, dried over MgSO4, and evaporated. The residue was dissolved in DMF (40 ml) and to the solution was added Na2S (600 mg). After being stirred for 30 minutes at 80°C, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3, and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to afford 2-(4,5-diphenyloxazol-2-yl)-3-(3-t-butyldiphenylsilyloxybenzyl)tetrahydrothiophene (3.2 g).
MS (m/z) : 652 (M++1)
IR (Neat) : 1600, 1580 cm-1
NMR (CDCl3, δ) : 1.08 (9H, s), 2.0-2.5 (4H, m),
2.6-3.2 (3H, m), 4.10 (2/3H, d, J=7Hz), 4.20 (1/3H, d, J=7Hz), 6.4-6.8 (3H, m), 6.9-7.1 (1H, m), 7.2- 7.8 (20H, m)
Preparation 3
(1) 3-[3-(4,5-Diphenyloxazol-2-yl)-3-hydroxy-2-(2-hydroxyethyl)propyl]-1-methyloxybenzene was obtained
according to a similar manner to that of Preparation 1 (4).
MS (m/z) : 430 (M++1) IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.8-2.0 (2H, m), 2.5-3.0 (3H, m),
3.71 (3H, s), 3.6-4.0 (2H, m), 4.95 (1H, d, J=2Hz), 6.6-6.9 (3K, m), 7.15 (1H, t, J=8Hz), 7.2-7.8 (10H, m)
(2) A mixture of 3-[3-(4,5-diphenyloxazol-2-yl)-3-hydroxy-2- (2-hydroxyethyl)propyl]-1-methoxybenzene (3.3 g) and
raethanesulfonyl chloride (1.8 ml) and triethylamine (4.3 ml) in THF (50 ml) was stirred at room temperature for 1 hour. The solution was diluted with ethyl acetate and washed with sat. NaHCO3 and brine, dried over MgSO4, and evaporated. The residue was dissolved in benzylamine (10 ml). After being stirred for 2 hours at 80°C, the mixture was partitioned between ether and water. The organic layer was washed with water and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to afford 1-benzyl-2-(4,5-diphenyloxazol-2-yl)-3-(3-methoxybenzyl)pyrrolidine (1.5 g).
MS (m/z) : 501 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCI3, δ) : 2.0-3.2 (7H, m), 3.60 (3H, s),
3.5-4.0 (3H, m), 6.5-6.8 (3H, m), 7.0-7.8 (16H, m) Preparation 4
(1) 2-(α-Hydroxy-3-methoxybenzyl)cycloheptanone was
obtained according to a similar manner to that of
Preparation 1 (1).
MS (m/z) : 231 (M+-17)
IR (Neat) : 3400, 1690 cm-1
NMR (CDCI3, δ) : 1.0-2.0 (8H, m), 2.3-2.7 (2H, m), 2.8 (1H, m), 3.20 (1H, d, J=2Hz), 3.78 (3H, s), 5.15 (1H, t, J=2Hz), 6.7-7.0 (3H, m), 7.26 (1H, t,
J=8Hz) (2) 2-(3-Methoxybenzyl)cycloheptanone was obtained according to a similar manner to that of Preparation 1 (2).
IR (Neat) : 1700 cm-1
NMR (CDCl3, δ) : 1.2-2.0 (8H, m), 2.4-2.6 (3H, m), 2.8 (1H, m), 3.05 (1H, dd, J=5.8, 13.5Hz), 3.77 (3H, s), 6.5-6.9 (3H, m), 7.21 (1H, t, J=8Hz)
(3) 1-Hydroxy-1-(4,5-diphenyloxazol-2-yl)-2-(3- methoxybenzyl)cycloheptane was obtained by reacting 2- (3-methoxybenzyl)cycloheptanone according to a similar manner to that of Preparation 1 (4).
MS (m/z) : 454 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCI3, δ) : 1.2-2.6 (11H, m), 3.20 (1H, br s), 3.64 (3H, s), 6.5-6.8 (3H, m), 7.10 (1H, t, J=8Hz),
7.3-7.8 (10H, m)
(4) A mixture of 1-hydroxy-1-(4,5-diphenyloxazol-2-yl)-2-(3-methoxybenzyl)cycloheptane (5.2 g) and p-toluenesulfonic acid (500 mg) in toluene (50 ml) was stirred under reflux for 4 hours. The solution was washed with water, sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-(4,5-diphenyloxazol-2-yl)-7-(3-methoxybenzyl)-1-cycloheptene (4.7 g).
MS (m/z) : 436 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCI3, δ) : 1.3-2.0 (6H, m), 2.4 (2H, m), 2.83 (1H, dd, J=10.0, 14Hz), 3.00 (1H, dd, J=6.0,
14.0Hz), 3.78 (3H, s), 6.7-7.0 (3H, m), 7.20 (1H, t, J=8Hz), 7.2-7.8 (11H, m)
Preparation 5
(1) A mixture of 1-azido-5-methoxy-1,2,3,4-tetrahydronaphthalene (1.0 g) and 10% Pd/C (0.5 g) in methanol (20 ml) was stirred under H2 for 10 hours. The catalyst was filtered off and filtrate was evaporated. The residue was dissolved in toluene (30 ml) and 4-hydroxy-1- (4,5-diphenyloxazol-2-yl)butan-1-one (1.3 g) and p-toluenesulfonic acid (200 mg) were added to the solution. After the mixture was heated under reflux in Dean-Stark apparatus for 4 hours, the solvent was removed in vacuo. The residue was dissolved in methanol (20 ml) and NaBH4 (0.4 g) was added. After being stirred for 4 hours, the solution was poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[[4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butyl]amino]-5-methoxy-1,2,3,4-tetrahydronaphthalene (0.9 g).
MS (m/z) : 469 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.6-2.8 (10H, m), 3.4-3.6 (2H, m), 3.79 (3H, s), 3.7-3.9 (1H, m),4.0-4.2 (1H, m), 6.6-6.8 (1H, m), 6.9-7.2 (2H, m), 7.3-7.7 (10H, m)
(2) To a solution of 1-[[4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butyl]amino]-5-methoxy-1,2,3,4-tetrahydronaphthalene (0.9 g) in CH2Cl2 (20 ml) was added SOCl2(3 ml). After being stirred for 4 hours, the solvent was removed. The residue was dissolved in CH3CN (20 ml) and K2CO3 (5 g) was added to the solution. After being stirred for 4 hours under reflux, the solution was poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[2-(4,5diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-methoxy-1,2,3,4-tetrahydronaphthalene (0.57 g).
MS (m/z) : 451 (M++1)
IR (Neat) : 1580 cm-1 NMR (CDCI3, δ) : 1.5-2.3 (8H, m), 2.4-3.2 (4H, m),
3.69 and 3.76 (3H, each s), 4.0-4.2 (2H, m), 6.4- 6.72 (3H, m), 7.3-7.7 (10H, m) Preparation 6
(1) To a solution of 5-t-butyldiphenylsilyloxy-1-tetralone (2.9 g) and (R)-5,5-diphenyl-2-methyl-3,4-propano-1,3,2-oxazaborolidine (2.3 g) in THF (5 ml) was added borane tetrahydrofuran complex (7.1 ml, 1M solution in THF) at
-18°C. After being stirred for 30 minutes, the reaction was quenched with 1N HCl solution. The mixture was poured into a mixture of ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The residue was
purified by chromatography on silica gel to afford (1S)-1-hydroxy-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (3.2 g).
MS (m/z) : 401 (M+-1)
NMR (CDCI3, δ) : 1.10 (9H, s), 1.8-2.2 (4H, m),
2.6-3.1 (2H, m), 4.79 (1H, t, J=4.8Hz), 6.30 (1H, d, J=8Hz), 6.77 (1H, t, J=8Hz), 6.97 (1H, d,
J=8Hz), 7.3-7.9 (10H, m)
HPLC; chiralcel AD, 2% isopropanol/hexane, 20.3 ml/min (2) A mixture of (1S)-1-hydroxy-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (1.0 g) and diphenyl
phosphorazidate (0.65 ml) was dissolved in toluene (10 ml). The mixture was cooled to 0°C under N2, and neat 1,8-diazabicyclo[5.4.0]-7-undecene (DBU) (0.45 ml) was added. The reaction mixture was stirred for 2 hours at 0°C then at 20°C for 16 hours. The resulting mixture was washed with water and 1N-HCl. The organic layer was concentrated in vacuo and purified by silica gel chromatography to give (1R)-1-azido-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (950 mg). MS (m/z) : 400 (M++1)
IR (Neat) : 2100 cm-1
NMR (CDCl3, δ) : 1.10 (9H, s), 1.8-2.2 (4H, m),
2.6-3.1 (2H, m), 4.5-4.7 (1H, m), 6.3-6.4 (1H, m), 6.7-7.0 (2H, m), 7.1-7.8 (10H, m)
(3) A mixture of (1R)-1-azido-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (0.95 mg) and 10% Pd/C (0.2 g) in a mixture of ethanol (20 ml) and THF (20 ml) was stirred under H2 for 2 hours. The catalyst was filtered off and filtrate was evaporated. The residue was dissolved in DMF (10 ml) and then K2CO3 (600 mg) and (4,5-diphenyloxazol-2-yl)methyl bromide (700 mg) were added thereto. After being stirred for 2 hours at room temperature, the mixture was poured into a mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford (1R)-1-(4,5-diphenyloxazol-2-yl)methylamino-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (1.4 g).
MS (m/z) : 636 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCI3, δ) : 1.09 (9H, s), 1.6-2.2 (4H, m),
2.6-3.2 (2H, m), 3.91 (1H, m), 4.06 (2H, s), 6.30 (1H, d, J=8Hz), 6.72 (1H, t, J=8Hz), 6.93 (1H, d,
J=8Hz), 7.2-7.8 (10H, m)
Preparation 7
(1) (1R)-1-Hydroxy-5-t-butyldiphenylsilyloxy-1,2,3,4- tetrahydronaphthalene was obtained according to a similar manner to that of Preparation 6 (1).
HPLC; chiralcel AD, 2% isopropanol/hexane, 23.8 ml/min
(2) (1S)-1-Azido-5-t-butyldiphenylsilyloxy-1,2,3,4- tetrahydronaphthalene was obtained according to a similar manner to that of Preparation 6 (2).
(3) (1S)-1-(4,5-Diphenyloxazol-2-yl)methylamino-5-t- butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene was obtained according to a similar manner to that of
Preparation 6 (3).
Preparation 8
To a solution of (1R)-1-hydroxy-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (1.5 g) in THF (20 ml) were added n-butyllithium (2.8 ml, 1.5M solution in hexane), (4,5-diphenyloxazol-2-yl) methyl bromide (1.8 g) and Nal (1.2 g) at -78°C under N2. The solution was warmed to the room temperature and stirred for 6 hours. The mixture was poured into a mixture of ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat.
NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford (1R)-1-(4,5-diphenyloxazol-2-yl)methyloxy-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (1.65 g), MS (m/z) : 636 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.09 (9H, s), 1.6-2.2 (4H, m),
2.6-3.2 (2H, m), 4.65 (1H, m), 4.75 (1H, d,
J=13.2Hz), 4.84 (1H, d, J=13.2Hz), 6.31 (1H, d,
J=8Hz), 6.75 (1H, t, J=8Hz), 6.98 (1H, d, J=8Hz), 7.2-7.8 (10H, m)
Preparation 9
(1S)-1-(4,5-Diphenyloxazol-2-yl)methyloxy-5-t-butyl-diphenylsilyloxy-1,2,3,4-tetrahydronaphthalene was obtained according to a similar manner to that of Preparation 8.
Preparation 10
To a solution of D-pyroglutamic acid (30 g) in CH2Cl2 (200 ml) were added benzoin (74 g), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (68 ml) and 4-dimethylaminopyridine (30 g) at room temperature under N2. After being stirred for 12 hours at room temperature, the solvent was evaporated in vacuo, and the residue was
partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The obtained compound and ammonium acetate (60 g) were dissolved in acetic acid (500 ml) and the mixture was stirred for 4 hours at 100°C. After the solvent was removed, the residue was partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (5R)-5-(4,5-diphenyloxazol-2-yl)pyrrolidin-2-one (21.2 g).
MS (m/z) : 305 (M++1)
IR (Neat) : 3200, 1680, 1640 cm-1
NMR (CDCl3, δ) : 2.3-2.8 (4H, m), 4.8-5.0 (1H, m),
6.24 (1H, br s), 7.2-7.7 (10H, m)
Preparation 11
To a solution of (5R)-5-(4,5-diphenyloxazol-2-yl)pyrrolidin-2-one (12 g) in tetrahydrofuran (THF) (200 ml) were added butyllithium (26 ml, 1.6N solution in hexane) and benzyloxycarbonyl chloride (6.8 ml) at -78°C under N2. The mixture was stirred for 1 hour at the same temperature and partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, water, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo, the residue was dissolved in THF (200 ml), and 1N-NaOH (87 ml) was added at 0°C. After being stirred for 12 hours at room temperature, the solvent was evaporated in vacuo. After the residue was partitioned between hexane and water, aqueous layer was adjusted to pH=2 and extracted with ethyl acetate. The organic layer was washed with water, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo and the residue was dissolved in THF (200 ml). To the solution were added triethylamine (9.0 ml) and ethyl chloroformate (5.0 ml) at -5°C under N2 and the mixture was stirred for 1 hour at the same temperature. After the filtration, the solution was dropwise added to the solution of NaBH4 (3.2 g) in a mixture of THF (100 ml) and water (100 ml) at 0°C and stirred for 1 hour. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (1R)-N-benzyloxycarbonyl-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butylamine (13 g).
MS (m/z) : 443 (M++1)
IR (Neat) : 3300, 1700 cm--1
NMR (CDCl3, δ) : 1.6-2.2 (4H, m), 3.68 (2H, m), 5.10- 5.2 (1H, m), 5.14 (2H, s), 5.73 (1H, d, J=10.0Hz), 7.2-7.7 (10H, m)
Preparation 12
A mixture of (1R)-N-benzyloxycarbonyl-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butylamine (12 g) and 10% Pd/C (2 g) in methanol (20 ml) was stirred under H2 for 5 hours. The catalyst was filtered off and filtrate was evaporated. The residue was recrystallized with ether to give (1R)-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butylamine (5.8 g).
MS (m/z) : 309 (M++1)
NMR (CDCI3, δ) : 1.7-2.0 (3H, m), 2.1-2.4 (1H, m),
2.6-2.8 (3H, m), 3.5-3.8 (2H, m), 4.0-4.2 (1H, m),
7.3-7.8 (10H, m)
Preparation 13
The mixture of (1R)-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butylamine (5.8 g), 5-tert-butyldiphenylsilyloxy-1- tetralone (11 g) and p-toluenesulphonic acid (32 mg) in toluene (150 ml) was heated under reflux in Dean-Stark apparatus for 48 hours. After the solvent was removed in vacuo, the residue was dissolved in a mixture of methanol (50 ml) and THF (200 ml) and NaBH4(0.4 g) was added to the solution at -78°C. After being stirred for 4 hours at the same temperature, the solution was allowed to stand at the room temperature for 30 minutes, then poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4 and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford (1R)-1-[[(1R)-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butyl]amino]-5-tert-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (10.2 g).
MS (m/z) : 693 (M+)
IR (Neat) : 3400, 1580 cm-1
NMR (CDCl3, δ) : 1.08 (9H, s), 1.6-2.2 (8H, m), 2.6- 3.1 (2H, m), 3.61 (2H, t, J=6.0Hz), 3.88 (1H, m), 4.13 (1H, m), 6.30 (1H, d, J=8.0Hz), 6.72 (1H, t, J=8.0Hz), 6.92 (1H, d, J=8.0Hz), 7.3-7.8 (20H, m)
Preparation 14
To a solution of (1R)-1-[[(1R)-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butyl]amino]-5-tert-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (2.6 g) in CH2Cl2 (50 ml) was added SOCl2 (3 ml). After being stirred for 12 hours, the solvent was removed. The residue was dissolved in N,N-dimethylformamide (DMF) (15 ml) and K2CO3 (2 g) was added to the solution. After being stirred for 4 hours at the room temperature, the solution was poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4 and evaporated in vacuo. The residue was purified by
chromatography on silica gel to afford (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-tert- butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (1.22 g) MS (m/z) : 675 (M+)
IR (Neat) : 1560 cm-1
NMR (CDCl3, δ) : 1.75 (9H, s), 1.5-2.4 (8H, m), 2.7- 3.2 (4H, m), 4.0-4.3 (2H, m), 6.15 (1H, d, J=8Hz),
6.45 (1H, t, J=8Hz), 6.92 (1H, d, u=8Hz), 7.2-7.8 (2OH, m)
Preparation 15
The following compounds were obtained according to a similar manner to that of Preparation 14.
(1) (1S)-1-[(2R)-2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1- yl]-5-tert-butyldiphenylsilyloxy-1,2,3,4- tetrahydronaphthalene
MS (m/z) : 675 (M+)
IR (Neat) : 1580 cm-1
NMR (CDCl3, δ) : 1.80 (9H, s), 1.5-2.4 (8H, m),
2.6-3.2 (4H, m), 3.9-4.1 (1H, m), 4.33 (1H t, J=7.4Hz), 6.25 (1H, d, J=8Hz), 6.72 (IK, t, J=8Hz)
7.2-7.8 (21H, m)
(2) (1S)-1-[(2S)-2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1- yl]-5-tert-butyldiphenylsilyloxy-1,2,3,4- tetrahydronaphthalene
MS (m/z) : 675 (M+)
IR (Neat) : 1560 cm-1
NMR (CDCI3, δ) : 1.75 (9H, s), 1.5-2.4 (8H, m),
2.7-3.2 (4H, m), 4.0-4.3 (2H, m), 6.15 (1H, d, J=8Hz), 6.45 (1H, t, J=8Hz), 6.92 (1H, d, J=8Hz),
7.2-7.8 (20H, m)
(3) (1R)-1-[(2S)-2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1- yl]-5-tert-butyldiphenylsilyloxy-1,2,3,4- tetrahydronaphthalene MS (m/z) : 675 (M+)
IR (Neat) : 1580 cm-1
NMR (CDCl3, δ) : 1.80 (9H, s), 1.5-2.4 (8H, m),
2.6-3.2 (4H, m), 3.9-4.1 (1H, m), 4.33 (1H, t, J=7.4Hz), 6.25 (1H, d, J=8Hz), 6.72 (1H, t, J=8Hz),
7.2-7.8 (21H, m)
Preparation 16
Dichloromethane solution (10 ml) of 1-amino-2,3-dihydro-4-methoxy-1H-indene (0.38 g), trifluoroacetic anhydride (0.50 ml), pyridine (0.35 ml) and 4-dimethylaminopyridine
(catalytic amount) were stirred for 40 minutes at 0°C and for 2 days at ambient temperature. The solvent was removed in vacuo. The residue was extracted with ethyl acetate. The mixture was washed with 1N HCl solution and brine, dried over MgSO4, and evaporated in vacuo to afford 1-trifluoroacetamido-2,3-dihydro-4-methoxy-1H-indene (0.47 g).
MS (m/z) : 147 (M+-CF3CONH)
IR (Nujol) : 1690 cm-1
NMR (CDCI3, δ) : 1.65-1.96 (1H, m), 2.58-3.08 (3H, m),
3.85 (3H, s ) , 5.50 (1H, q, J=7.6Hz), 6.44 (1H, br), 6.80 (1H, d, J=8.1Hz), 6.90 (1H, d, J=7.6Hz), 7.25 (1H, dd, J=7.6, 8.1Hz) Preparation 17
To a solution of 1-trifluoroacetamido-2,3-dihydro-4-methoxy-1H-indene (0.44 g) and 4,5-diphenyl-2-bromomethyloxazole (0.55 g) in DMF was added K2CO3 (0.30 g). After being stirred for 12 hours, the solution was extracted with ethyl acetate. The mixture was washed with brine, dried over MgSO4 and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[N-trifluoroacetyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.30 g).
MS (m/z) : 493 (M++l) IR (Nujol) : 1680 cm-1
NMR (CDCl3, δ) : 2.15-2.45 (1H, m), 2.78-3.20 (2H, m), 2.50-2.75 (1H, m), 3.82 (3H, s), 4.38 (1H, d,
J=16.2Hz), 4.62 (1H, d, J=16.2Hz), 5.77 (1H, t, J=7.5Hz), 6.73 (1H, d, J=8.1Hz), 6.76 (1H, d,
J=7.5Hz), 7.16 (1H, dd, J=7.5, 8.1Hz), 7.32-7.34 (6H, m), 7.48-7.59 (4H, m)
Preparation 18
To a solution of 1-[N-trifluoroacetyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.29 g) of methanol (2 ml) was added 1N NaOH aqueous solution (2 ml). The mixture was refluxed for 1 day and the solvent was removed in vacuo. The residue was extracted with ethyl acetate, dried over MgSO4 and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-(4,5-diphenyloxazol-2-yl)methylamino-2,3-dihydro-4-methoxy-1H-indene (0.19 g).
MS (m/z) : 397 (M++1)
NMR (CDCI3, δ) : 1.85-2.10 (1H, m), 2.10 (1H, br),
2.33-2.52 (1H, m), 2.68-2.87 (1H, m), 2.92-3.12 (1H, m), 3.82 (3H, s), 4.14 (2H, s), 4.45 (1H, t, J=6.1Hz), 6.74 (1H, d, J=7.9Hz), 7.05 (1H, d, J=7.4Hz), 7.20 (1H, dd, J=7.4, 7.9Hz), 7.32-7.40 (6H, m), 7.57-7.67 (4H, m)
Preparation 19
To a solution of 1-(4,5-diphenyloxazol-2-yl)methylamino-2,3-dihydro-4-methoxy-1H-indene (0.18 g) and methyl iodide (85 mg) in DMF (3 ml) was added K2CO3 (0.12 g). After being stirred for 16 hours, the solution was extracted with ethyl acetate. The mixture was washed with brine, dried over MgSO4 and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[N-methyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H- indene (0.13 g).
MS (m/z) : 411 (M++1)
NMR (CDCl3, δ) : 2.02-2.28 (1H, m), 2.44 (3H, s),
2.64-3.17 (3H, m), 3.82 (5H, s), 4.60 (1H, br), 6.73 (1H, d, J=7.9Hz), 7.08-7.32 (2H, m), 7.32-7.48
(6H, m), 7.58-7.72 (4H, m)
Example 1
To a solution of 2-(4,5-diphenyloxazol-2-yl)-3-(3-t-butyldiphenylsilyloxybenzyl)tetrahydrofuran (1.5 g) in THF
(30 ml) was added tetrabutylammonium fluoride (2.4 ml, 1N-THF solution). After being stirred for 1 hour at the room temperature, the solution was extracted with ethyl acetate. The extract was washed with water and brine. The dried solvent was evaporated in vacuo. The obtained oil was dissolved into DMF (10 ml) and then K2CO3 (2.0 g) and ethyl bromoacetate (0.4 ml) were added at room temperature. The mixture was stirred for 2 hours at the same temperature and partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)tetrahydrofuran-3-yl]methyl]phenoxy]acetate (680 mg).
MS (m/z) : 484 (M++1)
IR (Neat) : 1760 cm-1
NMR (CDCl3, δ) : 1.1-1.3 (3H, m), 1.8-3.2 (5H, m),
3.8-4.4 (4H, m), 4.51 and 4.53 (2H, each s), 4.78 (1/3H, d, J=6.6Hz), 5.23 (2/3H, d, J=7.2Hz), 6.6- 7.0 (3H, m), 7.1-7.8 (11H, m)
Example 2
To a solution of (1R)-1-(4,5-diphenyloxazol-2-yl)methylamino-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene in TKF (20 ml) was added tetrabutylammonium fluoride (3.3 ml, 1N-THF solution). After being stirred for 1 hour at the room temperature, the solution was extracted with ethyl acetate. The mixture was washed with water and brine. The dried solvent was
evaporated in vacuo. The obtained oil was dissolved into DMF (10 ml), and NaH (60% in oil, 93 mg) and ethyl bromoacetate (0.24 ml) were added at room temperature. The mixture was stirred for 2 hours at the same temperature and partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3, and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (1R)-1-(4,5-diphenyloxazol-2-yl)methylamino-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene (480 mg).
MS (m/z) : 483 (M++1)
IR (Neat) : 3400, 1720 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.6-2.2 (4H, m), 2.5-3.0 (2H, m), 3.92 (1H, t, J=4.4Hz), 4.10 (2H, s), 4.25 (2H, q, J=7Hz), 4.60 (2H, s), 6.57 (1H, m), 7.0-7.9 (12H, m)
HPLC; chiralcel AD, 10% isopropanol/hexane, 13.1 ml/min
Example 3
The following compounds were obtained according to similar manners to those of Examples 1 and 2.
(1) Ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)- tetrahydrothiophen-3-yl]methyl]phenoxy]acetate
MS (m/z) 500 (M++1)
IR (Neat) : 1740 cm-1
NMR (CDCI3, δ) : 1.25 (3H, t, J=7Hz), 1.8-3.2 (7H, m), 4.0-4.4 (3H, m), 4.42 (2H, s), 6.6-6.9 (3H, m), 7.18 (1H, t, J=8Hz), 7.2-7.8 (10H, m) (2) (1S)-1-(4,5-Diphenyloxazol-2-yl)methylamino-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene HPLC; chiralcel AD, 10% isopropanol/hexane, 12.0 ml/min
(3) (1R)-1-(4,5-Diphenyloxazol-2-yl)methyloxy-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene MS (m/z) : 484 (M++1)
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.6-2.2 (4H, m), 2.6-3.0 (2H, m), 4.25 (2H, q, J=7Hz), 4.60 (2H, s), 4.64 (1H, m), 4.75 (1H, d, J=13.0Hz), 4.82 (1H, d, J=13.0Hz), 6.65 (1H, m), 7.0-7.9 (12H, m)
HPLC; chiralcel AD, 5% isopropanol/hexane, 15.5 ml/min
(4) (1S)-1-(4,5-Diphenyloxazol-2-yl)methyloxy-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene HPLC; chiralcel AD, 5% isopropanol/hexane, 11.5 ml/min
Example 4
To a solution of 1-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-methoxy-1,2,3,4-tetrahydronaphthalene (0.57 g) in dichloromethane (10 ml) was added BBr3 (5 ml, 1M solution in dichloromethane) at 0°C. After being stirred for 2 hours, the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, and the mixture was washed with sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo. The obtained oil was dissolved into DMF (10 ml) and then K2CO3 (1.0 g) and ethyl bromoacetate (0.3 ml) were added at room temperature. The mixture was stirred for 2 hours at the same temperature and then partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3 and brine. The dried solvent was
evaporated in vacuo and the residue was purified by
chromatography on silica gel to give 1-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene (430 mg).
MS (m/z) : 523 (M++1) IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.5-2.4 (8H, m), 2.5-3.2 (4H, m), 4.22 (2H, q, J=7Hz), 4.0-4.4 (1H, m), 4.42 (2H, s), 4.4-4.6 (1H, m), 6.38 (1H, d, J=8Hz), 6.84 (1H, t, J=8Hz), 7.05 (1H, d, J=8Hz),
7.2-7.7 (10H, m)
Example 5
The following compounds were obtained according to a similar manner to that of Example 4.
(1) Ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-1- benzylpyrrolidin-3-yl]methyl]phenoxy]acetate
MS (m/z) : 573 (M++1)
IR (Neat) : 1740 cm-1
NMR (CDCI3, δ) : 1.8-3.2 (7H, m), 3.6-4.0 (2H, m),
4.0-4.4 (3H, m), 4.42, 4.38 (2H, each s), 6.5-6.9 (3H, m), 7.1-7.8 (16H, m) (2) Ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohepten-1- yl]methyl]phenoxy]acetate
MS (m/z) : 508 (M++1)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.3-2.0 (6H, m), 2.5 (2H, m), 2.82 (1H, dd, J=8.0, 12.0Hz), 3.01
(1H, dd, J=6.0, 12.0Hz), 3.74 (1H, m), 4.13 (2H, q, J=7Hz), 6.7-7.0 (3H, m), 7.0-7.9 (12H, m)
Example 6
To a solution of ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)tetrahydrothiophen-3-yl]methyl]phenoxy]acetate (0.6 g) in CH2Cl2 (20 ml) was added m-chloroperbenzoic acid (520 mg) at 0°C. After being stirred for 4 hours, the solvent was removed in vacuo. The residue was extracted with ethyl acetate. The mixture was washed with 1N-HCl solution, sat. NaHCO3 and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 2-(4,5-diphenyloxazol-2-yl)-3-[3- (ethoxycarbonylmethoxy)benzyl]tetrahydrothiophen 1,1-dioxide.
MS (m/z) : 532 (M++1)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.8-2.4 (2H, m),
2.7-3.5 (5H, m), 4.0-4.4 (3H, m), 4.47 (2H, s), 6.6 6.9 (3H, m), 7.16 (1H, t, J=8Hz), 7.2-7.8 (10H, m)
Example 7
To a solution of ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)tetrahydrofuran-3-yl]methyl]phenoxy]acetate (560 mg) in ethanol (20 ml) was added 1N-NaOH solution (1.2 ml). After being stirred for 4 hours at the same temperature, the solvent was removed in vacuo to give sodium [3-[[2-(4,5-diphenyloxazol-2-yl)tetrahydrofuran-3-yl]methyl]phenoxy]-acetate (0.46 g).
FABMS (m/z) : 478 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.6-3.0 (5H, m), 3.8-4.2 (4H, m), 4.68 (1/3H, d, J=7.0Hz), 5.13 (2/3H, d, J=8.0Hz), 6.6-6.8 (3H, m), 7.0 (1H, t, J=8Hz), 7.2-7.8 (10H, Example 8
To a solution of 1-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene (430 mg) in ethanol (20 ml) was added 1N-NaOH solution (0.82 ml). After being stirred for 4 hours at the same temperature, the solvent was- removed in vacuo to give sodium salt of 1-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene (0.24 g) .
FABMS (m/z ) : 517 (M++1 )
IR (Nujol ) : 3400 , 1600 cm- 1 NMR (DMSO-d6 δ) : 1.4-2.3 (8H, m), 2.4-3.1 (4H, m), 4.07 (2H, s), 4.0-4.4 (2H, m), 6.3-6.6 (1H, m), 6.6-7.1 (2H, m), 7.2-7.6 (10H, m) Example 9
The following compounds were obtained according to similar manners to those of Examples 7 and 8.
(1) Sodium [3-[[2-(4,5-diphenyloxazol-2- yl)tetrahydrothiophen-3-yl]methyl]phenoxy]acetate
FABMS (m/z) : 494 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.6-3.2 (7H, m), 4.05 (2H, s), 4.39 (2/3H, d, J=6.6Hz), 4.53 (1/3H, d, J=5.8Hz), 6.6- 6.8 (3H, m), 7.07 (1H, t, J=8Hz), 7.2-7.8 (10H, m)
(2) 2-(4,5-Diphenyloxazol-2-yl)-3-[3- (carboxymethoxy)benzyl]tetrahydrothiophene 1,1-dioxide MS (m/z) : 504 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (CDCl3, δ) : 1.8-2.4 (2H, m), 2.8-3.4 (5H, m),
4.28 (1H, d, J=10.3Hz), 4.48 (2H, s), 6.6-6.9 (3H, m), 7.16 (1H, t, J=8Hz), 7.2-7.8 (10H, m) (3) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-1- benzylpyrrolidin-3-yl]methyl]phenoxy]acetate
FABMS (m/z) : 567 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6,δ) : 1.8-3.2 (7H, m), 3.4-3.8 (2H, m), 4.10 (2H, s), 4.0-4.1 (1H, m), 6.5-6.8 (3H, m),
7.02 (1H, t, J=8Hz), 7.1-7.8 (15H, m)
(4) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohepten-1- yl]methyl]phenoxy]acetate
IR (Neat) : 1600 cm-1 NMR (DMSO-d6, δ) : 1.2-2.0 (6H, m), 2.3-2.5 (2H, m), 2.8 (2H, m), 4.10 (2H, s), 6.64 (1H, d, J=8Hz), 6.76 (1H, d, J=8Hz), 6.81 (1H, s), 7.0-7.2 (2H, m), 7.2-7.8 (10H, m)
(5) (1R)-1-(4,5-Diphenyloxazol-2-yl)methylamino-5- carboxymethoxy-1,2,3,4-tetrahydronaphthalene
FABMS (m/z) : 455 (M++1)
IR (Nujol) : 3400, 1700 cm-1
NMR (DMSO-d6, δ) : 1.4-2.2 (4H, m), 2.4-2.8 (2H, m),
3.40 (1H, m), 4.01 (2H, s), 4.64 (2H, s), 6.67 (1H, m), 7.0-7.8 (13H, m)
(6) (1S)-1-(4,5-Diphenyloxazol-2-yl)methylamino-5- carboxymethoxy-1,2,3,4-tetrahydronaphthalene
(7) Sodium salt of (1R)-1-(4,5-diphenyloxazol-2- yl)methyloxy-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 478 (M++1)
NMR (DMSO-d6, δ) : 1.6-2.2 (4H, m), 2.4-2.8 (2H, m),
4.11 (2H, m), 4.60 (1H, m), 4.72 (1H, d, J=13.4Hz), 4.80 (1H, d, J=13.4Hz), 6.61 (1H, d, J=7.5Hz), 6.88 (1H, d, J=7.5Hz), 7.03 (1H, t, J=7.5Hz), 7.2-7.8 (10H, m)
(8) Sodium salt of (1S)-1-(4,5-diphenyloxazbl-2- yl)methyloxy-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
Example 10
The following cc ound was obtained by reacting ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-1-benzylpyrrolidin-3-yl]methyl]phenoxy]acetate according to similar manners to those of Preparation 1 (2) and Example 7. [3-[[2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-3-yl]methyl]- phenoxy]acetic acid
FABMS (m/z) : 455 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.5-2.2 (2H, m), 2.4-3.2 (5H, m),
4.19 (2/3H, d, J=6Hz), 4.41 (2H, s), 4.57 (1/3H, d, J=7Hz), 6.5-6.8 (3H, m), 7.11 (1H, t, J=8Hz), 7.2- 7.8 (10H, m) Example 11
To a solution of [3-[[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-3-yl]methyl]phenoxy]acetic acid (140 mg) in a mixture of THF (10 ml) and water (10 ml) was added acetyl chloride (1.0 ml) dropwise at 0°C keeping pH 8-9 with 1N NaOH solution. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with water, 1N-HCl and brine. The dried solvent was evaporated in vacuo and the residue was purified by trituration with hexane to afford [3- [[2-(4,5-diphenyloxazol-2-yl)-1-acetylpyrrolidin-3-yl]methyl]phenoxy]acetic acid (150 mg).
FABMS (m/z) : 497 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.8-2.4 (5H, m), 2.6-3.1 (3H, m), 3.2-3.9 (2H, m), 4.58, 4.61 (2H, each s), 4.8-5.2 (1H, m), 6.6-7.0 (3H, m), 7.1-7.8 (11H, m)
Example 12
The following compound was obtained by reacting ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohepten-1-yl]methyl]phenoxy]acetate according to similar manners to those of Preparation 1 (2) and Example 7.
Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)cycloheptyl]methyl]phenoxy]acetate
IR (Neat) : 1600 cm-1 NMR (DMSO-d6, δ) : 1.0-2.0 (10H, m), 2.0-2.8 (4H, m),
4.07 (2H, s), 6.5-6.7 (3H, m), 7.08 (1H, t, J=8Hz), 7.2-7.8 (10H, m) Example 13
To a solution of (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2- yl)pyrrolidin-1-yl]-5-tert-butyldiphenylsilyloxy-1,2,3,4- tetrahydronaphthalene (1.22 g) in THF (20 ml) was added tetrabutylammonium fluoride (2.7 ml, 1M solution in THF) at 0°C. After being stirred for 2 hours at the room
temperature, the mixture was diluted with ethyl acetate and washed with water and brine. The dried solvent was
evaporated in vacuo. The obtained oil was dissolved into DMF (10 ml) and then K2CO3 (2.0 g) and ethyl bromoacetate (0.3 ml) were added at room temperature. The mixture was stirred for 2 hours at the same temperature and then partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene (800 mg).
MS (m/z) : 523 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.5-2.4 (8H, m),
2.5-3.2 (4H, m), 4.0-4.4 (2H, m), 4.22 (2H, q, J=7Hz), 4.44 (2H, s), 6.37 (1H, d, J=8Hz), 6.83 (1H, t, J=8Hz), 7.06 (1H, d, J=8Hz), 7.2-7.7 (10H, m)
Example 14
The following compounds were obtained according to a similar manner to that of Example 13. (1) (1S)-1-[(2R)-2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1- yl]-5-ethoxycarbonylmethoxy-1,2,3,4- tetrahydronaphthalene
MS (m/z) : 523 (M+)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.5-2.4 (8H, m), 2.5-2.7 (2H, m), 2.8-3.0 (2H, m), 3.9-4.1 (1H, m), 4.1-4.3 (1H, m), 4.24 (2H, q, J=7Hz), 4.55 (2H, s), 6.52 (1H, d, J=8Hz), 7.08 (1H, t, J=8Hz), 7.46 (1H, d, J=8Hz), 7.2-7.7 (10H, m)
(2) (1S)-1-[(2S)-2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1- yl]-5-ethoxycarbonylmethoxy-1,2,3,4- tetrahydronaphthalene
MS (m/z) : 523 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCI3, δ) : 1.24 (3H, t, J=7Hz), 1.5-2.4 (8H, m), 2.5-3.2 (4H, m), 4.0-4.4 (2H, m), 4.22 (2H, q, J=7Hz), 4.44 (2H, s), 6.37 (1H, d, J=8Hz), 6.83 (1H, t, J=8Hz), 7.06 (1H, d, J=8Hz), 7.2-7.7 (10H, m)
(3) (1R)-1-[(2S)-2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1- yl]-5-ethoxycarbonylmethoxy-1,2,3,4- tetrahydronaphthalene
MS (m/z) : 523 (M+)
IR (Neat) : 1750 cm-1
NMR (CDCI3, δ) : 1.24 (3H, t, J=7Hz), 1.5-2.4 (8H, m), 2.5-2.7 (2H, m), 2.8-3.0 (2H, m), 3.9-4.1 (1H, m), 4.1-4.3 (1H, m), 4.24 (2H, q, J=7Hz), 4.55 (2H, s), 6.52 (1H, d, J=8Hz), 7.08 (1H, t, J=8Hz), 7.46 (1H, d, J=8Hz), 7.2-7.7 (10H, m)
Example 15
To a solution of (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4- tetrahydronaphthalene (700 mg) in ethanol (20 ml) was added 1N-NaOH solution (1.3 ml). After being stirred for 12 hours at the same temperature, the solvent was removed in vacuo to give sodium salt of (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene (0.53 g).
FABMS (m/z) : 517 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.3 (8H, m), 2.4-3.1 (4H, m), 4.03 (2H, s), 4.0-4.3 (2H, m), 6.41 (1H, d,
J=7.2Hz), 6.6-6.8 (2H, m), 7.2-7.5 (10H, m)
Example 16
The following compounds were obtained according to a similar manner to that of Example 15.
(1) Sodium salt of (1S)-1-[(2R)-2-(4,5-diphenyloxazol-2- yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 517 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.3 (8H, m), 2.4-2.9 (4H, m), 3.9 (1H, m), 4.05 (2H, s), 4.30 (1H, t, J=7Hz), 6.49 (1H, d, J=8.2Hz), 6.99 (1H, t, J=8.2Hz), 7.14 (1H, d, J=8.2Hz), 7.2-7.6 (10H, m)
(2) Sodium salt of (1S)-1-[(2S)-2-(4,5-diphenyloxazol-2- yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 517 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.3 (8H, m), 2.4-3.1 (4H, m), 4.03 (2H, s), 4.0-4.3 (2H, m), 6.41 (1H, d, J=7.2Hz), 6.6-6.8 (2H, m), 7.2-7.5 (10H, m) (3) Sodium salt of (1R)-1-[(2S)-2-(4,5-diphenyloxazol-2- yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 517 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.3 (8H, m), 2.4-2.9 (4H, m), 3.9 (1H, m), 4.05 (2H, s), 4.30 (1H, t, J=7Hz), 6.49 (1H, d, J=8.2Hz), 6.99 (1H, t, J=8.2Hz), 7.14 (1H, d, J=8.2Hz), 7.2-7.6 (10H, m)
Example 17
To a solution of 1-[N-methyl-N-[(4,5-diphenyloxazol-2- yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene (109 mg) in dichloromethane (2 ml) was added 1M boron tribromide
dichloromethane solution (1 ml) at 0°C. After being stirred for 4 hours at 0°C, the solvent was evaporated in vacuo. The residue was extracted with ethyl acetate. The mixture was washed with brine, dried over MgSO4 and evaporated in vacuo to afford crude 1-[N-methyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-hydroxy-1H-indene (109 mg).
To a solution of crude 1-[N-methyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-hydroxy-1H-indene (109 mg) and ethyl bromoacetate (80 mg) in DMF (3 ml) was added K2CO3 (80 mg). After being stirred for 24 hours, the solution was extracted with ethyl acetate. The mixture was washed with brine, dried over MgSO4 and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[N-methyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-ethoxycarbonylmethoxy-1H-indene (80 mg).
MS (m/z) : 483 (M++1)
NMR (CDCl3, δ) : 1.29 (3H, t, J=7.1Hz), 1.98-2.21 (2H, m), 2.41 (3H, s), 2.75-3.18 (2H, m), 3.78 (1H, d, J=12Hz), 3.82 (1H, d, J=12Hz), 4.25 (2H, q,
J=7.1Hz), 4.63 (2H, s), 4.55-4.65 (1H, m), 6.62 (1H, m), 7.15-7.18 (2H, m), 7.25-7.45 (6H, m), 7.60-7.75 (4H, m)
Example 18
To a solution of 1-[N-methyl-N-[(4,5-diphenyloxazol-2- yl)methyl]amino]-2,3-dihydro-4-ethoxycarbonylmethoxy-1H- indene (80 mg) in ethanol (3 ml) was added 1N NaOH aqueous solution (0.18 ml) at room temperature. After being stirred for 1 day, the solution was evaporated. The residue was washed with ether to afford sodium salt of 1-[N-methyl-N- [(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4- carboxymethoxy-1H-indene (63 mg).
FABMS (m/z) : 499 (M++Na)
IR (Nujol) : 1600 cm-1
NMR (CDCl3, δ) : 1.89-2.25 (2H, m), 2.40 (3H, s),
2.78-3.10 (2H, m), 3.75 (1H, d, J=14.4Hz), 3.85
(1H, d, J=14.4Hz), 4.39 (2H, s), 4.55 (1H, t, J=6.9Hz), 6.68 (1H, d, J=7.3Hz), 7.04 (1H, dd, J=7.3, 7.6Hz), 7.14 (1H, d, J=7.6Hz), 7.35-7.40 (6H, m), 7.53-7.58 (4K, m)
Preparation 20
To a solution of 3-hydroxymethylphenol (7 g) in N,N-dimethylformamide (40 ml) were added K2CO3 (15 g) ethyl bromoacetate (6.9 ml) at the room temperature. The mixture was stirred for 2 hours at the same temperature and then partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3, and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give 3-hydroxymethyl-1-ethoxycarbonylmethoxybenzene (10 g).
MS (m/z) : 193 (M+-17)
NMR (CDCI3, δ) : 1.29 (3H, t, J=7.0Hz), 2.13 (1H, t,
J=6.0Hz), 4.24 (2H, d, J=7.0Hz), 4.61 (2H, s), 4.65 (2H, d, J=6.0Hz), 6.7-7.0 (3H, m), 7.26 (1H, t, J=8.4Hz) Preparation 21
To a solution of 3-hydroxymethyl-1- ethoxycarbonylmethoxybenzene (1 g) in dichloromethane (10 ml) was added BBr3 (0.45 ml). After 1 hour, the solvent was evaporated in vacuo and the residue was dissolved in ethyl acetate. The organic layer was washed with NaHCO3 and brine. The dried solvent was evaporated in vacuo to give 3-bromomethyl-1-ethoxycarbonylmethoxybenzene (0.76 g).
NMR (CDCl3, δ) : 1.29 (3H, t, J=7Hz), 4.24 (2H, d,
J=7Hz), 4.61 (2H, s), 5.00 (1H, d, J=3.0Hz), 5.05
(1H, d, J=3.0Hz), 6.7-7.1 (3H, m), 7.2-7.3 (1H, m)
Preparation 22
To a solution of (2R)-N-benzyloxycarbonylproline (5 g) in CH2Cl2 (50 ml) were added benzoin (4.5 g), 1-ethyl 3-(3-dimethylaminopropyl)carbodiimide (3.9 ml), and
dimethylaminopyridine (2.6 g) at room temperature under N2. After being stirred for 12 hours at room temperature, the solvent was evaporated in vacuo, and the residue was
partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3, and brine, dried over MgSO4, and evaporated in vacuo. The obtained compound and CH3COONH4 (8.2 g) were dissolved in acetic acid (50 ml) and the mixture was stirred for 4 hours at 100°C. After the solvent was removed, the residue was partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (2R)-1-benzyloxycarbonyl-2-(4,5-diphenyloxazol-2-yl)pyrrolidine (4 g).
MS (m/z) : 425 (M++1)
IR (Neat) : 1700 cm-1
NMR (CDCI3, δ) : 1.8-2.4 (4H, m), 3.4-3.8 (2H, m),
4.8-5.3 (3H, m), 7.0-7.7 (15H, m) Preparation 23
The following compound was obtained according to a similar manner to that of Preparation 22. (2S)-1-Benzyloxycarbonyl-2-(4,5-diphenyloxazol-2- yl)pyrrolidine
Preparation 24
A mixture of (2R)-1-benzyloxycarbonyl-2-(4,5- diphenyloxazol-2-yl)pyrrolidine (4 g) and 10% Pd/C (0.5 g) in ethanol (120 ml) was stirred under H2 for 10 hours. The catalyst was filtered off and filtrate was evaporated in vacuo to give (2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidine.
NMR (CDCl3, δ) : 1.7-2.3 (4H, m), 2.9-3.2 (2H, m),
3.6-3.8 (1H, m), 4.44 (1H, t, J=6.0Hz), 7.2-7.7
(10H, m)
Preparation 25
The following compound was obtained according to a similar manner to that of Preparation 24.
(2S)-2-(4,5-Diphenyloxazol-2-yl)pyrrolidine
Preparation 26
To a solution of cyclooctanone (4.0 g) in THF (40 ml) was added LDA (23 ml, 1.5M solution in cyclohexane) at -78°C under N2, and then after 30 minutes, a solution of
m-anisaldehyde (4.1 g) in THF (10 ml) was added in the solution. After being stirred for 2 hours at the same temperature, the solution was poured into the mixture of ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3, and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by
chromatography on silica gel to afford 2-(hydroxy-(3-methoxyphenyl)methyl}cyclooctanone (6.9 g). MS (m/z) : 245 (M+-17)
IR (Neat) : 3400, 1690 cm-1
NMR (CDCl3, δ) : 1.0-2.3 (10H, m), 2.8-3.2 (2H, m), 3.3-3.6 (1H, m), 3.79 (3H, s), 4.8-5.0 (1H, m), 6.7-7.0 (3H, m), 7.1-7.3 (1H, m)
Preparation 27
A mixture of 2-{hydroxy-(3-methoxyphenyl)methyl}- cyclooctanone (6.0 g) and 10% Pd/C (2 g) in ethanol (120 ml) was stirred under H2 for 10 hours. The catalyst was filtered off and filtrate was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 2-(3-methoxybenzyl)cyclooctanone (2.4 g).
MS (m/z) : 247 (M++1)
IR (Neat) : 1700 cm-1
NMR (CDCI3, δ) : 1.0-2.4 (12H, m), 2.4-2.6 (1H, m),
2.8-3.0 (2H, m), 3.77 (3H, s), 6.6-6.8 (3H, m), 7.17 (1H, t, J=8Hz) Preparation 28
To a solution of 4, 5-diphenyloxazole (2.1 g) in THF (30 ml) at -78°C under N2 was added butyllithium (1.6M in hexane, 6.7 ml). After 30 minutes, a solution of 2-(3-methoxybenzyl)cyclooctanone (2.4 g) in THF (10 ml) was added thereto and stirred for 1 hour at the same temperature. The reaction mixture was poured into the mixture of ethyl acetate and water. The organic layer was washed with 1N-HCl
solution, sat. NaHCO3, and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by
chromatography on silica gel to afford 1-(hydroxy)-1-(4,5-diphenyloxazol-2-yl)-2-(3-methoxybenzyl)cyclooctane (3.7 g).
MS (m/z) : 468 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.2-2.0 (12H, m), 2.2-2.8 (3H, m),
3.38 (1H, s), 3.66 (3H, s), 6.5-6.8 (3H, m), 7.07 ( 1H, t, J=8Hz), 7 . 3-7 . 8 ( 10H, m)
Preparation 29
A mixture of 1-(hydroxy)-1-(4,5-diphenyloxazol-2-yl)-2- (3-methoxybenzyl)cyclooctane (3.5 g) and p-toluenesulfonic acid (500 mg) in toluene (50 ml) was stirred for 4 hours under reflux. The solution was washed with water, sat.
NaHCO3, and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-(4,5-diphenyloxazol-2-yl)-8-(3-methoxybenzyl)-1- cyclooctene (3.8 g).
MS (m/z) : 450 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (8H, m), 2.2-2.4 (2H, m), 3.0 (1H, m), 3.2-3.5 (2H, m), 3.78 (3H, s), 6.65 (1H, s), 6.7-7.0 (3H, m), 7.18 (1H, t, J=8Hz), 7.2-7.8 (11H, m)
Preparation 30
The following compound was obtained according to a similar manner to that of Preparation 26.
2-Oxo-3-[hydroxy(3-methoxyphenyl)methyl]bicyclo[2.2.1]-heptane
MS (m/z) : 229 (M+-17)
IR (Neat) : 3400, 1720 cm-1
NMR (CDCl3, δ) : 1.2-2.2 (9H, m), 2.5-2.7 (1H, m),
3.81 (3H, -s), 4.58 (1H, d, J=10Hz), 6.7-7.0 (3H, m), 7.26 (1H, t, J=8Hz)
Preparation 31
The following compound was obtained according to a similar manner to that of Preparation 27. 2-Oxo-3-(3-methoxybenzyl)bicyclo[2.2.1]heptane MS (m/z) : 231 (M++1)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.2-2.0 (7H, m), 2.3-2.5 (2H, m),
2.6 (1H, m), 2.8-3.0 (1H, m), 3.79 (3H, s), 6.7-6.8 (3H, m), 7.21 (1H, t, J=8Hz)
Preparation 32
2-(Hydroxy)-2-(4,5-diphenyloxazol-2-yl)-3-(3- methoxybenzyl)bicyclo [2.2.1] heptane was obtained according to a similar manner to that of Preparation 28.
MS (m/z) : 452 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.2-1.8 (7H, m), 2.0-2.6 (4H, m),
3.59 (1H, s), 3.68 (3H, s), 6.5-6.8 (3H, m), 7.08 (1H, t, J=8Hz), 7.3-7.8 (10H, m)
Preparation 33
2-(4,5-Diphenyloxazol-2-yl)-3-(3-methoxybenzyl)bicyclo- [2.2.1]hept-2-ene was obtained according to a similar manner to that of Preparation 29.
MS (m/z) : 434 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.0-2.0 (6H, m), 2.87 (1H, br s),
3.61 (1H, br s), 3.76 (3H, s), 3.79 (1H, d, J=16Hz), 4.30 (1H, J=16Hz), 6.6-7.0 (3H, m), 7.1-
7.8 (11H, m)
Preparation 34
To a solution of 2-(1,4-dihydroxybutyl)-4,5-diphenyloxazole (1 g) in tetrahydrofuran (10 ml) were added methanesulfonyl chloride (1.6 g) and triethylamine (1.5 ml) at 0°C. The solution was diluted with ethyl acetate and washed with sat. NaHCO3 and brine, dried over MgSO4, and evaporated. The residue was dissolved in benzylamine (10 ml). After being stirred for 2 hours at 80°C, the mixture was partitioned between ether and water. The or-ganic layer was washed with water and brine. The dried solvent was evaporated in vacuo and the residue was purified by
chromatography on silica gel to afford 1-benzyl-2-(4,5- diphenyloxazol-2-yl)pyrrolidine (1.3 g).
MS (m/z) : 381 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.8-2.6 (5H, m), 3.0-3.2 (1H, m),
3.60 (1H, d, J=13Hz), 3.85 (1H, t, J=7.8Hz), 3.89 (1H, d, J=13Hz), 7.0-7.8 (15H, m)
Preparation 35
A mixture of 1-benzyl-2-(4,5-diphenyloxazol-2- yl)pyrrolidine (1.3 g) and 10% Pd/C (2 g) in ethanol (120 ml) was stirred under H2 for 10 hours. The catalyst was filtered off and filtrate was evaporated in vacuo. The residue was dissolved in dichloromethane (20 ml) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.31 ml) and
dimethylaminopyridine (0.21 g) were added to the solution at room temperature under N2. After being stirred for 12 hours at room temperature, the solvent was evaporated in vacuo, and the residue was partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat.
NaHCO3, and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to give 2-(4,5-diphenyloxazol-2-yl)-1-(3-methoxyphenylcarbonyl)-pyrrolidine (0.57 g).
MS (m/z) : 425 (M++1)
IR (Neat) : 1630 cm-1
NMR (CDCl3, δ) : 1.8-2.4 (4H, m), 3.4-4.0 (6H, m),
6.6-7.0 (3H, m), 7.0-7.8 (11H, m)
Preparation 36
2-(2-Methoxybenzyl)cyclohexanone was obtained according to similar manners to those of Preparations 26 and 27. MS (m/z) : 219 (M++1)
IR (Neat) : 1700 cm-1
NMR (CDCl3, δ) : 1.2-2.2 (6H, m), 2.2-2.6 (4H, m),
3.22 (1H, dd, J=4.4, 13.2Hz), 3.79 (3H, s), 6.7-7.2 (3H, m)
Preparation 37
1-(4,5-Diphenyloxazol-2-yl)-6-(2-methoxybenzyl)-1- cyclohexene was obtained according to similar manners to those of Preparations 28 and 29.
MS (m/z) : 422 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.2-2.0 (4H, m), 2.2-2.4 (2H, m), 2.9 (1H, m), 3.1-3.4 (2H, m), 3.77 (3H, s), 6.7-6.9 (3H, m), 7.09 (1H, t, J=8Hz), 7.2-7.8 (11H, m)
Preparation 38
1-(4,5-Diphenyloxazol-2-yl)-6-(4-methoxybenzyl)-1-cyclohexene was obtained according to similar manners to those of Preparations 28 and 29.
MS (m/z) : 422 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (4H, m), 2.3-2.4 (2H, m),
2.44 (1H, m), 3.1-3.3 (2H, m), 3.74 (3H, s), 6.7- 6.9 (3H, m), 7.1-7.8 (12H, m)
Preparation 39
1-(4,5-Diphenyloxazol-2-yl)-6-(4-hydroxybenzyl)-1-cyclohexene was obtained according to a similar manner to that of the first step of Example 24.
MS (m/z) : 408 (M++1)
IR (Neat) : 3300 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (4H, m), 2.3-2.6 (3H, m),
3.0-3.3 (2H, m), 6.70 (2H, d, J=8.0Hz), 6.90 (1H, m), 7.15 (2H, d, J=8.0Hz), 7.2-7.8 (10H, m) Preparation 40
2-(3-Methoxy-6-methylbenzyl)cyclohexanone was obtained according to similar manners to those of Preparations 26 and 27.
MS (m/z) : 233 (M++1)
IR (Neat) : 1700 cm-1
NMR (CDCl3, δ) : 1.2-2.6 (10H, m), 2.20 (3H, s), 3.22
(1H, dd, J=4.0, 14.0Hz), 3.76 (3H, s), 6.6-6.8 (2H, m), 7.03 (1H, d, J=8.0Hz)
Preparation 41
2-(3-Methoxy-4-methylbenzyl)cyclohexanone was obtained according to similar manners to those of Preparations 26 and 27.
MS (m/z) : 233 (M++1)
IR (Neat) : 1700 cm-1
NMR (CDCl3, δ) : 1.2-2.6 (10H, m), 2.17 (3H, s), 3.20
(1H, dd, J=4.0, 14.0Hz), 3.78 (3H, s), 6.5-6.7 (2H, m), 6.99 (1H, d, J=8.0Hz)
Preparation 42
2-(3-Methohy-2-methylbenzyl)cyclohexanone was obtained according to similar manners to those of Preparations 26 and 27.
MS (m/z) : 233 (M++1)
IR (Neat) : 1700 cm-1
NMR (CDCl3, δ) : 1.2-2.6 (10H, m), 2.17 (3H, s), 3.2- 3.4 (1H, m), 3.79 (3H, s), 6.72 (2H, d, J=8.0Hz), 7.01 (1H, t, J=8.0Hz)
Preparation 43
The following compounds were obtained according to similar manners to those of Preparations 28 and 29. (1) 1-(4,5-Diphenyloxazol-2-yl)-6-(3-methoxy-6- methylbenzyl)-1-cyclohexene
MS (m/z) : 436 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.4-2.4 (6H, m), 2.41 (3H, s), 2.5- 2.8 (1H, m), 3.1-3.4 (2H, m), 3.74 (3H, s), 6.6-6.9
(3H, m), 7.04 (1H, t, J=8Hz), 7.2-7.8 (10H, m)
(2) 1-(4,5-Diphenyloxazol-2-yl)-6-(3-methoxy-4- methylbenzyl)-1-cyclohexene
MS (m/z) : 436 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.4-2.4 (6H, m), 2.17 (3H, s), 2.51 (1H, dd, J=10.0, 12.0Hz), 3.1-3.3 (2H, m), 3.78 (3H, s), 6.7-7.1 (4H, m), 7.2-7.8 (10H, m)
(3) 1-(4,5-Diphenyloxazol-2-yl)-6-(3-methoxy-2- methylbenzyl)-1-cyclohexene
MS (m/z) : 436 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.4-2.4 (6H, m), 2.41 (3H, s), 2.5- 2.8 (1H, m), 3.1-3.4 (2H, m), 3.74 (3H, s), 6.6-7.1 (4H, m), 7.2-7.8 (10H, m)
Preparation 44
The following compounds were obtained according to a similar manner to that of the first step of Example 24.
(1) 1-(4,5-Diphenyloxazol-2-yl)-6-(3-hydroxy-6- methylbenzyl)-1-cyclohexene
MS (m/z) : 422 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.4-2.4 (6H, m), 2.37 (3H, s), 2.58
(1H, dd, J=10.0, 13.6Hz), 3.1-3.3 (2H, m), 6.6-7.0 (4H, m), 7.2-7.8 (10H, m) (2) 1-(4,5-Diphenyloxazol-2-yl)-6-(3-hydroxy-4- methylbenzyl)-1-cyclohexene
MS (m/z) : 422 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.4-2.4 (6H, m), 2.22 (3H, s), 2.46
(1H, dd, J=10.0, 12.0Hz), 3.1-3.3 (2H, m), 6.6-7.0 (4H, m), 7.2-7.8 (10H, m)
(3) 1-(4,5-Diphenyloxazol-2-yl)-6-(3-hydroxy-2- methylbenzyl)-1-cyclohexene
MS (m/z) : 422 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 1.4-2.4 (6H, m), 2.44 (3H, s), 2.61
(1H, dd, J=4.0, 13.0Hz), 3.1-3.4 (2H, m), 6.62 (1H d, J=8Hz), 6.81 (1H, d, J=8.0Hz), 6.9-7.1 (2H, m),
7.2-7.8 (10H, m)
Preparation 45
(1) 2-[3-(2-Ethoxycarbonylethyl)benzyl]cyclohexanone was obtained from 2-[3-(2-ethoxycarbonylvinyl)benzyl]- cyclohexanone [which was obtained according to similar manners to those of Preparations 26 and 27] in a simila manner to that of Preparation 24.
MS (m/z) : 289 (M++1)
IR (Neat) : 1720, 1700 cm-1
NMR (CDCl3, δ) : 1.22 (3H, r, J=7Hz), 1.3-2.7 (14H, m), 2.92 (2H, t, J=8Hz), 3.20 (1H, dd, J=5.6, 10.6Hz), 4.12 (2H, q, J=8Hz), 6.9-7.1 (2H, m), 7.20 (1H, t, J=8Hz)
(2) 2-(3-Methoxy-6-phenylbenzyl)cyclohexanone was obtained according to similar manners to those of Preparations 26 and 27.
MS (m/z) : 295 (M++1)
IR (Neat) : 1700 cm-1 NMR (CDCl3, δ) : 1.0-2.6 (10H, m), 3.20 (1H, dd,
J=5.0, 9.8Hz), 3.78 (3H, s), 6.6-6.8 (2H, m), 7.1- 7.5 (5H, m) Preparation 46
1-(4,5-Diphenyloxazol-2-yl)-6-(3-methoxy-6-phenylbenzyl)-1-cyclohexene was obtained according to similar manners to those of Preparations 28 and 29.
MS (m/z) : 498 (M++1)
IR (Neat) : 1600 cm-1
NMR (CDCl3, δ) : 1.2-2.0 (4H, m), 2.0-2.2 (2H, m),
2.80 (1H, dd, J=11.2, 14.0Hz), 3.1-3.4 (2H, m), 3.80 (3H, s), 6.6-6.9 (3H, m), 7.1-7.5 (12H, m), 7.6-7.8 (4H, m)
Preparation 47
To a solution of 2-(4,5-diphenyloxazol-2-yl)pyrrolidine (0.6 g) and 5-tert-butyldiphenylsilyloxy-2-oxo-1,2,3,4-tetrahydronaphthalene (0.5 g) in a mixture of methanol (10 ml) and acetic acid (2 ml) was added NaBH3CN (250 mg) at room temperature. After being stirred for 2 hours at the same temperature, the mixture was poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 2-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-tert-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalen (0.84 g).
MS (m/z) : 676 (M+)
IR (Neat) : 1580 cm-1
NMR (CDCl3, δ) : 1.08 (9H, s), 1.5-2.4 (6H, m), 2.6- 3.3 (6H, m), 4.42 (1H, m), 6.10 (1H, m), 6.4-6.7 (2H, m), 7.2-7.8 (20H, m)
Preparation 48
To a solution of 2-(4,5-diphenyloxazol-2-yl)pyrrolidine (0.66 g) and 5-tert-butyldiphenylsilyloxy-1,2-epoxy-1,2,3,4- tetrahydronaphthalene (0.6 g) in tetrahydrofuran (10 ml) was added Ti[O-CH(CH3)2]4 (0.66 ml) at room temperature. After being stirred for 5 days at the same temperature, the mixture was poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[2-(4,5- diphenyloxazol-2-yl)pyrrolidin-1-yl]-2-hydroxy-5-tert- butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (0.31 g).
MS (m/z) : 691 (M+)
IR (Neat) : 3300 cm-1
NMR (CDCl3, δ) : 1.07 (9H, s), 1.7-2.4 (6H, m), 2.6- 3.3 (2H, m), 3.4-3.6 (2H, m), 4.1-4.4 (2H, m), 6.28 (1H, d, J=8.0Hz), 6.75 (1H, t, J=8.0Hz), 6.88 (1H, d, J=8.0Hz), 7.3-7.8 (20H, m)
Preparation 49
1-(2-Oxotetrahydrofuran-3-yl)-5-tert-butyldiphenylsilyloxy-3,4-dihydronaphthalene was obtained according to similar manners to those of Preparations 28 and 29.
MS (m/z) : 469 (M++1)
IR (Neat) : 1760 cm-1
NMR (CDCl3, δ) : 1.10 (9H, s), 2.1-2.8 (4H, m),
2.8-3.1 (2H, m), 3.73 (1H, m), 4.3-4.4 (2H, m),
6.04 (1H, m), 6.37 (1H, d, J=8Hz), 6.5-6.9 (2H, m), 7.2-7.8 (10H, m) Preparation 50
1-[2-(4,5-Diphenyloxazol-2-yl)-2-oxo-1-(2-hydroxyethyl)ethyl]-5-tert-butyldiphenylsilyloxy-3,4-dihydronaphthalene was obtained from 1-(2-oxotetrahydrofuran-3-yl)-5-tert-butyldiphenylsilyloxy-3,4-dihydronaphthalene in a conventional manner. MS (m/z) : 690 (M++1)
IR (Neat) : 3400, 1700 cm-1
NMR (CDCl3, δ) : 1.07 (9H, s), 2.0-2.5 (4H, m), 2.90 (2H, t, J=8.0Hz), 3.71 (2H, t, J=6.0Hz), 5.0-5.2 (1H, m), 6.06 (1H, t, J=4.6Hz), 6.41 (1H, d,
J=8.0Hz), 6.83 (1H, t, J=8.0Hz), 7.2-7.8 (21H, m)
Preparation 51
1-[2-(4,5-Diphenyloxazol-2-yl)-2-hydroxy-1-(2- hydroxyethyl)ethyl]-5-tert-butyldiphenylsilyloxy-3,4- dihydronaphthalene was obtained by treating 1-[2-(4,5- diphenyloxazol-2-yl)-2-oxo-1-(2-hydroxyethyl)ethyl]-5-tert-butyldiphenylsilyloxy-3,4-dihydronaphthalene with NaBH4.
MS (m/z) : 692 (M++1)
IR (Neat) : 3300 cm-1
NMR (CDCl3, δ) : 1.07 (9H, s), 2.0-2.5 (4H, m),
2.7-3.2 (2H, m), 3.6-3.9 (3H, m), 5.03 (1H, d, J=3.8Hz), 6.01 (1H, t, J=4.6Hz), 6.22 (1H, d, J=8.0Hz), 6.55 (1H, t, J=8.0Hz), 6.82 (1H, d, J=8Hz), 7.2-7.8 (20H, m)
Preparation 52
To a solution of 1-[2-(4,5-diphenyloxazol-2-yl)-2-hydroxy-1-(2-hydroxyethyl)ethyl]-5-tert-butyldiphenylsilyloxy-3,4-dihydronaphthalene (1.5 g) in tetrahydrofuran (30 ml) were added triphenylphosphine (1.8 g) and diethyl azodiformate (1.2 ml) at room temperature. After being stirred for 12 hours at the same temperature, the mixture was poured into the mixture of ethyl acetate and water. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[2-(4,5-diphenyloxazol-2-yl)tetrahydrofuran-3-yl]-5-tert-butyldiphenylsilyloxy-3,4-dihydronaphthalene (1.0 g).
MS (m/z) : 674 (M++1) IR (Neat) : 1580 cm-1
NMR (CDCl3, δ) : 1.07 (9H, s), 2.0-2.4 (3H, m), 2.6-3.1 (2H, m), 3.8-4.5 (4H, m), 5.47 (1H, d, J=8.0Hz), 5.93 (1H, m), 6.39 (1H, d, J=8.0Hz), 6.82 (1H, t, J=8.0Hz), 7.02 (1H, d, J=8Hz), 7.2-7.8 (10H, m)
Preparation 53
A mixture of 1-azido-5-t-butyldiphenylsilyloxy-1,2,3,4- tetrahydronaphthalene (2.2 g) and 10% Pd/C (0.5 g) in ethanol (120 ml) was stirred under H2 for 5 hours. The catalyst was filtered off and filtrate was evaporated in vacuo. The obtained oil and 2-formyl-4,5-diphenyloxazole (1.2 g) was dissolved in toluene (20 ml). After stirred for 12 hours at room temperature, the solvent was removed to obtain the imine compound. To a solution of ethyl acetate (1.1 ml) in THF (20 ml) was added LDA (7.4 ml, 1.5M solution in cyclohexane) at -78°C under N2, and then after 30 minutes, a solution of the above imine (1.0 g) in THF (10 ml) was added in the solution. After being stirred for 2 hours at the same temperature, the solution was allowed to the room temperature for 4 hours and poured into the mixture of ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3, and brine, dried over MgSO4, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 1-[4-(4,5-diphenyloxazol-2-yl)-2-oxoazetidin-1-yl]-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (420 mg).
MS (m/z) : 765 (M+)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.05 (9H, s), 1.8-2.9 (4H, m), 3.3- 3.6 (2H, m), 4.0-4.3 (2H, m), 4.6-5.2 (2H, m), 6.0- 6.4 (1H, m), 6.8-7.0 (1H, m), 7.1-7.8 (21H, m)
Preparation 54
The following compounds were obtained according to a similar manner to that of Preparation 5 (2).
(1 ) 1-[2-(4,5-Diphenyloxazol-2-.yl)azetidin-1-yl]-5-t- butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene MS (m/z) : 661 (M+)
NMR (CDCl3, δ) : 1.04 (9H, s), 1.6-3.0 (8H, m), 3.3- 3.8 (3H, m), 4.4-4.7 (1H, m), 6.2-6.9 (2H, m), 7.1- 7.8 (21H, m) (2) 1-[2-(4,5-Diphenyloxazol-2-yl)piperidin-1-yl]-5-t- butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene MS (m/z) : 689 (M+)
IR (Neat) : 1580 cm-1
NMR (CDCI3, δ) : 1.06 (9H, s), 1.4-2.4 (10H, m),
2.5-3.1 (4H, m), 3.50-4.2 (2H, m), 6.15, 6.25 (1H, each d, J=8Hz), 6.53, 6.76 (1H, each d, J=8Hz), 7.1-7.8 (21H, m)
Preparation 55
2-Vinyl-4,5-diphenyloxazole was obtained according to a similar manner to that of Preparation 10.
MS (m/z) : 248 (M++1)
IR (Neat) : 1460 cm-1
NMR (CDCI3, δ) : 5.65 (1H, d, J=11.2Hz), 6.25 (1H, d, J=17.6Hz), 6.67 (1H, dd, J=11.2, 17.6Hz), 7.2-7.7
(10H, m)
Preparation 56
A solution of AD-mix-β (trade name, Aldrich) (114 g) in a mixture of t-butyl alcohol (400 ml) and water (400 ml) was stirred for 1 hour, and then methanesulfonamide (7.6 g) and 2-vinyl-4,5-diphenyloxazole (20 g) was added to the solution at 0°C. After being stirred for 8 hours at the same
temperature, sodium sulfite (50 g) was added, and the mixture was stirred for 30 minutes. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO3, and brine, dried over MgSO4, and evaporated in vacuo. The residue was
purified by trituration with hexane-ether to afford 2-((1S)-1,2-dihydroxyethyl)-4,5-diphenyloxazole (21 g).
MS (m/z) : 282 (M++1)
IR (Neat) : 3400 cm-1
NMR (CDCl3, δ) : 4.03 (1H, d, J=4.6Hz), 4.90 (1H, t,
J=4.6Hz), 7.2-7.6 (10H, m)
Preparation 57
To a solution of 2-((1S)-1,2-dihydroxyethyl)-4,5-diphenyloxazole (20 g) in CH2Cl2 (400 ml) were added
orthoacetic acid trimethyl ester (12.8 ml) and
p-toluenesulfonic acid (130 mg) at room temperature under N2. After being stirred for 30 minutes, the solvent was
evaporated in vacuo. The residue was diluted with CH2Cl2 (200 ml) and acetyl bromide (7.6 ml) was added to the
solution at 0°C under N2- After being stirred for 2 hours at room temperature, the solvent was evaporated in vacuo, the residue was diluted with methanol (200 ml), and K2CO3 (16 g) was added to the solution at 0°C. The mixture was stirred for 30 minutes at the same temperature and partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, water, sat. NaHCO3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by trituration with ether-hexane to give (2S)-2-(4,5-diphenyloxazol-2-yl)oxirane (14.2 g).
MS (m/z) : 264 (M++1)
IR (Neat) : 1460 cm-1
NMR (CDCl3, δ) : 3.23 (1H, dd, J=4.0, 5.6Hz), 3.43
(1H, dd, J=2.6, 5.6Hz), 4.08 (1H, dd, J=2.6,
4.0Hz), 7.2-7.6 (10H, m)
HPLC; chiralcel OD, 10% isopropanol/hexane, 11.3 ml/min Preparation 58
To a solution of (2S)-2-(4,5-diphenyloxazol-2-yl)oxirane (12 g) and Cul (0.19 g) in THF (240 ml) was dropwise added a solution of vinylmagnesium chloride in THF (1.0M solution, 101 ml) at -78°C under N2. The mixture was stirred for 1 hour at room temperature and partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, water, sat. NaHCO3 and brine. The dried solvent was
evaporated in vacuo and the residue was purified by
chromatography on silica gel to give (4S)-4-(4,5-diphenyloxazol-2-yl)-4-hydroxy-1-butene (9.2 g).
MS (m/z) : 292 (M++1)
IR (Nujol) : 3300, 1600 cm-1
NMR (CDCl3, δ) : 2.7-2.9 (2H, m), 3.17 (1H, d,
J=5.8Hz), 4.8-5.0 (1H, m), 5.1-5.3 (2H, m), 5.8-6.0
(1H, m), 7.2-7.8 (10H, m)
Preparation. 59
To a solution of (4S)-4-(4,5-diphenyloxazol-2-yl)-4-hydroxy-1-butene (9.2 g) in THF (100 ml) were added
phthalimide (7.0 g) and triphenylphosphine (12.5 g) and diethyl azodiformate (7.5 ml) at room temperature. The mixture was stirred for 2 hours at room temperature and partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, water, sat. NaHCO3 and brine.
The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (4R)-4-(4,5-diphenyloxazol-2-yl)-4-phthalimido-1-butene (9.7 g).
MS (m/z) : 421 (M++1)
IR (Nujol) : 1760, 1710 cm-1
NMR (CDCl3, δ) : 3.1-3.4 (2H, m), 5.0-5.3 (2H, m),
5.63 (1H, dd, J=6.0, 10.0Hz), 5.7-6.0 (1H, m), 7.2- 8.0 (14H, m)
HPLC; chiralcel OD, 10% isopropanol/hexane, 32.2 ml/min Preparation 60
(4R)-4-(4,5-Diphenyloxazol-2-yl)-4-benzyloxycarbonylamino-1-butene was obtained according to similar manners to those of Preparations 82 and 103.
MS (m/z) : 425 (M++1)
IR (Nujol) : 3300, 1710 cm-1
NMR (CDCl3, δ) : 2.75 (1H, m), 5.0-5.3 (5H, m),
5.5-6.0 (2H, m), 7.2-7.7 (15H, m) HPLC; chiralcel OD, 5% isopropanol/hexane, 12.9 ml/min
Preparation 61
To a solution of (4R)-4-(4,5-diphenyloxazol-2-yl)-4-benzyloxycarbonylamino-1-butene (5.2 g) in THF (50 ml) was added 9-borabicyclo[3.3.1]nonane (9-BBN) (98 ml, 0.5M
solution of THF) at 0°C. After stirred for 4 hours at room temperature, 2N NaOH solution (20 ml) and 35% H2O2 solution (20 ml) were added to the mixture at the 0°C. The mixture was stirred for 1 hour at the same temperature and
partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, water, sat. NaHCO3 and brine.
The dried solvent was evaporated in vacuo and the residue was purified by chromatogaphy on silica gel to give (1R)-N-benzyloxycarbonyl-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butylamine (13 g).
MS (m/z) : 443 (M++1)
IR (Neat) : 3300, 1700 cm-1
NMR (CDCl3, δ) : 1.6-2.2 (4H, m), 3.68 (2H, m), 5.10- 5.2 (1H, m), 5.14 (2H, s), 5.73 (1H, d, J=10.0Hz), 7.2-7.7 (15H, m)
Preparation 62
A suspension of methyl 3-hydroxybenzoate (25.0 g), benzyl bromide (19.5 ml), and K2CO3 (31.73 g) in N,N-dimethylformamide (150 ml) was stirred under ice cooling for 1 hour and at room temperature for 15 hours and partitioned between water and ethyl acetate. The organic layer was separated, washed with water (three times) and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to methyl 3-benzyloxybenzoate (38.90 g) as colorless crystals.
(+) APCI-MS (m/z) : 243 (M++1)
mp : 72.3-75.1°C
IR (Nujol) : 1710, 1235 cm-1
NMR (CDCl3, δ) : 3.91 (3H, s), 5.10 (2H, s),
7.17-7.67 (9H, m)
Preparation 63
A solution of methyl 3-benzyloxybenzoate (38.0 g) and 5N NaOH solution (207 ml) in 1, 2-dimethoxyethane (207 ml) was stirred at room temperature for 3 hours 30 minutes and at
100ºC for 1 hour 20 minutes. The reaction mixture was cooled with ice water, mixed with 6N HCl (1.1 mole), and extracted with diethyl ether. The extract was washed with brine, dried over MgSO4, and evaporated in vacuo to afford 3-benzyloxybenzoic acid (34.96 g) as a colorless powder.
(-) APCI-MS (m/z) : 227 (M+-1)
mp : 134.1-135.8°C
IR (Nujol) : 2700-2150, 1680, 1250 cm-1
NMR (CDCI3, δ) : 5.12 (2H, s), 7.19-7.49 (7H, m),
7.71-7.76 (2H, m)
Preparation 64
Triethylamine (3.36 ml) was added to a stirred solution of 3-benzyloxybenzoic acid (5.0 g) and isobutyl chloroformate (3.13 ml) in THF (67 ml) under ice-cooling and the resulting mixture was stirred at the same temperature for 1 hour.
A solution of 2-piperidinecarboxylic acid (4.14 g) and NaHCO3 (3.32 g) in water (40 ml) was added dropwise to the stirred mixture at the same temperature and the mixture was stirred at the same temperature for 2 hours and at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and 1N HCl. The organic layer was separated, washed with 1N HCl (twice) and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford 1-(3-benzyloxybenzoyl)-2-piperidinecarboxylic acid (2.01 g) as a amorphous powder.
(+) APCI-MS (m/z) : 340 (M++1)
IR (Nujol) : 2590, 1710, 1595, 1575, 1230 cm-1 Preparation 65
Sodium (54 mg) was dissolved in ethanol (8.0 ml), and then 1-(3-benzyloxybenzoyl)-2-piperidinecarboxylic acid (665 mg), cone, sulfuric acid (1 drop), and desyl bromide (539 mg) was successively dissolved thereto. The resulting mixture was stirred at 70°C for 2 days, cooled to room temperature, and partitioned between ethyl acetate and 1N HCl. The organic layer was washed with 1N HCl, aqueous sodium
bicarbonate, and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford 2-oxo-1,2-diphenylethyl 1-(3-benzyloxybenzoyl)-2-piperidinecarboxylate (297 mg) as a pale yellow oil.
(+) APCI-MS (m/z) : 534 (M++1)
IR (Nujol) : 1735, 1690, 1630, 1225 cm-1 Preparation 66
A mixture of 2-oxo-1,2-diphenylethyl 1-(3-benzyloxybenzoyl)-2-piperidinecarboxylate (288 mg) and ammonium acetate (427 mg) in acetic acid (1.4 ml) was stirred under reflux for 3 hours, cooled to room temperature, and partitioned between ethyl acetate and aqueous NaHCO3. The organic layer was washed with aqueous NaHCO3 (twice) and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford 1-(3-benzyloxybenzoyl)-2-(4,5-diphenyl-2-oxazolyl)piperidine (104 mg) as amorphous powder. (+ ) APCI-MS (m/z ) : 515 (M++1 )
IR (Nuj ol ) : 1630 cm- 1
NMR (CDCl3, δ ) : 1 . 45-2 . 05 ( 6H, m), 2 . 4-3 . 75 (2H, m), 4 . 7-5 .25 ( 3H, m), 7 . 01-7 . 37 ( 15H, m), 7 . 57-7 . 67 ( 4K, m)
Preparation 67
A mixture of 1-(3-benzyloxybenzoyl)-2-(4,5-diphenyl-2- oxazolyl)piperidine (95 mg) and 10% Pd-C (501 wet, 15 mg) in ethyl acetate (3 ml) - 10% methanolic hydrogen chloride was stirred in the presence of atmospheric H2 gas at room temperature for 7 hours and filtered. The filtrate was evaporated in vacuo to afford 1-(3-hydroxybenzoyl)-2-(4,5- diphenyl-2-oxazolyl)piperidine (100 mg) as a crude oil.
Preparation 68
A mixture of 3-[3-(tert-butyldiphenylsilyloxy)phenyl]-1- (4,5-diphenyl-2-oxazolyl)-1-propanone (526 mg), ethyl bromoacetate (1.61 g), and K2CO3 (1.34 g) in N,N-dimethylformamide (2.0 ml) was stirred at room temperature for 5 hours and poured into ethyl acetate - water. The organic layer was separated, washed with water (three times) and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford ethyl 3-[3-(tert-butyldiphenylsilyloxy)benzyl]-4-(4,5-diphenyl-2-oxazolyl)-4-oxobutyrate (436 mg) as an oil.
(+) APCI-MS (m/z) : 694 (M++1)
IR (Nujol) : 1740, 1700, 1600, 1580 cm-1 Preparation 69
NaBH4 (119 mg) was added to a stirred solution of ethyl 3-[3-(tert-butyldiphenylsilyloxy)benzyl]-4-(4,5-diphenyl-2-oxazolyl)-4-oxobutyrate (430 mg) in methanol (2.0 ml) and 1,2-dimethoxyethane (0.5 ml) at room temperature and the resulting mixture was stirred at the same temperature for 3 hours. The reaction mixture was partitioned between ethyl acetate - 1N hydrochloric acid. The organic layer was washed with 1N hydrochloric acid, aqueous sodium bicarbonate, and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford 3-[3- (tert-butyldiphenylsilyloxy)benzyl]-2-(4,5-diphenyl-2-oxazolyl)-5-oxotetrahydrofuran (366 mg) as an amorphous powder.
NMR (CDCl3, δ) : 1.08 and 1.09 (9H, each s), 1.40-1.62 (1H, m), 2.31-2.97 (2H, m), 3.48-3.88 (2H, m), 4.58 and 4.80 (1H, each m), 6.54-7.05 (2H, m), 7.32-7.73 (22H, m)
Preparation 70
A 1.0M solution of tetrabutylammonium fluoride in tetrahydrofuran (THF) (0.75 ml) was added to a solution of 3-[3-(tert-butyldiphenylsilyloxy)benzyl]-2-(4,5-diphenyl-2-oxazolyl)-5-oxotetrahydrofuran (0.26 g) in THF (0.75 ml) at room temperature. The resulting mixture was stirred at the same temperature for 5 hours and partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford
2-(4,5-diphenyl-2-oxazolyl)-3-(3-hydroxybenzyl)-5-oxotetrahydrofuran (133 mg) as a colorless oil.
(+) APCI-MS (m/z) : 412 (M++1)
IR (Nujol) : 3340, 1770, 1590 cm-1
NMR (CDCl3, δ) : 2.30-3.26 (4H, m), 3.35-3.47 (1H, m), 5.22 and 5.31 (1H, each d, J=18.2 and 6.1Hz, respectively), 6.53-6.68 (2H, m), 7.12-7.65 (13H, m)
Preparation 71
A solution of ethyl 2-piperidinecarboxylate (10.0 ml), 3-methoxybenzyl chloride (9.2 ml), and triethylamine (26.6 ml) in N,N-dimethylformamide (64.0 ml) was stirred at room temperature overnight and partitioned between ethyl acetate and water. The organic layer was separated, washed with water (four times) and brine, dried over MgSO4, and
evaporated in vacuo. The residue was chromatographed over silica gel to afford ethyl 1-(3-methoxybenzyl)-2-piperidinecarboxylate (12.06 g) as a colorless oil.
(+) APCI-MS (m/z) : 278 (M++1)
IR (Film) : 1725, 1600, 1260 cm-1
NMR (CDCl3, δ) : 1.29 (3H, t, J=7.1Hz), 1.50-1.85 (6H, m), 2.10-2.22 (1H, m), 2.88-3.00 (1H, m), 3.14 (1H, dd, J=6.8, 5.2Hz), 3.40 (1H, d, J=13.4Hz), 3.78 (1H, d, J=13.4Hz), 3.81 (3H, s), 4.21 (2H, q, J=7.1Hz), 6.77-6.82 (1H, m), 6.89-6.93 (2H, m), 7.17-7.27 (1H, m)
Preparation 72
A solution of ethyl 1-(3-methoxybenzyl)-2-piperidinecarboxylate (3.0 g) and 1N NaOH (21.6 ml) in ethanol (31.6 ml) was stirred at 70°C overnight. The
reaction mixture was cooled to room temperature, acidified with 1N hydrochloric acid, and evaporated in vacuo. The residue was extracted with methylene chloride and the extract was evaporated in vacuo to afford 1-(3-methoxybenzyl)-2-piperidinecarboxylic acid (2.64 g) as an amorphous powder.
(+) APCI-MS (m/z) : 250 (M++1)
mp : 186.0-187.3°C
IR (Film) : 1600, 1265 cm-1
NMR (CDCl3, δ) : 1.3-1.85 (6H, m), 2.2-2.3 (1H, m), 2.86-2.93 (1H, m), 3.09 (1H, dd, J=7.6, 4.3Hz),
3.52 (1H, d, J=13.4Hz), 3.74 (3H, s), 3.87 (1H, d, J=13.4Hz), 6.81-6.93 (3H, m), 7.24 (1H, d, J=8.0Hz)
Preparation 73
2-Oxo-1,2-diphenylethyl 1-(3-methoxybenzyl)-2- piperidinecarboxylate was prepared from 1-(3-methoxybenzyl)-2-piperidinecarboxylic acid and desyl bromide in a similar manner to that of Preparation 65.
(+) APCI-MS (m/z) : 444 (M++1)
IR (Film) : 1730, 1690, 1260 cm-1
Preparation 74
2-(4,5-Diphenyl-2-oxazolyl)-1-(3-methoxybenzyl)-piperidine was prepared from 2-oxo-1,2-diphenylethyl 1-(3-methoxybenzyl)-2-piperidinecarboxylate in a similar manner to that of Preparation 66.
(+) APCI-MS (m/z) : 425 (M++1), 424
mp : 72.2-86.6°C
IR (Film) : 1600, 1260 cm-1
NMR (CDCl3, δ) : 1.22-1.86 (6H, m), 2.04-2.23 (1H, m),
3.01-3.08 (1H, m), 3.20 (1H, d, J=13.9Hz), 3.62 (1H, dd, J=10.8, 3.0Hz), 3.75 (3H, s), 3.76 (1H, d, J=13.9Hz), 6.73-6.78 (1H, m), 6.84-6.89 (2H, m), 7.16-7.37 (9H, m), 7.60 (2H, dd, J=7.8, 1.4Hz)
Preparation 75
A 1.0M solution of boron tribromide in methylene chloride (2.08 ml) was added dropwise to a solution of 2- (4,5-diphenyl-2-oxazolyl)-1-(3-methoxybenzyl)piperidine (440 mg) in methylene chloride (2.5 ml) under ice cooling. The resulting mixture was stirred at the same temperature for 3 hours and partitioned between ethyl acetate and aqueous sodium bicarbonate. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford 2-(4,5-diphenyl-2-oxazolyl)-1-(3-hydroxybenzyl)piperidine (388 mg) as a pale yellow powder.
FABMS (m/z) : 410 (M+)
mp : 204.7-208.3°C
IR (Film) : 1600, 1585, 1255 cm-1 NMR (CDCl3, δ) : 1.2-1.95 (6H, m), 2.0-2.25 (1H, m), 3.05-3.11 (1H, m), 3.25-3.37 (1H, m), 3.73-3.81 (2H, m), 6.71-6.83 (3H, m), 7.13 (1H, t, J=7.7Hz), 7.25-7.48 (11H, m)
Preparation 76
2-Oxo-1,2-diphenylethyl 2-oxo-5-pyrrolidinecarboxylate was prepared from 2-oxo-5-pyrrolidinecarboxylic acid in a similar manner to that of Preparation 65.
(+) APCI-MS (m/z) : 324 (M++1)
mp : 123.2-131.4°C
IR (Nujol) : 3350, 3190, 1730, 1700, 1675 cm-1
NMR (CDCI3, δ) : 2.25-2.64 (4H, m), 4.35-4.45 (1H, m), 6.10 (1H, br d, J=11.4Hz), 6.89 (1H, s), 7.26-7.53 (10H, m)
Preparation 77
2-(5-Imino-2-pyrrolidinyl)-4,5-diphenyloxazole was prepared from 2-oxo-1,2-diphenylethyl 2-oxo-5-pyrrolidine- carboxylate in a similar manner to that of Preparation 66.
(+) APCI-MS (m/z) : 304 (M++1)
IR (Nujol) : 3370, 1670 cm-1
NMR (CDCI3, δ) : 2.2-2.6 (4H, m), 4.94 (1H, m),
6.99 (1H, s), 7.26-7.50 (10H, m)
Preparation 78
60% Sodium hydride (289 mg) was added to a stirred solution of 2-(5-imino-2-pyrrolidinyl)-4,5-diphenyloxazole (2.0 g) in N,N-dimethylformamide (20.0 ml) in the presence of an atmospheric N2 gas under ice cooling and the resulting mixture was stirred at the same temperature for 20 minutes and at room temperature for 1 hour 20 minutes.
3-Methoxybenzyl chloride (1.72 g) was added to the mixture under ice cooling and stirring was continued at room
temperature overnight. The reaction mixture was partitioned between 1N hydrochloric acid and ethyl acetate. The organic layer was separated, washed with water and aqueous sodium bicarbonate, dried over MgSO4, and evaporated in vacuo. The oily residue was chromatographed to afford 2-[5-imino-1-(3-methoxybenzyl)-2-pyrrolidinyl]-4,5-diphenyloxazole (1.80 g) as an amorphous powder.
(+) APCI-MS (m/z) : 424 (M++1)
IR (Nujol) : 3400-3180, 1675, 1255 cm-1
NMR (CDCl3, δ) : 2.23-2.67 (4H, m), 3.75 (3H, s),
4.68-4.75 (1H, m), 4.98 (2H, s), 6.02 (1H, br s),
6.49-6.55 (2H, m), 6.78-6.84 (1H, m), 7.15-7.51 (11H, m)
Preparation 79
2-[1-(3-Hydroxybenzyl)-5-imino-2-pyrrolidinyl]-4,5-diphenyloxazole was prepared from 2-[5-imino-1-(3-methoxybenzyl)-2-pyrrolidinyl]-4,5-diphenyloxazole in a similar manner to that of Preparation 75.
(+) APCI-MS (m/z) : 410 (M++1)
IR (Nujol) : 3150, 1665 cm-1
NMR (DMSO-d6, δ) : 2.14-2.40 (4H, m), 4.66-4.73 (1H, m), 4.87 (1H, d, J=17.2Hz), 5.12 (1H, d, J=17.2Hz), 6.32-6.40 (2H, m), 6.59-6.65 (1H, m), 7.04-7.47 (11H, m), 7.99 (1H, s), 9.45 (1H, s)
Preparation 80
To a solution of N-phthaloyl-β-alanine (207 g) in THF (10 ml) was added SOCl2 at 0°C. After being stirred for 2 hours at room temperature, the solvent was evaporated in vacuo. The residue was diluted with THF (10 ml), and benzoin (2.01 g) and pyridine (2 ml) were added to the solution at 0°C. After being stirred for 4 hours at room temperature, the solvent was evaporated in vacuo, and the residue was partitioned between ethyl acetate and 1N-HCl solution. The organic layer was washed with water and brine, dried over MgSO4, and evaporated in vacuo. The obtained compound and CH3COONH4 (15.09 g) were dissolved in acetic acid (100 ml) and the mixture was stirred for 8 hours at 100°C. After the solvent was removed, the residue was partitioned between ethyl acetate and sat. NaHCO3. The organic layer was washed with water and brine. The dried solvent was evaporated in vacuo and the residue was triturated with Et2O to give N-phthaloyl-2-(4,5-diphenyloxazol-2-yl)ethylamine (2.84 g).
MS (m/z) : 395 (M++1)
IR (Nujol) : 1715, 1770 cm-1
NMR (DMSO-d6, δ) : 3.21 (2H, t, J=6.8Hz), 4.03 (2H, t, J=6.8Hz), 7.32-7.44 (10H, m), 7.82-7.93 (4H, m)
Preparation 81
The following compound was obtained according to a similar manner to that of Preparation 80.
N-Phthaloyl-1-(4,5-diphenyloxazol-2-yl)ethylamine
MS (m/z) : 395 (M++1)
IR (Nujol) : 1700, 1770 cm-1
NMR (DMSO-d6, δ) : 1.88 (3H, d, J=7.1Hz), 5.69 (1H, q, J=7.1Hz), 7.37-7.57 (10H, m), 7.87-7.97 (4H, m)
Preparation 82
To a solution of N-phthaloyl-2-(4,5-diphenyloxazol-2-yl)ethylamine (0.55 g) in DMF (5 ml) was added aqueous methylamine solution (7 ml). After being stirred for 3.5 hours at room temperature, the solution was partitioned between ethyl acetate and sat. NaHCO3. The organic layer was washed three times with 1N-HCl. To the acidic aqueous layer was added powdered NaHCO3. The aqueous layer was extracted with ethyl acetate. The dried organic solvent was evaporated in vacuo, and the residue was triturated with Et2O-n-hexane to give 2-(4,5-diphenyloxazol-2-yl)ethylamine (0.33 g).
MS (m/z) : 265 (M++1) NMR (CDCl3, δ) : 3.32 (2H, t, J=5.9Hz), 3.52 (2H, t, J=5.9Hz), 5.60 (2H, br), 7.25-7.50 (6H, m), 7.55- 7.70 (4H, m) Preparation 83
The following compound was obtained according to a similar manner to that of Preparation 82.
1-(4,5-Diphenyloxazol-2-yl)ethylamine
MS (m/z) : 265 (M++1)
NMR (CDCI3, δ) : 1.59 (3H, d, J=6.9Hz), 4.25 (1H, q, J=6.9Hz), 7.30-7.42 (6H, m), 7.56-7.68 (4H, m)
Preparation 84
A solution of 5-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalene (0.67 g), 1-(4,5-diphenyloxazol-2-yl)ethylamine (0.98 g) and p-toluenesulfonic acid (catalytic amount) in toluene (30 ml) was refluxed for 7 hours with Dean-stark equipment. The solution was evaporated in vacuo and methanol (MeOH) (10 ml) was added to the residue. To the MeOH solution, NaBH4 (0.21 g) was added at 0°C. After being stirred for 2 hours at room temperature, the solution was evaporated in vacuo. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was evaporated in vacuo, and the residue was purified by chromatography on silica gel to give 1-[1-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-methoxynaphthalene (0.73 g).
MS (m/z) : 425 (M++1)
NMR (CDCI3, δ) : 1.60 (3H, d, J=6.8Hz), 1.60-2.08 (6H, m), 2.42-2.86 (2H, m), 3.80 (1.5H, s), 3.81 (0.5H, q, J=6.8Hz), 3.82 (1.5H, s), 3.90 (0.5H, m), 4.29 (0.5H, q, J=6.8Hz), 4.77 (0.5H, m), 6.73 (1H, m), 7.00-7.20 (2H, m), 7.33-7.39 (6H, m), 7.57-7.68 (4H, m) Preparation 85
To a solution of 1-[1-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-methoxynaphthalene (0.33 g) in CH2Cl2 (7 ml) was added 1M BBr3-CH2Cl2 solution (1.5 ml) at 0°C. After being stirred for 3 hours at the same temperature, the solvent was evaporated in vacuo. The residue was partitioned between ethyl acetate and sat.
NaHCO3. The organic layer was washed with water and brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-[1-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-hydroxynaphthalene (0.23 g).
MS (m/z) : 411 (M++1)
NMR (CDCl3, δ) : 1.57 (3H, d, J=6.8Hz), 1.84-2.20 (4H, m), 2.44-2.86 (2H, m), 3.89 (0.5H, m), 4.12 (0.5H, q, J=6.8Hz), 4.29 (0.5H, q, J=6.8Hz), 4.78 (0.5H, m), 6.62-6.72 (1H, m), 6.97-7.14 (2H, m), 7.32-7.41 (6H, m), 7.58-7.68 (4H, m) Preparation 86
A solution of 5-(t-butyldiphenylsilyloxy)-1-oxo-1,2,3,4-tetrahydronaphthalene (0.52 g), 2-(4,5-diphenyloxazol-2-yl)ethylamine (0.33 g) and p-toluenesulfonic acid (catalytic amount) in toluene (30 ml) was refluxed for 15 hours with Dean-stark equipment. The solution was evaporated in vacuo and MeOH (10 ml) was added to the residue. To the MeOH solution, NaBH4 (0.21 g) was added at 0°C. After being stirred for 30 minutes at room temperature, the solution was evaporated in vacuo. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was evaporated in vacuo, and the residue was purified by chromatography on silica gel to give 1-[2-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-(t-butyldiphenylsilyloxy)naphthalene (0.25 g) and 1-[2-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5- hydroxynaphthalene (0.11 g). To a solution of 1-[2-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-(t-butyldiphenylsilyloxy)naphthalene (0.25 g) in THF (2 ml) was added 1M-THF solution (2 ml) of tetra-n-butyl ammonium fluoride (TBAF). After being stirred for 1 hour at room temperature, the reaction mixture was partitioned between ethyl acetate and sat. NaHCO3. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-[2-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-hydroxynaphthalene (0.06 g).
MS (m/z) : 411 (M++1)
NMR (CDCl3, δ) : 1.65-2.10 (4H, m), 2.38-2.85 (2H, m), 3.12 (2H, t, J=5.9Hz), 3.22 (2H, t, J=5.9Hz), 6.60- 6.79 (1H, m), 6.89-7.12 (2H, m), 7.20-7.42 (6H, m),
7.52-7.75 (4H, m)
Preparation 87
A solution of 1,2,3,4-tetrahydro-5-methoxy-1-naphthalenamine (0.34 g), (4,5-diphenyloxazol-2-yl)methyl bromide (0.50 g) and potassium carbonate (0.60 g) in DMF (7 ml) was stirred for 5 hours at room temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was
evaporated in vacuo. The residue was purified by
chromatography on silica gel to give 1-[(4,5-diphenyloxazol-2-yl)methylamino]-1,2,3,4-tetrahydro-5-methoxynaphthalene (0.50 g).
MS (m/z) : 411 (M++1)
NMR (CDCl3, δ) : 1.64-2.12 (4K, m), 2.38-2.92 (2H, m),
3.81 (3H, s), 3.94 (1H, m), 4.07 (2H, s), 6.73 (1H, d, J=7.9Hz), 7 .04 (1H, d, J=7.9Hz), 7.15 (1H, dd, J=7.9, 7.9Hz), 7.32-7.42 (6H, m), 7.58-7.69 (4H, m) Preparation 88 The following compound was obtained according to a similar manner to that of Example 30.
1-[N-methyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-1,2,3,4-tetrahydro-5-methoxynaphthalene
MS (m/z) : 425 (M++1)
NMR (CDCl3, δ) : 1.50-1.72 (2H, m), 1.96-2.18 (2H, m), 2.42 (3H, s), 2.40-2.62 (1H, m), 2.72-2.92 (1H, m), 3.83 (5H, s), 4.06 (1H, m), 6.70 (1H, d, J=8.1Hz), 7.16 (1H, dd, J=8.1, 8.1Hz), 7.28-7.42 (6H, m),
7.54 (1H, d, J=8.1Hz), 7.60-7.67 (4H, m)
Preparation 89
The following compounds were obtained according to a similar manner to that of Example 20.
(1) 1-Hydroxy-1,2,3,4-tetrahydro-5- methoxycarbonylmethoxynaphthalene
MS (m/z) : 219 (M+-OH)
NMR (CDCl3, δ) : 1.78-2.02 (4H, m), 2.60-2.72 (1H, m),
2.79-2.91 (1H, m), 3.80 (3H, s), 4.65 (2H, s), 4.77 (1H, m), 6.60-6.64 (1H, m), 7.09-7.20 (2H, m)
(2) 2,3-Dihydro-4-ethoxycarbonylmethoxy-1H-inden-1-ol
MS (m/z) : 219 (M+-OH)
IR (Nujol) : 3290, 3190, 1720 cm-1
NMR (CDCl3, δ) : 1.30 (3H, t, J=7.1Hz), 1.72 (1H, d, J=6.2Hz), 1.87-2.04 (1H, m), 2.43-2.60 (1H, m), 2.75-2.90 (1H, m), 3.03-3.18 (1H, m), 4.27 (2H, q, J=7.1Hz), 4.65 (2H, s), 5.25 (1H, q, J=6.2Hz), 6.65
(1H, d, J=7.9Hz), 7.08 (1H, d, J=7.9Hz), 7.20 (1H, dd, J=7.9, 7.9Hz)
Preparation 90
To a solution of NaH (60% oil, 28 mg), 5-(4,5- diphenyloxazol-2-yl)pyrrolidin-2-one (0.15 g) and sodium iodide (catalytic amount) in THF (1 ml) was added a solution of 3-methoxybenzyl chloride (0.11 g) in THF (2 ml). After being stirred for 4 days at room temperature, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by
chromatography on silica gel to give 1-(3-methoxybenzyl)-5-(4,5-diphenyloxazol-2-yl)pyrrolidin-2-one (0.14 g).
MS (m/z) : 425 (M++1)
NMR (CDCl3, δ) : 2.32-2.96 (4H, m), 3.65 (3H, s), 4.32 (1H, d, J=14.8Hz), 4.70 (1H, d, J=14.8Hz), 4.78 (1H, m), 6.68-6.82 (3H, m), 7.13 (1H, t, J=7.8Hz), 7.33-7.48 (6H, m), 7.56-7.61 (4H, m)
Preparation 91
The following compound was obtained according to a similar manner to that of Preparation 75. 1-(3-Hydroxybenzyl)-5-(4,5-diphenyloxazol-2-yl)pyrrolidin-2-one
MS (m/z) : 411 (M++1)
NMR (CDCl3, δ) : 2.18-2.98 (4H, m), 4.43 (1H, d,
J=14.7Hz), 4.56 (1H, d, J=14.7Hz), 5.02 (1H, m), 6.64 (1H, d, J=7.8Hz), 6.73 (1H, d, J=7.8Hz), 6.84
(1H, m), 7.04 (1H, t, J=7.8Hz), 7.35-7.42 (6H, m) , 7.57-7.59 (4H, m)
Preparation 92
The following compound was obtained according to a similar manner to that of Preparation 84.
2-Benzylamino-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene
FABMS (m/z) : 492 (M++1) NMR (CDCl3, δ) : 1.13 (9H, s), 1.50-1.80 (1H, m),
2.08-2.32 (1H, m), 2.52-3.24 (5H, m), 3.94 (2H, s), 6.23 (1H, d, J=7.5Hz), 6.61 (1H, d, J=7.5Hz), 6.68 (1H, dd, J=7.5, 7.5Hz), 7.28-7.39 (10H, m), 7.66- 7.74 (5H, m)
Preparation 93
A mixture of 2-benzylamino-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (3.15 g), ammonium formate (4.41 g) and Pd/C (0.15 g) in ethanol (EtOH) (40 ml) was refluxed for 3.5 hours. The insoluble material was filtered off and the solvent was evaporated in vacuo. The residue was partitioned between ethyl acetate and sat. NaHCO3. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by
chromatography on silica gel to give 2-amino-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (1.18 g).
FABMS (m/z) : 402 (M++1)
NMR (CDCl3, δ) : 1.10 (9H, s), 1.56-1.82 (1H, m),
2.05-2.35 (1H, m), 2.52-2.39 (5H, m), 6.24 (1H, d,
J=6.4Hz), 6.59-6.73 (2H, m), 7.32-7.42 (6H, m), 7.67-7.74 (4H, m)
Preparation 94
A solution of 2-amino-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene (0.96 g), (4,5-diphenyloxazol-2-yl)methyl bromide (0.80 g) and potassium carbonate (0.41 g) in DMF (14 ml) was stirred for 3.5 hours at room temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was evaporated in vacuo to give crude
2-[(4,5-diphenyloxazol-2-yl)methylamino]-1,2,3,4-tetrahydro-5-t-butyldiphenylsilyloxynaphthalene. To a solution of crude 2-[(4,5-diphenyloxazol-2-yl)methylamino]-1,2,3,4-tetrahydro-5-t-butyldiphenylsilyloxynaphthalene in THF (5 ml) was added 1M THF (3 ml) solution of tetrabutylammonium fluoride. After being stirred for 1 hour at room temperature, the mixture was partitioned between ethyl acetate and sat. NaHCO3. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by
chromatography on silica gel to give 2-[(4,5-diphenyloxazol-2-yl)methylamino]-1,2,3,4-tetrahydro-5-hydroxynaphthalene (0.66 g).
MS (m/z) : 397 (M++1)
NMR (CDCl3, δ) : 1.54-1.84 (2H, m), 2.08-2.22 (1H, m),
2.48-3.20 (5H, m), 4.13 (2H, s), 6.58 (1H, d,
J=7.8Hz), 6.68 (1H, d, J=7.8Hz), 6.99 (1H, dd, J=7.8, 7.8Hz), 7.34-7.40 (6H, m), 7.55-7.66 (4H, m) Preparation 95
A solution of 1-amino-2,3-dihydro-4-methoxy-1H-indene (0.30 g), 4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butan-1-one (0.56 g) and p-toluenesulfonic acid (catalytic amount) in toluene (50 ml) was refluxed for 2 days with Dean-stark equipment. The solvent was evaporated in vacuo and the residue was dissolved in methanol (10 ml). To the methanol solution was added NaBH4 (0.20 g) at 0°C. After being stirred for 1 hour at the same temperature, the solvent was evaporated in vacuo and the residue was partitioned between ethyl acetate and sat. NaHCO3. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-[[4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.27 g).
MS (m/z) : 455 (M++1)
NMR (CDCl3, δ) : 1.60-3.20 (10H, m), 3.76 (2.5H, s), 3.84 (3.5H, s), 4.02-4.52 (2H, m), 7.59-7.69 (4H, m), 6.69-7.39 (9H, m) Preparation 96 To a solution of 1-[[4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.27 g) in CH2Cl2 (5 ml) was added SOCl2 (1 ml) at 0°C. After being stirred for 17 hours at room temperature, the solvent was evaporated in vacuo and the residue was dissolved in DMF (5 ml). To the mixture was added K2CO3 (2.07 g). After being stirred for 1 day at room temperature, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was
evaporated in vacuo. The residue was purified by
chromatography on silica gel to give 1-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-2,3-dihydro-4-methoxy-1H-indene (0.15 g).
MS (m/z) : 437 (M++1)
NMR (CDCl3, δ) : 1.42-3.20 (10H, m), 3.74 (2.5H, s),
3.81 (3.5H, s), 4.02-4.76 (2H, m), 6.58-7.72 (13H, m)
Preparation 97
The following compound was obtained according to a similar manner to that of Preparation 95.
1-[[6-Hydroxy-1-(4,5-diphenyloxazol-2-yl)hexyl]amino]-2,3-dihydro-4-methoxy-1H-indene
MS (m/z) : 469 (M++1)
NMR (CDCl3, δ) : 1.40-3.20 (12H, m), 3.82 (3H, m), 4.15-4.94 (2H, m), 6.68-7.41 (9H, m), 7.57-7.69 (4H, m) Preparation 98
The following compound was obtained according to a similar manner to that of Preparation 96.
1-[2-(4,5-Diphenyloxazol-2-yl)piperidin-1-yl]-2,3-dihydro-4-methoxy-1H-indene MS (m/z ) : 451 (M++1 )
NMR (CDCl3, δ ) : 1 . 58-3 . 02 ( 12H, m), 3 . 77 ( 3H, s),
3 . 80 ( 3H, s), 4 . 07-4 . 44 (2H, m), 6 . 63-7 . 36 ( 9H, m), 7 . 36-7 . 70 ( 4H, m)
Preparation 99
To a solution of 4-hydroxy-1-[4,5-bis(4-methylphenyl)-oxazol-2-yl)butan-1-one (0.78 g) and triethylamine (2 ml) in DMSO (10 ml) was added a solution of pyridinesulfonic acid (1.16 g) in DMSO (4 ml) at room temperature. After being stirred for 20 minutes at the same temperature, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with 1M-HCl, water and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give 1-[4,5-bis(4-methylphenyl)oxazol-2-yl)butan-1,4-dione (0.22 g).
MS (m/z) : 334 (M++1)
IR (Nujol) : 1735, 1690 cm-1
NMR (CDCl3, δ) : 2.38 (3H, s), 2.40 (3H, s), 2.97 (2H, t, J=6.4Hz), 3.47 (2H, t, J=6.4Hz), 7.17-7.26 (4H, m), 7.53-7.59 (4H, m), 9.88 (1H, s)
Preparation 100
A solution of 1,2,3,4-tetrahydro-5-t-butyldiphenylsilyloxy-1-naphthaleneamine (0.21 g), 1-[4,5-bis(4-methyIphenyl)oxazol-2-yl)butan-1,4-dione (0.12 g), NaBH3CN (84 mg) and KOH (30 mg) in acetic acid (0.5 ml) and methanol (4 ml). After being stirred for 3 days at room temperature, the solvent was evaporated in vacuo. The residue was partitioned between ethyl acetate and sat.
NaHCO3. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-[2-[4,5-bis(4-methylphenyl)oxazol-2-yl]pyrrolidin-1-yl]-1,2,3,4-tetrahydro-5-t-butyldiphenylsilyloxynaphthalene (0.24 g). FABMS (m/z) : 702 (M+-1)
NMR (CDCl3, δ) : 1.08 (9H, s), 1.58-3.04 (12H, m),
2.34 (3H, s), 2.36 (3H, s), 6.18-7.80 (21H, m) Preparation 101
The following compound was obtained according to a similar manner to that of Preparation 70.
1-[2-[4,5-Bis(4-methylphenyl)oxazol-2-yl]pyrrolidin-1-yl]-1,2,3,4-tetrahydro-5-hydroxynaphthalene
MS (m/z) : 465 (M++1)
NMR (CDCl3, δ) : 1.46-3.00 (12H, m), 2.36 (6H, s),
3.86-4.70 (2H, m), 6.42-7.62 (11H, m) Preparation 102
To a solution of 1-(4,5-diphenyloxazol-2-yl)methylamino-2,3-dihydro-4-methoxy-1H-indene (0.13 g) in formic acid (5 ml) was added acetic anhydride (1 ml) at 0°C. After being stirred for 5 hours at room temperature, the solvent was evaporated in vacuo. The residue was partitioned between ethyl acetate and 1N hydrochloric acid. The organic layer was washed with water, sat. NaHCO3, and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give 1-[N-formyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.12 g).
MS (m/z) : 425 (M++1)
NMR (CDCl3, δ) : 8.52 (0.25H, s), 8.43 (0.75H, s),
7.60-7.40 (4H, m), 7.38-7.24 (6H, m), 7.18-6.95 (1H, m), 6.78-6.55 (2H, m), 6.18 (0.25H, m), 5.28
(0.75H, m), 4.72 (0.75H, d, J=16.2Hz), 4.51 (0.75H, d, J=16.2Hz), 4.12 (0.5H, m), 3.79 (2.25H, s), 3.72 (0.75H, s), 3.20-2.94 (1H, m), 2.92-2.66 (1H, m), 2.62-2.38 (1H, m), 2.35-2.05 (1H, m) Preparation 103
To a solution of 1-(4,5-diphenyloxazol-2-yl)methylamino-2,3-dihydro-4-methoxy-1H-indene (0.22 g) and pyridine (0.2 ml) in dichloromethane (5 ml) was added acetyl chloride (0.15 ml) at 0°C. The mixture was stirred for 1.5 hours at the same temperature and partitioned between ethyl acetate and IN hydrochloric acid. The organic layer was washed with water, sat. NaHCO3, and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give 1-[N-acetyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.08 g).
MS (m/z) : 439 (M++1)
IR (Nujol) : 1640 cm-1
NMR (CDCl3, δ) : 7.65-7.45 (4H, m), 7.40-7.20 (6H, m), 7.19-7.02 (1H, m), 6.82-6.60 (2H, m), 6.40 (0.5H, t, J=7.5Hz), 5.56 (0.5H, t, J=7.5Hz), 4.72 (0.5H, d, J=8.1Hz), 4.42 (1H, m), 4.19 (0.5H, d, J=8.1Hz), 3.81 (1.5H, s), 3.78 (1.5H, s), 2.37 (1.5H, s), 3.15-2.92 (1H, m), 2.90-2.64 (1H, m) , 2.62-2.42 (1H, m), 2.40-2.10 (1H, m) , 2.37 (1.5H. s), 2.35
(1.5H, s)
Preparation 104
To a solution of 1-[N-acetyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.40 g) in THF (10 ml) was added 1M solution of borane-THF complex in THF (9 ml) at room temperature. The reaction mixture was refluxed for 8 hours and cooled down to room temperature. 1N aqueous HCl solution (25 ml) was added to the reaction mixture. After being stirred for 1 hour at room temperature, the mixture was partitioned between ethyl acetate and 1N aqueous NaOH solution. The organic layer was washed with brine. The dried solvent was evaporated in vacuo to give 1- [N-ethyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene (0.47 g). MS (m/z) : 425 (M++1)
NMR (CDCl3, δ) : 7.66-7.58 (4H, m), 7.39-7.08 (8H, m), 6.70 (1H, d, J=7.7Hz), 4.67 (1H, t, J=7.6Hz), 3.81 (3H, s), 3.18-2.80 (2H, m), 2.73 (2H, q, J=7.2Hz), 2.35-1.84 (2H, m), 1.14 (3H, t, J=7.2Kz)
Preparation 105
To a solution of 4-methoxy-1-indanone (0.71 g) and isopropylamine (8 ml) in dichloromethane (10 ml) was added 1M solution of titanium(IV) chloride in dichloromethane (11 ml) at -60°C for 15 minutes. The reaction mixture was stirred for 3 hours at the same temperature. Methanol (15 ml) was added to the reaction mixture. After being stirred for 2 hours at room temperature, the solution was evaporated in vacuo. The residue was partitioned between ethyl acetate and 1N aqueous NaOH solution. The insoluble material was filtered off by zeolite. The organic layer was washed with brine. The dried solvent was evaporated in vacuo to give 1-isopropylamino-2,3-dihydro-4-methoxy-1H-indene (0.89 g).
MS (m/z) : 206 (M++1)
NMR (CDCl3, δ) : 7.18 (1H, dd, J=7.8, 7.8Hz), 6.97
(1H, d, J=7.8Hz), 6.71 (1H, d, J=7.8Hz), 4.30 (1H, t, J=6.7Hz), 3.83 (3H, s), 3.20-2.87 (2H, m), 2.80- 2.60 (1H, m), 2.50-2.35 (1H, m), 2.00-1.68 (1H, m), 1.13 (3H, d, J=6.9Hz), 1.12 (3H, d, J=6.9Hz)
Preparation 106
The following compound was obtained according to a similar manner to that of Preparation 17.
1-[N-isopropyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]-2,3-dihydro-4-methoxy-1H-indene
MS (m/z) : 439 (M++1)
NMR (CDCl3, δ) : 7.61-7.57 (4H, m), 7.50-7.20 ( 6H, m), 7.18-7.05 (2H, m), 6.85-6.60 (1H, m), 4.67 (1H, t, J=8.0Hz), 3.80 (3H, s), 3.83-3.78 (2H, m), 3.25- 2.85 (2H, m), 2.80-2.60 (1H, m), 2.28-2.00 (2H, m), 1.21 (3H, d, J=6.6Hz), 1.14 (3H, d, J=6.6Hz) Example 19
To a solution of 1-[2-[4,5-bis(4-methylphenyl)oxazol-2-yl]pyrrolidin-1-yl]-1,2,3,4-tetrahydro-5-hydroxynaphthalene (0.13 g) and ethyl bromoacetate (0.10 g) in DMF (5 ml) was added K2CO3 (0.13 g). After being stirred for 2 days at room temperature, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-[2-[4,5-bis(4-methylphenyl)oxazol-2-yl]pyrrolidin-1-yl]-1,2,3,4-tetrahydro-5-ethoxycarbonylmethoxynaphthalene (0.13 g).
MS (m/z) : 551 (M++1)
NMR (CDCl3, δ) : 1.18-1.40 (4H, m), 1.52-2.98 (18H,
m), 3.90-4.70 (6H, m), 6.34-7.60 (11H, m) Example 20
A solution of 1-(3-hydroxybenzyl)-5-(4,5-diphenyloxazol-2-yl)pyrrolidin-2-one (0.13 g), ethyl bromoacetate (0.21 g), potassium carbonate (99 mg) and potassium iodide (catalytic amount) in acetonitrile (10 ml) was refluxed for 9 hours.
The reaction mixture was partitioned between ethyl acetate and brine. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-(3-ethoxycarbonylmethoxybenzyl)-5-(4,5-diphenyloxazol-2-yl)pyrrolidin-2-one (0.16 g).
MS (m/z) : 497 (M++1)
NMR (CDCl3, δ) : 1.28 (3H, t, J=7.1Hz), 2.20-2.96 (4H, m) , 4.23 (2H, q, J=7.1Hz), 4.38 (1H, d, J=14.7Hz), 4.43 (2H, s), 4.70 (1H, d, J=14.7Hz), 4.76 (1H, m), 6.70-6.87 (3H, m), 7.15 (1H, t, J=7.8Hz), 7.33-7.56 (6H, m), 7.57-7.61 (4H, m)
Example 21
A solution of NaH (60% oil, 66 mg) and 1-[1-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-hydroxynaphthalene (0.55 g) in DMF (10 ml) was stirred for 30 minutes at room temperature. To the reaction mixture was added ethyl bromoacetate (0.26 g). After being stirred for 7 hours at room temperature, the solution was partitioned between ethyl acetate and sat. NaHCO3. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-[1-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-ethoxycarbonylmethoxynaphthalene (0.38 g).
MS (m/z) : 497 (M++1)
IR (Film) : 1740 cm-1
NMR (CDCl3, δ) : 1.29 (3H, t, J=7.1Hz), 1.60 (3H, t, J=6.6Hz), 1.70-1.85 (3H, m), 1.90-2.15 (1H, m), 2.44-2.98 (2H, m), 3.89 (1H, m), 4.24-4.31 (3H, m),
4.60 (2H, s), 6.55-6.60 (1H, m), 7.08-7.11 (2H, m), 7.32-7.40 (6H, m), 7.58-7.69 (4H, m)
Example 22
A mixture of 1-(3-hydroxybenzoyl)-2-(4,5-diphenyl-2-oxazolyl)piperidine (100 mg), ethyl bromoacetate (61 mg), and K2CO3 (84 mg) in acetonitrile (1.0 ml) was stirred at room temperature overnight and partitioned between water and ethyl acetate. The organic layer was separated, washed with water and brine, dried over MgSO4, and evaporated in vacuo. The residue was chromatographed over silica gel to afford 1-[3- (ethoxycarbonylmethoxy)benzoyl]-2-(4,5-diphenyl-2-oxazolyl)piperidine (90 mg) as a colorless oil. Example 23 The following compounds were obtained according to similar manners to those of Examples 19-22.
(1) Ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]-4-methylphenoxy]acetate
MS (m/z) : 508 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.4-2.6 (7H, m), 2.42 (3H, s), 3.1-3.3 (2H, m), 4.22 (2H, q, J=7Hz), 4.58 (2H, s), 6.63 (1H, d, J=8.0Hz), 6.8-7.0 (2H, m), 7.03 (1H, t, J=8Hz), 7.2-7.8 (11H, m)
(2) Ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]-6-methylphenoxy]acetate
MS (m/z) : 508 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.26 (3H, t, J=7Hz), 1.4-2.5 (6H, m), 2.22 (3H, s), 2.41 (1H, dd, J=10.0, 12.4Hz), 3.0- 3.3 (2H, m), 4.22 (2H, q, J=7Hz), 4.62 (2H, s), 6.7-7.2 (4H, m), 7.2-7.8 (11H, m)
(3) Ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]-2-methylphenoxy]acetate
MS (m/z) : 508 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 2.48 (3H, s), 2.61 (1H, dd,
J=12.0, 13.4Hz), 4.22 (2H, q, J=7Hz), 4.64 (2H, s), 6.58 (1H, d, J=8.0Hz), 6.8-7.0 (2H, m), 7.03 (1H, t, J=8Hz), 7.2-7.8 (11H, m)
(4) Ethyl [4-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]phenoxy]acetate
MS (m/z) : 494 (M++1)
IR (Neat) : 1740 cm-1 NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.6-2.0 (4H, m),
2.1-2.3 (2H, m), 2.50 (1H, dd, J=10, 13.2Hz), 3.0- 3.3 (2H, m), 4.22 (2H, q, J=7Hz), 4.58 (2H, s),
6.81 (2H, d, J=8.0Hz), 6.83 (1H, m), 7.2-7.8 (12H, m)
(5) 2-[1-[3-(Ethoxycarbonylmethoxy)benzyl]-5-imino-2- pyrrolidinyl]-4,5-diphenyloxazole
(+) APCI-MS (m/z) : 496 (M++1)
IR (Nujol) : 3400-3180, 1740, 1680 cm-1
NMR (CDCl3, δ) : 1.22 (3H, t, J=7.1Hz), 2.23-2.64 (4H, m), 4.22 (2H, q, J=7.1Hz), 4.55 (2H, s), 4.70-4.77 (1H, m), 5.00 (2H, s), 5.87 (1H, br s), 6.48 (1H, m), 6.57-6.62 (1H, m), 6.78-6.84 (1H, m), 7.13-7.52 (11H, m)
(6) 2-(4,5-Diphenyl-2-oxazolyl)-1-[3- (ethoxycarbonylmethoxy)benzyl]piperidine
FABMS (m/z) : 496 (M+)
mp : 56.6-65.0°C
IR (Film) : 1750, 1600, 1265 cm-1
NMR (CDCl3, δ) : 1.27 (3H, t, J=7.1Hz), 1.41-2.17 (7H, m), 2.99-3.05 (1H, m), 3.20 (1H, d, J=14.0Hz), 3.61 (1H, dd, J=10.7, 2.9Hz), 3.75 (1H, d, J=14.0Hz), 4.23 (2H, q, J=7.1Hz), 4.56 (2H, s), 6.71-6.76 (1H, m), 6.86-6.91 (2H, m), 7.15-7.36 (9H, m), 7.60 (2H, dd, J=7.9, 1.4Hz)
(7) 2-(4,5-Diphenyl-2-oxazolyl)-3-[3- (ethoxycarbonylmethoxy)benzyl]-5-oxotetrahydrofuran
(+) APCI-MS (m/z) : 498 (M++1)
IR (Film) : 1780, 1750, 1600, 1585, 1200 cm-1
NMR (CDCl3, δ) : 1.28 and 1.29 (3H, each t, J=7.1Hz), 2.35-3.03 (4H, m), 3.28-3.49 (1H, m), 4.25 (2H, q, J=7.1Hz), 4.53 (2H, s), 5.30 and 5.66 (1H, each d, J=5.9 and 7.7Hz, respectively), 6.69-6.85 (3H, m), 7.15-7.41 (7H, m), 7.53-7.66 (4H, m)
(8) 1-[2-(4,5-Diphenyloxazol-2-yl)ethylamino]-1,2,3,4- tetrahydro-5-methoxycarbonylmethoxynaphthalene
MS (m/z) : 483 (M++1)
NMR (CDCl3, δ) : 1.65-2.08 (4H, m), 2.56-2.92 (2H, m), 3.10 (2H, t, J=5.9Hz), 3.20 (2H, t, J=5.9Hz), 3.51 (1H, m), 3.84-3.90 (1H, m), 3.79 (3H, s), 4.62 (2H, s), 6.50-6.60 (1H, m), 7.00-7.14 (2H, m), 7.22-7.40
(6H, m), 7.48-7.68 (4H, m)
(9) 2-[(4,5-Diphenyloxazol-2-yl)methylamino]-1,2,3,4- tetrahydro-5-methoxycarbonylmethoxynaphthalene
MS (m/z) : 469 (M++1)
NMR (CDCl3, δ) : 1.52-1.80 (1H, m), 2.04-2.21 (1H, m), 2.58-2.81 (2H, m), 2.92-3.18 (3H, m), 3.79 (3H, s), 4.13 (2H, s), 4.63 (2H, s), 6.52 (1H, d, J=7.8Hz), 6.75 (1H, d, J=7.8Hz), 7.05 (1H, dd, J=7.8, 7.8Hz), 7.33-7.40 (6H, m), 7.56-7.66 (4H, m)
Example 24
To a solution of 1-(4,5-diphenyloxazol-2-yl)-8-(3-methoxybenzyl)-1-cyclooctene (3.0 g) in dichloromethane (80 ml) was added BBr3 (17 ml, 1M solution in dichloromethane) at 0°C. After being stirred for 2 hours, the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, and the mixture was washed with water and brine. The dried solvent was evaporated and the residue was
dissolved in DMF (40 ml) and then K2CO3 (3 g) and ethyl bromoacetate (1.2 ml) were added at room temperature. The mixture was stirred for 2 hours at the same temperature and partitioned between ethyl acetate and water. The organic layer was washed with water and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give 1-(4,5-diphenyloxazol-2-yl)-8-(3-ethoxycarbonylmethoxybenzyl)-1-cyclooctene (2.3 g).
MS (m/z) : 522 (M++1)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.4-2.0 (8H, m),
2.2-2.4 (2H, m), 3.0-3.5 (3H, m), 4.22 (2H, q, J=7Hz), 4.49 (2H, s), 6.66 (1H, s), 6.7-7.0 (3H, m), 7.15 (1H, t, J=8Hz), 7.2-7.8 (10H, m) Example 25
The following compounds were obtained according to similar manners to those of Examples 17 and 24.
(1) 1-[2-(4,5-Diphenyloxazol-2-yl)piperidin-1-yl]-2,3- dihydro-4-ethoxycarbonylmethoxy-1H-indene
MS (m/z) : 522 (M++1)
NMR (CDCl3, δ) : 1.22-1.33 (3H, m), 1.42-3.08 (12H, m), 4.10-4.61 (6H, m), 6.48-7.45 (9H, m), 7.54-7.78 (4H, m)
(2) 1-[2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1-yl]-2,3- dihydro-4-ethoxycarbonylmethoxy-1H-indene
MS (m/z) : 509 (M++1)
NMR (CDCl3, δ) : 1.22-1.40 (3H, m), 1.60-3.20 (10H, m), 4.02-4.76 (6H, m), 6.40-7.78 (13H, m)
(3) 1-[N-Methyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]- 1,2,3,4-tetrahydro-5-methoxycarbonylmethoxynaphthalene MS (m/z) : 483 (M++1)
IR (Film) : 1730 cm-1
NMR (CDCl3, δ) : 1.56-1.78 (2H, m), 1.92-2.20 (2H, m), 2.41 (3H, s), 3.05-4.43 (2H, m), 3.80 (5H, s), 4.00 (1H, m), 4.63 (2H, s), 6.60 (1H, m), 7.15 (1H, m), 7.28-7.43 (6H, m), 7.55-7.70 (5H, m) (4) 1-[N-Isopropyl-N-[(4,5-diphenyloxazol-2-yl)methyl]- amino]-2,3-dihydro-4-ethoxycarbonylmethoxy-1H-indene MS (m/z) : 511 (M++1)
NMR (CDCl3, δ) : 7.75-7.50 (4H, m), 7.50-7.25 (6H, m), 7.20-7.05 (2H, m), 6.60-6.45 (1H, m), 4.59 (2H, s), 4.75-4.55 (1H, m), 4.24 (2H, q, J=7.1Hz), 3.80 (2H, m), 3.25-2.95 (2H, m), 2.90-2.60 (1H, m), 2.34-2.00 (2H, m), 1.29 (3H, t, J=7.1Hz), 1.21 (3H, d,
J=6.6Hz), 1.15 (3H, d, J=6.6Hz)
(5) 1-[N-Ethyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]- 2,3-dihydro-4-ethoxycarbonylmethoxy-1H-indene
MS (m/z) : 497 (M++1)
IR (Film) : 1740 cm-1
NMR (CDCl3, δ) : 7.70-7.58 (4H, m), 7.45-7.25 (6H, m),
7.16-7.13 (2H, m), 6.57 (1H, m), 4.67 (1H, m), 4.61 (2H, s), 4.24 (2H, q, J=7.1Hz), 3.85 (2H, s), 3.18- 2.65 (4H, m), 2.35-1.85 (2H, m), 1.29 (3H, t,
J=7.1HZ), 1.14 (3H, t, J=7.1Hz)
(6) 1-[N-Acetyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]- 2,3-dihydro-4-ethoxycarbonylmethoxy-1H-indene
MS (m/z) : 511 (M++1)
NMR (CDCl3, δ) : 7.68-7.45 (4H, m), 7.42-7.24 (6H, m), 7.20-7.00 (1H, m), 6.92-6.72 (1H, m), 6.60-6.45
(1H, m), 6.40 (0.5H, m), 5.58 (0.5H, m), 4.80-4.40 (2H, m), 4.25 (2H, q, J=7.1Hz), 3.20-2.97 (1H, m), 2.95-2.70 (1H, m), 2.68-2.40 (1H, m), 2.38-2.20 (1H, m), 2.36 (1.5H, s), 2.35 (1.5H, s), 1.29 (3H, s, J=7.1Hz)
(7) 1-[N-Formyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]- 2,3-dihydro-4-ethoxycarbonylmethoxy-1H-indene
MS (m/z) : 497 (M++1)
NMR (CDCl3, δ) : 8.52 (0.25H, s), 8.43 (0.75H, s), 7.60-7.43 (4H, m), 7.42-7.22 (6H, m), 7.18-6.48 (3.25H, m), 5.32 (0.75H, m), 4.80-4.20 (6H, m), 3.24-2.38 (4H, m), 1.29 (3H, t, J=7.1Hz) (8) Ethyl [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]-4-phenylphenoxy]acetate
MS (m/z) : 570 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.2-2.0 (4H,
m), 2.0-2.2 (2H, m), 2.78 (1H, dd, J=12.0, 14.6Hz),
3.1-3.3 (2K, m), 4.22 (2H, q, J=7Hz), 4.58 (2H, s), 6.7-7.0 (3H, m), 7.1-7.5 (12K, m), 7.6-7.8 (4H, m)
(9) Ethyl [2-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]phenoxy]acetate
MS (m/z) : 494 (M++1)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 2.7-3.4 (3H, m), 4.22 (2H, q, J=7Hz), 4.58 (2H, s), 6.68 (1H, d, J=8.0Hz), 6.8- 7.0 (2H, m), 7.11 (IK, t, J=8Hz), 7.2-7.8 (11H, m)
(10) 1-(3-Ethoxycarbonyimethoxyphenylcarbonyl)-2-(4,5- diphenyloxazol-2-yl)pyrrolidine
MS (m/z) : 497 (M++1)
IR (Neat) : 1750, 1640 cm-1
NMR (CDCl3, δ) : 1.2 (2H, m), 2.1-2.5 (4H, m), 3.5-4.4 (5H, m), 4.6 (2H, s), 6.6-7.0 (3H, m), 7.1-7.8 (11H, m)
(11) 2-(4,5-Diphenyloxazol-2-yl)-3-(3- ethoxycarbonylmethoxybenzyl)bicyclo[2.2.1]hept-2-ene MS (m/z) : 506 (M+÷l)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.22 (3H, t, J=7Hz), 1.2-2.0 (6H, m), 2.80 (1H, br s), 3.61 (1H, br s), 3.79 (1H, d, J=16.6Hz), 4.22 (2H, q, J=7Hz), 4.32 (1H, d,
J=16.6Hz), 4.65 (2H, s), 6.7-7.0 (3H, m), 7.22 (1H, t, J=8Hz), 7.2-7.8 (10H, m)
(12) 1-[(4,5-Diphenyloxazol-2-yl)methylamino]-2,3-dihydro-4- ethoxycarbonylmethoxy-1H-indene
MS (m/z) : 469 (M++1)
IR (Film) : 1750 cm-1
NMR (CDCl3, δ) : 7.75-7.50 (4H, m), 7.45-7.20 (6H, m), 7.18-7.02 (2H, m), 6.65-6.58 (1H, m), 4.62 (2H, s), 4.45 (1H, m), 4.26 (2H, q, J=7.1Hz), 4.10 (2H, s), 3.22-3.00 (1H, m), 2.95-2.72 (1H, m), 2.55-2.25 (1H, m), 2.12-1.86 (1H, m), 1.70 (1H, br), 1.29 (3H, t, J=7.1Hz)
Example 26
The following compounds were obtained according to similar manners to those of Examples 1 and 2.
(1) 1-[2-(4,5-Diphenyloxazol-2-yl)piperidin-1-yl]-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene MS (m/z) : 537 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.4-2.4 (10H,
m), 2.5-3.1 (2H, m), 3.6-4.2 (2H, m), 4.49, 4.58 (2H, each s), 6.43, 6.53 (1H, each d, J=8.0Hz), 7.03, 7.20 (1H, each t, J=8Hz), 7.3-7.8 (11H, m) (2) 1-[2-(4,5-Diphenyloxazol-2-yl)azetidin-1-yl]-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene
MS (m/z) : 509 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.4-3.0 (8H, m), 3.1-3.4 (2H, m), 4.24 (2H, q, J=7Hz), 4.57 (2H, s), 4.4-4.7 (2H, m), 6.40, 6.59 (1H, each d, J=8.0Hz), 6.8-7.1 (2H, m), 7.3-7.7 (10H, m)
(3) 1-[4-(4,5-Diphenyloxazol-2-yl)-2-oxoazetidin-1-yl]-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene
MS (m/z) : 523 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.6-2.2 (4H, m), 2.6-2.8 (2H, m), 3.3-3.7 (2H, m), 4.24 (2H, q, J=7Hz), 4.57 (2H, s), 4.6-4.8 (1H, m), 5.0-5.3 (1H, m), 6.59 (1H, d, J=8.0Hz), 6.84 (1H, d, J=8.0Hz), 7.16 (1H, t, J=8.0Hz), 7.3-7.7 (10H, m)
(4) 1-[2-(4,5-Diphenyloxazol-2-yl)tetrahydrofuran-3-yl]-5- ethoxycarbonylmethoxy-3,4-dihydronaphthalene
MS (m/z) : 522 (M+)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7Hz), 2.0-3.0 (6H, m),
3.7-4.2 (3H, m), 4.24 (2H, q, J=7Hz), 4.44 (2H, s), 5.48 (1H, d, J=8.0Hz), 5.94 (1H, m), 6.68 (1H, d,
J=8Hz), 7.0-7.7 (12H, m)
(5) 1-[2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1-yl]-2- hydroxy-5-ethoxycarbonylmethoxy-1,2,3,4- tetrahydronaphthalene
MS (m/z) : 539 (M+)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.5-2.4 (6H, m),
2.4-2.7 (1H, m), 2.9-3.1 (1H, m), 3.4-3.7 (3H, m), 4.0-4.1 (1H, m), 4.24 (2H, q, J=7Hz), 4.4-4.5 (1H, m), 4.59 (2H, s), 6.57 (1H, d, J=8Hz), 6.99 (1H, d, J=8.0Hz), 7.14 (1H, t, J=8.0Hz), 7.2-7.7 (10H, m)
(6) 2-[2-(4,5-Diphenyloxazol-2-yl)pyrrolidin-1-yl]-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene MS (m/z) : 523 (M+)
IR (Neat) : 1740 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz) , 1.5-2.0 (6H, m),
2.4-2.7 (1H, m), 2.8-3.3 (6H, m), 4.24 (2H, q, J=7Hz), 4.40 (1H, m), 4.56 (2H, s), 6.4-7.1 (3H, m), 7.2-7.7 (10H, m)
(7) 1-[3-Hydroxy-1-(4,5-diphenyloxazol-2-yl)propylamino]-5- ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene MS (m/z) : 527 (M+)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.28 (3H, t, J=7Hz), 1.4-2.5 (6H, m), 2.5-3.0 (2H, m), 3.8-4.0 (3H, m), 4.0-4.3 (1H, m), 4.22 (2H, q, J=7Hz), 4.60 (2H, s), 6.58 (1H, m), 6.9-7.1 (2H, m), 7.3-7.8 (10H, m)
(8) (1R)-1-[4-Hydroxy-1-(4,5-diphenyloxazol-2- yl)butylamino]-5-ethoxycarbonylmethoxy-1,2,3,4- tetrahydronaphthalene
MS (m/z) : 541 (M+)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.24 (3H, t, J=7Hz), 1.4-2.4 (8H, m), 2.6-3.0 (2H, m), 3.5-3.7 (2H, m), 3.9 (1H, m), 4.0- 4.2 (1H, m), 4.24 (2H, q, J=7Hz), 4.59 (2H, s), 6.57 (1H, m), 6.9-7.2 (2H, m), 7.3-7.8 (10H, m)
Example 27
A solution of 1-hydroxy-1,2,3,4-tetrahydro-5-methoxycarbonylmethoxynaphthalene (0.42 g) and Lawesson's reagent (0.40 g) in toluene (4 ml) was refluxed under N2 atmosphere for 1 hour. The reaction mixture was purified by chromatography on silica gel to give 1-mercapto-1,2,3,4-tetrahydro-5-methoxycarbonylmethoxynaphthalene (0.26 g).
A solution of 1-mercapto-1,2,3,4-tetrahydro-5-methoxycarbonylmethoxynaphthalene (0.26 g), (4,5- diphenyloxazol-2-yl) methyl bromide (0.32 g) and potassium carbonate (0.14 g) in DMF (5 ml) was stirred for 6 hours at room temperature. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-[(4,5-diphenyloxazol-2-yl)methylthio]-1,2,3,4-tetrahydro-5-methoxycarbonylmethoxynaphthalene (0.29 g).
MS (m/z) : 486 (M++1)
NMR (CDCl3, δ) : 1.75-1.92 (1H, m), 2.00-2.22 (3H, m),
2.45-2.72 (1H, m), 2.80-3.02 (1H, m), 3.79 (3H, s), 3.91 (1H, s), 3.94 (1H, s), 4.36 (1H, m), 4.60 (2H, s), 6.50-6.55 (1H, m), 7.04-7.06 (2H, m), 7.33-7.40 (6H, m), 7.59-7.68 (4H, m)
Example 28
The following compound was obtained according to a similar manner to that of Example 27. 1-[(4,5-Diphenyloxazol-2-yl)methylthio]-2,3-dihydro-4-ethoxycarbonylmethoxy-1H-indene
MS (m/z) : 486 (M++1)
NMR (CDCl3, δ) : 1.29 (3H, t, J=7.1Hz), 2.22-2.28 (1H, m), 2.55-2.65 (1H, m), 2.96-3.12 (2H, m), 3.90 (1H, s), 3.91 (1H, s), 4.26 (2H, s), 4.60 (2H, s), 4.52- 4.63 (1H, m), 6.55-6.59 (2H, m), 7.09-7.13 (2H, m), 7.34-7.38 (6H, m), 7.57-7.67 (4H, m)
Example 29
A solution of 1-[1-(4,5-diphenyloxazol-2-yl)ethylamino]- 1,2,3,4-tetrahydro-5-ethoxycarbonylmethoxynaphthalene (0.24 g), iodomethane (77 mg) and K2CO3 (82 mg) in DMF (5 ml) was stirred for 5 hours at room temperature. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by
chromatography on silica gel to give 1-[N-methyl-N-[1-(4,5-diphenyloxazol-2-yl)ethyl]amino]-1,2,3,4-tetrahydro-5-ethoxycarbonylmethoxynaphthalene (0.12 g).
MS (m/z) : 511 (M+÷l)
IR (Film) : 1730 cm-1
NMR (CDCl3, δ) : 1.29 (3H, t, J=7.1Hz), 1.63 (3H, d, J=7.1Hz), 1.58-1.88 (3K, m), 1.95-2.18 (1H, m), 2.26 (3H, m), 2.46-2.68 (1H, m), 2.80-3.00 (1H, m), 4.12 (2H, q, J=7.1Hz), 4.26 (3H, q, J=7.1Hz), 4.60
(2E, s), 6.56 (1H, d, J=7.9Hz), 7.11 (1H, dd, J=7.9, 7.9Hz), 7.26-7.50 (7H, m), 7.59-7.68 (4H, m)
Example 30
To a solution of (2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidine (400 mg) and 3-bromomethyl-1-ethoxycarbonylmethoxybenzene (0.76 g) in N,N-dimethylformamide (10 ml) was added K2CO3 (1 g) at room temperature. The mixture was stirred for 2 hours at the same temperature and then partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO3, and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (2R)-2-(4,5-diphenyloxazol-2-yl)-1-(3-ethoxycarbonylmethoxybenzyl)pyrrolidine (0.27 g).
MS (m/z) : 483 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7.0Hz), 1.8-2.5 (5H, m), 3.14 (1H, m), 3.60 (1H, d, J=14Hz), 3.84 (1H, m), 3.85 (IK, d, J=14Hz), 4.23 (2H, q, J=7.0Hz),
4.48 (2H, s), 6.71 (1H, d, J=8Hz), 6.8-7.0 (2H, m), 7.16 (1H, t, J=8.0Hz), 7.3-7.8 (16H, m)
Example 31
The following compound was obtained according to a similar manner to that of Example 30.
(2S)-2-(4,5-Diphenyloxazol-2-yl)-1-(3-ethoxycarbonylmethoxybenzyl)pyrrolidine
MS (m/z) : 483 (M++1)
IR (Neat) : 1750 cm-1
NMR (CDCl3, δ) : 1.25 (3H, t, J=7.0Hz), 1.8-2.5 (5H, m), 3.14 (1H, m), 3.60 (1H, d, J=14Hz), 3.84 (1H, m), 3.85 (1H, d, J=14Hz), 4.23 (2H, q, J=7.0Hz), 4.48 (2H, s), 6.71 (1H, d, J=8Hz), 6.8-7.0 (2H, m),
7.16 (1H, t, J=8.0Hz), 7.3-7.8 (16H, m)
Example 32
The following compound was obtained according to similar manners to those of Preparations 28 and 29.
1-(4,5-Diphenyloxazol-2-yl)-6-[3-(2-ethoxycarbonylethyl)benzyl]-1-cyclohexene
MS (m/z) : 492 (M++1)
IR (Neat) : 1730 cm-1
NMR (CDCl3, δ) : 1.22 (3H, t, J=7Hz), 1.4-2.0 (4H, m), 2.2-2.8 (5H, m), 2.95 (2H, t, J=8Hz), 3.0-3.4 (2H, m), 4.15 (2H, q, J=8Hz), 6.8-7.1 (2H, m), 7.1-7.8 (13H, m)
Example 33
To a solution of (2R)-2-(4,5-diphenyloxazol-2-yl)-1-(3-ethoxycarbonylmethoxybenzylpyrrolidine (270 mg) in ethanol (10 ml) was added 1N-NaOH solution (0.56 ml). After being stirred for 12 hours at the same temperature, the solvent was removed in vacuo to give sodium [3-[[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetate (0.21 g).
FABMS (m/z) : 477 (M++1)
IR (Nujol) : 1600 cm-1 NMR (DMSO-d6, δ) : 1.7-2.4 (4H, m), 2.5 (1H, m), 2.9
(1H, m), 3.52 (1H, d, J=12Hz), 3.81 (1H, d,
J=12Hz), 3.86 (1H, t, J=6.8Hz), 4.03 (2H, s), 6.6- 6.9 (3H, m), 7.08 (1H, t, J=8Hz), 7.3-7.8 (10H, m)
Example 34
The following compounds were obtained according to similar manners to those of Examples 7, 8, 18 and 33. (1) Sodium salt of 1-[2-[4,5-bis(4-methylphenyl)oxazol-2- yl]pyrrolidin-1-yl]-1,2,3,4-tetrahydro-5- carboxymethoxynaphthalene
FABMS (m/z) : 567 (M++Na), 545 (M++1)
NMR (CD3OD, δ) : 1.50-3.08 (18H, m), 3.80-4.38 (4H, m), 6.38-7.42 (11H, m)
(2) Sodium salt of 1-[2-(4,5-diphenyloxazol-2-yl)piperidin- 1-yl]-2,3-dihydro-4-carboxymethoxy-1H-indene
FABMS (m/z) : 539 (M++Na), 517 (M++1)
NMR (CD3OD, δ) : 1.40-3.12 (12H, m), 4.02-4.42 (4H, m), 6.48-6.68 (1H, m), 6.92-7.18 (2H, m), 7.28-7.65 (10H, m)
(3) Sodium salt of 1-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin- 1-yl]-2,3-dihydro-4-carboxymethoxy-1H-indene
MS (m/z) : 481 (free M++l)
NMR (CD3OD, δ) : 1.72-3.12 (10H, m), 4.04-4.40 (4H, m), 6.42-7.60 (13H, m) (4) Sodium salt of 2-[(4,5-diphenyloxazol-2-yl)methylamino]- 1,2,3,4-tetrahydro-5-carboxymethoxynaphthalene
FABMS (m/z) : 499 (M++Na), 477 (M++1)
NMR (CD3OD, δ) : 1.48-1.76 (1H, m), 2.06-2.32 (1H, m), 2.52-2.80 (2H, m), 2.88-3.18 (3H, m), 4.12 (2H, s), 4.37 (2H, s), 6.52-6.68 (2H, m), 6.92-7.04 (1H, m), 7.30-7.42 (6H, m), 7.53-7.62 (4H, m)
(5) Sodium salt of 1-(3-carboxymethoxybenzyl)-5-(4,5- diphenyloxazol-2-yl)pyrrolidin-2-one
FABMS (m/z) : 513 (M++Na), 491 (M++1)
NMR (CD3OD, δ) : 2.27-2.86 (4H, m), 4.16 (2H, s), 4.46 (1H, d, J=14.8Hz), 4.52 (1H, d, J=14.8Hz), 6.68- 6.76 (3H, m), 7.05 (1H, m), 7.31-7.51 (10H, m) (6) Sodium salt of 1-[(4,5-diphenyloxazol-2-yl)methylthio]- 2,3-dihydro-4-carboxymethoxy-1H-indene
FABMS (m/z) : 502 (M++Na), 480 (M++1)
NMR (CD3OD, δ) : 2.06-2.38 (1H, m), 2.42-2.75 (1H, m), 2.84-3.20 (2H, m), 3.94 (1H, s), 3.95 (1H, s), 4.34 (2H, s), 4.50 (1H, m), 6.61 (1H, d, J=8.0Hz), 6.90
(1H, d, J=8.0Hz), 7.03 (1H, d, J=8.0, 8.0Hz), 7.35- 7.40 (6H, m), 7.50-7.57 (4H, m)
(7) Sodium salt of 1-[(4,5-diphenyloxazol-2-yl)methylthio]- 1,2,3,4-tetrahydro-5-carboxymethoxynaphthalene
FABMS (m/z) : 516 (M++Na), 494 (M++1)
NMR (DMSO-d6, δ) : 1.05-2.20 (4H, m), 2.32-2.95 (2H, m), 4.06 (4H, m), 4.36 (1H, m), 6.51 (1H, d, J=8.0Hz), 6.79 (1H, , d, J=8.0Hz), 6.91 (1H, J=8.0Hz), 7.35-7.65 (10H, m)
(8) Sodium salt of 1-[N-methyl-N-[(4,5-diphenyloxazol-2- yl)methyl]amino]-1,2,3,4-tetrahydro-5- carboxymethoxynaphthalene
FABMS (m/z) : 513 (M++Na), 467 (M++1)
NMR (CD3OD, δ) : 1.58-1.82 (2H, m), 2.00-2.18 (2H, m), 2.48-2.74 (1H, m), 2.82-3.02 (1H, m), 2.42 (3H, s), 3.81 (2H, m), 3.99 (1H, m), 4.36 (2H, s), 6.64 (1H, d, J=7.7Hz), 7.02 (1H, d, J=7.7Hz), 7.32-7.65 (11H, m) (9) Sodium salt of 1-[2-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-carboxymethoxynaphthalene FABMS (m/z) : 491 (M++1)
NMR (CD3OD, δ) : 1.64-2.17 (4H, m), 2.56-2.98 (2H, m), 3.19 (2H, m), 3.29 (2H, m), 3.98 (1H, m), 4.38 (2H, s), 6.66-6.72 (1H, m), 6.88-7.12 (2H, m), 7.25-7.44 (6H, m), 7.46-7.63 (4H, m)
(10) Sodium salt of 1-[N-methyl-N-[1-(4,5-diphenyloxazol-2- yl)ethyl]amino]-1,2,3,4-tetrahydro-5- carboxymethoxynaphthalene
FABMS (m/z) : 527 (M++Na), 505 (M++1)
NMR (CD3OD, δ) : 1.62 (3H, d, J=7.0Hz), 1.60-1.80 (3H, m), 1.95-2.08 (1H, m), 3.27 (3H, s), 2.44-2.68 (1H, m), 2.80-3.00 (1H, m), 4.11 (1H, m), 4.28 (1H, m),
4.36 (2H, s), 6.61 (1H, d, J=7.7Hz), 7.02 (1H, dd, J=7.7, 7.7Hz), 7.28 (1H, d, J=7.7Hz), 7.36-7.44 (6H, m), 7.53-7.60 (4H, m) (11) Sodium salt of 1-[1-(4,5-diphenyloxazol-2-yl)ethylamino]-1,2,3,4-tetrahydro-5-carboxymethoxynaphthalene FABMS (m/z) : 513 (M++Na), 491 (M++1)
NMR (DMSO-d6, δ) : 1.56 (3H, d, J=6.8Hz), 1.64-2.18
(4H, m), 2.55-3.00 (2H, m), 3.86 (1H, m), 4.28 (1H, q, J=6.8Hz), 4.34 (2H, s), 6.63 (1H, d, J=7.8Hz),
6.91 (1H, d, J=7.8Hz), 7.02 (1H, dd, J=7.8, 7.8Hz), 7.35-7.43 (6H, m), 7.53-7.59 (4H, m)
(12) Sodium salt of 1-[N-isopropyl-N-[(4,5-diphenyloxazol-2- yl)methyl]amino]-2,3-dihydro-4-carboxymethoxy-1H-indene
FABMS (m/z) : 527 (M++Na)
NMR (CD3OD, δ) : 7.55-7.28 (10H, m), 7.05-6.95 (2H,
m), 6.68-6.50 (1H, m), 4.72 (1H, t, J=8.0Hz), 4.33 (2H, s), 3.82 (2H, s), 3.40-2.60 (3H, m), 2.30-2.00 (2H, m), 1.23 (3H, d, J=6.8Hz), 1.20 (3H, d, J=6.8Hz)
(13) Sodium salt of 1-[N-ethyl-N-[(4,5-diphenyloxazol-2- yl)methyl]amino]-2,3-dihydro-4-carboxymethoxy-1H-indene FABMS (m/z) : 513 (M++Na)
NMR (CD3OD, δ) : 7.60-7.44 (4H, m), 7.42-7.32 (6H, m), 7.12-6.99 (2H, m), 6.66-6.62 (1H, m), 4.66 (1H, t, J=7.4Hz), 4.36 (2H, s), 3.85 (2H, dd, J=3.6,
3.6Hz), 3.18-2.99 (1H, m), 2.98-2.70 (3H, m), 2.35- 1.90 (2H, m), 1.16 (3H, t, J=7.2Hz)
(14) Sodium salt of 1-[N-acetyl-N-[(4,5-diphenyloxazol-2- yl)methyl]amino]-2,3-dihydro-4-carboxymethoxy-1H-indene FABMS (m/z) : 527 (M++Na)
NMR (CD3OD, δ) : 7.60-7.24 (10H, m), 7.15-6.55 (3H,
m), 6.35-6.20 (0.25H, m), 5.78-5.65 (0.75H, m), 4.56-4.34 (4H, m), 3.32-3.08 (1H, m), 3.04-2.80 (1H, m), 2.75-2.04 (2H, m), 2.38 (3H, s) (15) 1-[N-Formyl-N-[(4,5-diphenyloxazol-2-yl)methyl]amino]- 2,3-dihydro-4-carboxymethoxy-1H-indene
MS (m/z) : 469 (M++1), 411 (M++1-CH2COO)
NMR (CDCl3, δ) : 8.53 (0.3H, s), 8.45 (0.7H, s), 7.60- 7.50 (10H, m), 7.12-6.44 (3H, m), 6.20 (0.3H, m), 5.31 (0.7H, m), 4.61 (2H, d, J=18.3Hz), 4.51 (2H, d, J=20.6Hz), 3.42-3.06 (1H, m), 3.02-2.78 (1H, m), 2.68-2.40 (1H, m), 2.32-2.02 (1H, m)
(16) Sodium salt of 1-[(4,5-diphenyloxazol-2-yl)methylamino]- 2,3-dihydro-4-carboxymethoxy-1H-indene
FABMS (m/z) : 485 (M++Na)
NMR (CD3OD, δ) : 7.60-7.53 (4H, m), 7.46-7.31 (6H, m), 7.11 (1H, dd, J=7.6, 7.6Hz), 7.01 (1H, d, J=7.6Hz), 6.68 (1H, d, J=7.6Hz), 4.38 (2H, s), 4.38 (1H, t, J=6.3Hz), 4.03 (1H, s), 3.19-2.79 (2H, m), 2.47- 2.35 (1H, m), 2.05-1.87 (1H, m)
(17) Sodium salt of 1-[3-(carboxymethoxy)benzoyl]-2-(4,5- diphenyl-2-oxazolyl)piperidine
FABMS (m/z) : 505 (M++1)
mp : 205.4-211.3°C
IR (Nujol) : 1610, 1580 cm-1
NMR (DMSO-d6, δ) : 1.4-2.0 (6H, m), 3.35 (1H, m), 2.7- 3.75 (1H, m), 4.14 (2H, s), 4.4 and 6.01 (1H, each m), 6.87-6.94 (3H, m), 7.27-7.64 (11H, m)
(18) 3-[3-(Carboxymethoxy)benzyl]-2-(4,5-diphenyl-2- oxazolyl)-5-oxotetrahydrofuran
(+) APCI-MS (m/z) : 470 (M++1)
mp : 65.2-72.2°C
IR (Film) : 1775, 1730, 1580, 1200 cm-1
NMR (CDCl3, δ) : 2.35-3.02 (4H, m), 3.24-3.47 (1H, m), 4.56 and 4.58 (2H, each s), 5.33 and 5.69 (1H, each d, J=6.1 and 7.7Hz, respectively), 6.65-6.86 (3H, m), 7.16-7.41 (7H, m), 7.52-7.64 (4H, m)
(19) Sodium salt of 1-[3-(carboxymethoxy)benzyl]-2-(4,5- diphenyl-2-oxazolyl)piperidine
FABMS (m/z) : 490 (M+)
mp : >250°C
IR (Film) : 1625, 1600, 1260 cm-1
NMR (DMSO-d6, δ) : 1.2-2.1 (7H, m), 2.85-2.92 (1H, m), 3.01 (1H, d, J=13.5Hz), 3.23-3.6 (2H, m), 4.08 (2H, s), 6.62-6.67 (1H, m), 6.77-6.82 (1H, m), 6.87 (1H, m), 7.10 (1H, t, J=7.7Hz), 7.19-7.34 (6H, m), 7.45- 7.50 (4H, m)
(20) Sodium salt of 2-[1-[3-(carboxymethoxy)benzyl]-5-imino- 2-pyrrolidinyl]-4,5-diphenyloxazole
FABMS (m/z) : 490 (M++1) mp : 239.9-241.7°C
IR (Nujol) : 3200, 1680, 1605 cm-1
NMR (DMSO-d6, δ) : 2.1-2.5 (4H, m), 4.00 (2H, s), 4.69
(1H, m), 4.93 (1H, d, J=17.2Hz), 5.08 (1H, d, J=17.2Hz), 6.40 (2H, m), 6.69 (1H, m), 7.14-7.44
(11H, m), 8.09 (1H, s)
(21) Sodium salt of (1R)-1-[4-hydroxy-1-(4,5-diphenyloxazol- 2-yl)butylamino]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 535 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.3 (8H, m), 2.3-2.8 (2H, m),
3.3-3.5 (2H, m), 3.7 (1H, m), 3.9-4.1 (1H, m), 4.08 (2H, s), 6.53 (1H, d, J=8.0Hz), 6.8-7.0 (2H, m),
7.2-7.6 (10H, m)
(22) Sodium salt of 1-[3-hydroxy-1-(4,5-diphenyloxazol-2- yl)propylamino]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 521 (M++1)
IR (Nujol) : 3400, 1600 cm-1
NMR (DMSO-d6, δ) : 1.5-2.2 (6H, m) , 2.4-2.8 (2H, m), 3.3-3.8 (4H, m), 4.09 (2H, s), 4.0-4.2 (1H, m), 6.54 (1H, d, J=8.0Hz), 6.8-7.1 (2H, m), 7.2-7.6
(10H, m)
(23) Sodium [3-[[(2S)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin- 1-yl]methyl]phenoxy]acetate
FABMS (m/z) : 477 (M++1)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.7-2.4 (4H, m), 2.5 (1H, m), 2.9
(1H, m), 3.52 (1H, d, J=12Hz), 3.81 (1H, d,
J=12Hz), 3.86 (1H, t, J=6.8Hz), 4.03 (2H, s) , 6.6- 6.9 (3H, m), 7.08 (1H, t, J=8Hz), 7.3-7.8 (10H, m) (24) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cycloocten-1- yl]methyl]phenoxy]acetate
FABMS (m/z) : 516 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.0-2.1 (SH, m), 2.3-2.5 (2H, m),
2.9 (1H, m), 3.3-3.6 (2H, m), 3.98 (2H, s), 6.6-6.6 (3H, m), 6.74 (1H, t, J=8Hz), 7.00 (1H, t, J=8.0Hz), 7.2-7.8 (10H, m) (25) Sodium salt of 2-(4,5-diphenyloxazol-2-yl)-3-(3- carboxymethoxybenzyl)bicyclo[2.2.1]hept-2-ene
FABMS (m/z) : 500 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.0-1.8 (6H, m), 2.83 (1H, br s), 3.48 (1H, br s), 3.78 (1H, d, J=14Hz), 4.01 (2H, s), 4.18 (1H, d, J=14Hz), 6.6-6.8 (3H, m), 7.13 (1K, t, J=8.0Hz), 7.3-7.8 (10H, m)
(26) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1- yl]carbonyl]phenoxy]acetate
IR (Neat) : 1580-1620 cm-1
NMR (DMSO-d6, δ) : 1.8-2.4 (4H, m), 3.5-3.8 (2H, m),
4.9-4.2 (2H, m), 5.0-5.3 (1H, m), 6.6-7.0 (3K, m), 7.1-7.8 (UK, m)
(27) Sodium [2-[[2-(4,5-diphenyloxazol-2-yI)-2-cyclohexen-1- yl]methyl]phenoxy]acetate
FABMS (m/z) : 488 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.2-2.2 (4H, m), 2.0-2.4 (2H, m),
2.6-3.2 (3H, m), 4.16 (2H, s), 6.6-6.8 (3H, m),
6.10 (1H, t, J=8Hz), 7.19 (1H, d, J=8.0Hz), 7.3-7.8 (10H, m) (28) Sodium [4-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]phenoxy]acetate
FAEMS (m/z) : 488 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.0 (4H, m), 2.0-2.4 (2H, m), 2.8-3.2 (3H, m), 4.05 (2H, s), 6.75 (2H, d,
J=8.0Hz), 6.88 (1H, m), 7.13 (2H, d, J=8.0Hz),
7.3-7.8 (10H, m)
(29) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]-4-methylphenoxy]acetate
FABMS (m/z) : 502 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.2-2.4 (4H, m), 2.30 (3H, s), 2.8- 3.2 (2H, m), 4.12 (2H, s), 6.6-6.9 (3H, m), 6.99 .(1H, d, J=8Hz), 7.3-7.8 (10H, m)
(30) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]-6-methylphenoxy]acetate
FABMS (m/z) : 502 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.2-2.4 (4H, m), 2.12 (3H, s), 4.17 (2H, s), 6.6-7.0 (3H, m), 6.98 (1H, d, J=8Hz), 7.3- 7.8 (10H, m) (31) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl-2-methylphenoxy]acetate
FABMS (m/z) : 502 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.2-2.0 (4H, m), 2.37 (3H, s), 4.15 (2H, s), 6.60 (1H, d, J=8.0Hz), 6.71 (1H, d,
J=8.0Hz), 6.8-7.0 (2H, m), 7.2-7.8 (10H, m)
(32) Sodium 3-[3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen- 1-yl]methyl]phenyl]propionate
IR (Neat) : 1580 cm-1 NMR (DMSO-d6, δ) : 1.4-2.0 (4K, m), 2.0-2.9 (7H, m),
3.0-3.2 (2H, m), 6.80 (IK, br s), 6.9-7.2 (3H, m), 7.3-7.8 (10H, m) (33) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1- yl]methyl]-4-phenylphenoxy]acetate
FABMS (m/z) : 564 (M++1)
IR (Neat) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.2-2.0 (4H, m), 2.0-2.4 (2H, m), 2.5-3.2 (3H, m), 4.17 (2H, s), 6.6-7.0 (3H, m),
7.0-7.8 (16H, m)
(34) Sodium salt of 2-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin- I-yl]-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene FABMS (m/z) : 516 (M+)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.5-3.2 (13H, m), 4.08 (2H, s),
4.33 (IK, m), 6.3-6.6 (2H, m), 6.7-7.0 (1H, m), 7.2-7.6 (10H, m)
(35) Sodium salt of 1-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin- 1-yl]-2-hydroxy-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 533 (M++1)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.5-2.4 (5H, m), 2.8-3.0 (3H, m),
3.8-3.9 (1H, m), 3.9-4.2 (3H, m), 4.8-5.0 (2H, m), 6.49 (1H, d, J=8Hz), 6.98 (1H, d, J=8Hz), 7.22 (1H, d, J=8Hz), 7.3-7.6 (10H, m)
(36) Sodium salt of 1-[2-(4,5-diphenyioxazol-2- yl)tetrahydrofuran-3-yl]-5-carboxymethoxy-3,4- dihydronaphthalene
FABMS (m/z) : 516 (M++1)
IR (Nujol) : 1600 cm-1 NMR (DMSO-d6, δ) : 1.7-2.4 (3H, m), 2.7-2.9 (1H, m),
4.09 (2H, s), 4.37 (1H, n), 5.38 (1H, d, J=8.0Hz), 5.92 (1H, m), 6.6-6.8 (1H, m), 7.0-7.8 (12H, m) (37) Sodium salt of 1-[2-(4,5-diphenyloxazol-2- yl)tetrahydrofuran-3-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 518 (M++1)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.2 (5H, m), 2.7-2.9 (2H, m),
3.8-4.0 (2H, m), 4.12 (2H, s), 4.0-4.2 (1H, m), 5.25 (1H, d, J=6.8Hz), 6.5-6.8 (2H, m), 6.93 (1H, t, J=8Hz), 7.3-7.8 (10H, m) (38) Sodium salt of 1-[4-(4,5-diphenyloxazol-2-yl)-2- oxoazetidin-1-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene
FABMS (m/z) : 517 (M++1)
IR (Nujol) : 1740, 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.2 (4H, m), 2.3-2.8 (2H, m),
3.2-3.5 (2H, m), 3.8-4.1 (2H, m), 4.6-5.0 (2H, m), 6.60 (1H, d, J=8.0Hz), 6.80 (1H, d, J=8.0Hz), 7.08 (1H, t, J=8.0Hz) 7.2-7.6 (10H, m) (39) Sodium salt of 1-[2-(4,5-diphenyloxazol-2-yl)azetidin-1- yl]-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene FABMS (m/z) : 503 (M++1)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-2.9 (8H, m), 3.9-4.0 (1H, m), 4.10 (2H, s), 4.3-4.7 (IK, m), 6.58 (1H, d,
J=8.0Hz), 6.68 (1H, d, J=8.0Hz), 6.95 (1H, t, J=8Hz), 7.2-7.6 (10H, m)
(40) Sodium salt of 1-[2-(4,5-diphenyloxazol-2-yl)piperidin- 1-yl]-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene FABMS (m/z) : 531 (M++1)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.4-3.1 (12H, m), 3.8-4.0 (1H, m), 4.00, 4.10 (2H, each s), 4.1-4.3 (1H, m), 6.43, 6.51 (1H, each d, J=8.0Hz), 6.90, 7.02 (1H, each t,
J=8.0Hz), 7.15, 7.26 (1H, each d, J=8Hz), 7.2-7.8 (10H, m)
(41) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-1-cyclopenten-1- yl]carbonyl]phenoxy]acetate
FABMS (m/z) : 488 (M++1)
IR (Nujol) : 1660, 1600 cm-1
NMR (DMSO-d6, δ) : 2.0-2.3 (2H, m), 2.8-3.2 (4H, m), 4.15 (2H, s), 6.9-7.2 (4H, m), 7.2-7.5 (10H, m)
(42) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1- yl]carbonyl]phenoxy]acetate
FABMS (m/z) : 488 (M++1)
NMR (DMSO-d6, δ) : 1.9-2.1 (2H, m), 2.6-2.8 (2H, m), 4.17 (2H, s), 6.8-7.2 (4H, m), 7.2-7.6 (10H, m)
(43) Sodium salt of 2-(4,5-diphenyloxazol-2-yl)-3-(3- carboxymethoxybenzyl)bicylco[2.2.1]heptane
FABMS (m/z) : 502 (M++1)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.2-3.0 (11H, m), 4.02 (2H, s),
6.3-6.8 (3H, m), 6.95 (1H, t, J=8.0Hz), 7.3-7.8 (10H, m) (44) Sodium [3-[[2-(4,5-diphenyloxazol-2-yl)cyclooctan-1- yl]methyl]phenoxy]acetate
FABMS (m/z) : 518 (M++1)
IR (Nujol) : 1600 cm-1
NMR (DMSO-d6, δ) : 1.2-3.0 (15H, m), 4.05, 4.10 (2H, each s), 6.4-7.1 (4H, m), 7.2-7.8 (10H, m)

Claims

C L A I M S 1. A compound of the formula :
Figure imgf000123_0008
wherein
R1 is carboxy or protected carboxy,
R2 is aryl which may have suitable substituent (s),
R3 is aryl which may have suitable substituent (s),
R4 is hydrogen, lower alkyl, hydroxy or aryl,
A1 is lower alkylene.
is , , or ,
Figure imgf000123_0002
Figure imgf000123_0003
Figure imgf000123_0004
Figure imgf000123_0005
Figure imgf000123_0006
-A3- is (in which -A4- is bond, -CH2- or -CO-,
Figure imgf000123_0001
and is cyclo (C5-C8) alkene,
Figure imgf000123_0007
cyclo(C7-C8)alkane, bicycloheptane, bicycloheptene, tetrahydrofuran, tetrahydrothiophene, azetidine. pyrrolidine or piperidine, each of which may have suitable substituent (s)) or
-X-A6- [in which -X- is -O-, -S- or
Figure imgf000124_0003
(in which R5 is hydrogen, lower alkyl or acyl) and
A6 is lower alkylene which may have suitable substituent (s)], and
n is 0 or 1,
and a pharmaceutically acceptable salt thereof.
2. A compound of claim 1, wherein
R2 is phenyl or lower alkylphenyl,
R3 is phenyl or lower alkylphenyl,
R4 is hydrogen, lower alkyl, hydroxy or phenyl, and
-A3- is (in which -A4- is bond, -CH2- or
Figure imgf000124_0002
-CO-, and is cyclo (C5-C8) alkene,
Figure imgf000124_0001
cyclo (C7-C8) alkane, bicycloheptane, bicycloheptene, tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have one to three suitable substituent (s) selected from the group consisting of imino, oxo, acyl and imino protective group) or
-X-A6- [in which -X- is -O-, -S- or
Figure imgf000124_0004
(in which R5 is hydrogen, lower alkyl or
acyl) and
A6 is lower alkylene which may have one to three suitable substituent (s) selected from the group consisting of lower alkyl and
hydroxy (lower) alkyl].
3. A compound of claim 2, wherein
-A3- is (in which -A4- is bond, -CH2- or
Figure imgf000125_0001
CO-, and is cyclo (C5-C8) alkene,
Figure imgf000125_0002
cyclo (C7-C8) alkane, bicyclo[2.2.1]heptane, bicyclo[2.2.1]heptene, tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have one or two suitable substituent (s) selected from the group consisting of imino, oxo, lower alkanoyl and mono (or di or tri) phenyl(lower)alkyl) or
-X-A6- [in which -X- is -O-, -S- or
Figure imgf000125_0004
(in which R5 is hydrogen, lower alkyl or lower alkanoyl) and
A6 is lower alkylene which may have a
suitable substituent selected from the group consisting of lower alkyl and hydroxy (lower) alkyl].
4. A compound of claim 3, wherein
R1 is carboxy or esterified carboxy, and
-A3- is (in which -A4- is bond, -CH2- or
Figure imgf000125_0003
-CO-, and is cyclo (C5-C8) alkene,
Figure imgf000126_0001
cyclo(C7-C8)alkane, bicyclo[2.2.1]heptane, bicyclo[2.2.1]hept-2-ene, tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have one or two suitable substituent (s) selected from the group consisting of imino, oxo, lower alkanoyl and phenyl (lower) alkyl) or
-X-A6- [in which -X- is -O-, -S- or
Figure imgf000126_0004
(in which R5 is hydrogen, lower alkyl or lower alkanoyl) and
A6 is lower alkylene which may have a suitable
substituent selected from the group consisting of lower alkyl and hydroxy (lower) alkyl].
5. A compound of claim 4, wherein
R1 is carboxy or lower alkoxycarbonyl,
R2 is phenyl or C1-C4 alkylphenyl,
R3 is phenyl or C1-C4 alkylphenyl,
R4 is hydrogen, C1-C4 alkyl, hydroxy or phenyl,
A1 is C1-C4 alkylene, and
-A3- is (in which -A4- is bond, -CH2- or
Figure imgf000126_0002
-CO-, and is cyclo (C5-C8)alkene,
Figure imgf000126_0003
cyclo(C7-C8)alkane, bicyclo[2.2.1]heptane, bicyclo[2.2.1]hept-2-ene, tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have one or two suitable substituent (s) selected from the group consisting of imino, oxo, C1-C4 alkanoyl and phenyl(C1-C4)alkyl) or
-X-A6- [in which -X- is -O-, -S- or
Figure imgf000127_0002
(in which R5 is hydrogen, C1-C4 alkyl or
C1-C4 alkanoyl) and
A6 is C1-C4 alkylene which may have a suitable
substituent selected from the group consisting of C1-C4 alkyl and hydroxy¬
(C1-C4)alkyl].
6. A compound of claim 1, which is a compound of the
formula :
Figure imgf000127_0001
wherein R1 is carboxy or protected carboxy,
R2 is phenyl or lower alkylphenyl,
R3 is phenyl or lower alkylphenyl and A1 is lower alkylene,
or a pharmaceutically acceptable salt thereof.
7. A compound of claim 6, which is selected from the group consisting of ( 1) sodium salt of (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2- yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene and (2) sodium salt of (1S)-1-[(2S)-2-(4,5-diphenyloxazol-2- yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4- tetrahydronaphthalene.
8. A compound of claim 1, which is a compound of the
formula :
Figure imgf000128_0001
wherein R1 is carboxy or protected carboxy,
R2 is phenyl or lower alkylphenyl, R is phenyl or lower alkylphenyl and
A1 is lower alkylene,
or a pharmaceutically acceptable salt thereof.
9. A compound of claim 8, which is selected from the group consisting of
(1) sodium [3-[[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin- 1-yl]methyl]phenoxy]acetate and (2) sodium [3-[[(2S)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin- 1-yl]methyl]phenoxy]acetate.
10. A process for preparing a compound of the formula :
Figure imgf000128_0002
wherein
R1 is carboxy or protected carboxy,
R2 is aryl which may have suitable substituent (s),
R3 is aryl which may have suitable substituent (s),
R4 is hydrogen, lower alkyl, hydroxy or aryl,
A1 is lower alkylene,
Figure imgf000129_0001
-A3- is (in which -A4- is bond, -CH2- or -CO-,
Figure imgf000129_0002
and is cyclo (C5-C8) alkene,
Figure imgf000129_0003
cyclo (C7-C8) alkane, bicycloheptane, bicycloheptene, tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, each of which may have suitable substituent (s)) or
-X-A6- [in which -X- is -O-, -S- or
Figure imgf000129_0004
(in which R5 is hydrogen, lower alkyl or acyl) and
A6 is lower alkylene which may have suitable
substituent (s)], and
n is 0 or 1,
or a salt thereof,
which comprises (1) reacting a compound of the formula :
Figure imgf000130_0004
wherein R2, R3, R4, and -A3- are each as defined
Figure imgf000130_0003
above,
or a salt thereof with a compound of the formula :
Y1-A1-R1 wherein R1 and A1 are each as defined above, and
Y1 is acid residue,
or a salt thereof to give a compound of the formula :
Figure imgf000130_0002
wherein R1, R2, R3, R4 A1, and -A3- are each as
Figure imgf000130_0001
defined above,
or a salt thereof, or (2) subjecting a compound of the formula :
Figure imgf000131_0001
wherein R2, R3, R4, n, A1, and -A3- are each as
Figure imgf000131_0004
defined above, and
R1 is protected carboxy,
or a salt thereof to elimination reaction of the carboxy protective group to give a compound of the formula :
Figure imgf000131_0002
wherein R2, R3, R4, n, A1, and -A3- are each as
Figure imgf000131_0003
defined above,
or a salt thereof, or (3) subjecting a compound of the formula :
Figure imgf000132_0001
wherein R1, R2, R3, R4, n, A1, and -A4- are each
Figure imgf000132_0002
as defined above,
or a salt thereof to oxidation reaction to give a compound of the formula :
Figure imgf000132_0003
wherein R1, R2, R3, R4, n, A1, and -A4- are each
Figure imgf000132_0004
as defined above,
or a salt thereof, or
(4) subjecting a compound of the formula :
Figure imgf000133_0001
wherein R1, R2, R3, R4, n, A1, and -A4- are each
Figure imgf000133_0002
as defined above, and
R6 is imino protective group,
or a salt thereof to elimination reaction of the imino protective group to give a compound of the formula :
Figure imgf000133_0003
wherein R1, R2, R3, R4, n, A1, and -A4- are each
Figure imgf000133_0004
as defined above,
or a salt thereof, or (5) subjecting a compound of the formula :
Figure imgf000134_0001
wherein R1, R2, R3, n, A1, are each
Figure imgf000134_0002
as defined above, and
is cyclo (C7-C8 ) alkene,
Figure imgf000134_0003
or a salt thereof to reduction reaction to give a compound of the formula :
Figure imgf000134_0004
wherein R1, R2, R3, R4, n, A1, and -A4- are each
Figure imgf000135_0001
as defined above, and is cyclo (C7-C8) alkane,
Figure imgf000135_0002
or a salt thereof, or (6) reacting a compound of the formula :
Figure imgf000135_0003
wherein R1, R4, n, A1, and -A4- are each
Figure imgf000135_0004
as defined above, and
Y2 is halogen,
or a salt thereof with a compound of the formula :
Figure imgf000136_0001
wherein R2 and R3 are each as defined above,
or a salt thereof to give a compound of the formula :
Figure imgf000136_0002
wherein R 1, R2, R3, R4, n, A1, and -A4- are
Figure imgf000136_0003
each as defined above,
or a salt thereof.
11. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a
pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers.
12. A use of a compound of claim 1 or a pharmaceutically acceptable salt thereof as a prostaglandin I2 agonist.
13. A method for treating or preventing arterial
obstruction, restenosis after percutaneous transluminal coronary angioplasty, arteriosclerosis, cerebrovascular disease or ischemic heart disease which comprises administering a compound of claim 1 or a
pharmaceutically acceptable salt thereof to human or animals.
14. A process for preparing a pharmaceutical composition which comprises admixing a compound of claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.
PCT/JP1996/001996 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives WO1997003973A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EA199800141A EA002156B1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives, process for preparing and use as medicaments
EP96924137A EP0842161B1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives
AU64697/96A AU716304B2 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives
MX9800577A MX9800577A (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives.
DE69623785T DE69623785T2 (en) 1995-07-21 1996-07-18 4,5-DIARYL OXAZOLE DERIVATIVES
AT96924137T ATE224380T1 (en) 1995-07-21 1996-07-18 4,5-DIARYL OXAZOLE DERIVATIVES
CA002227442A CA2227442A1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives
DK96924137T DK0842161T3 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives
US08/983,139 US5972965A (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives
JP9504319A JPH11509191A (en) 1995-07-21 1996-07-18 4,5-diaryloxazole derivative

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9515085.0 1995-07-21
GBGB9515085.0A GB9515085D0 (en) 1995-07-21 1995-07-21 Heterocyclic compounds
AUPN9002A AUPN900296A0 (en) 1996-03-29 1996-03-29 Heterocyclic compounds
AUPN9002 1996-03-29

Publications (1)

Publication Number Publication Date
WO1997003973A1 true WO1997003973A1 (en) 1997-02-06

Family

ID=25645150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/001996 WO1997003973A1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives

Country Status (17)

Country Link
US (2) US5972965A (en)
EP (2) EP1213285A3 (en)
JP (1) JPH11509191A (en)
KR (1) KR19990063582A (en)
CN (1) CN1095839C (en)
AT (1) ATE224380T1 (en)
AU (1) AU716304B2 (en)
CA (1) CA2227442A1 (en)
DE (1) DE69623785T2 (en)
DK (1) DK0842161T3 (en)
EA (1) EA002156B1 (en)
ES (1) ES2181902T3 (en)
HU (1) HUP9900881A3 (en)
MX (1) MX9800577A (en)
PT (1) PT842161E (en)
TW (1) TW401408B (en)
WO (1) WO1997003973A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
WO1999021843A1 (en) * 1997-10-27 1999-05-06 Fujisawa Pharmaceutical Co., Ltd. 4, 5-diaryloxazole compounds
WO1999036419A1 (en) * 1998-01-17 1999-07-22 Bayer Aktiengesellschaft Substituted lactones as modulators of metabotropic glutamate receptors
WO1999045006A1 (en) * 1998-03-02 1999-09-10 Pfizer Inc. Heterocyclic compounds as inhibitors of rotamase enzymes
WO2000016760A2 (en) * 1998-09-23 2000-03-30 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin e2 antagonists
WO2000018744A1 (en) * 1998-09-25 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
WO2000078350A1 (en) * 1999-06-21 2000-12-28 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
WO2001016132A1 (en) * 1999-08-30 2001-03-08 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds with prostaglandin 12 (pg12) agonistic activity
WO2002085412A1 (en) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Tissue fibrosis inhibitors
KR100468352B1 (en) * 2002-09-24 2005-01-27 한국과학기술연구원 New pyrazolopyrimidine derivatives, process for their preparation and pharmaceutical composition comprising the same
WO2007134085A3 (en) * 2006-05-12 2008-01-10 Allergan Inc Isothiazolidines useful in the treatment of ocular hypertensive conditions
US7622471B2 (en) 2003-02-07 2009-11-24 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives having a pyridazine and pyridine functionality
WO2010010909A1 (en) 2008-07-23 2010-01-28 東レ株式会社 Therapeutic agent for chronic renal failure
WO2011111714A1 (en) * 2010-03-08 2011-09-15 科研製薬株式会社 Novel ep4 agonist
WO2012024559A1 (en) * 2010-08-20 2012-02-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US8394844B2 (en) 2008-09-10 2013-03-12 Asahi Glass Company, Limited EP4 agonist
US8513027B2 (en) 1997-09-25 2013-08-20 Asterand Uk Acquisition Limited Method of identifying an inhibitor of the prostanoid EP4 receptor
WO2014031928A3 (en) * 2012-08-24 2014-05-22 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014031933A3 (en) * 2012-08-24 2014-05-22 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014031936A3 (en) * 2012-08-24 2014-05-22 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US9663504B2 (en) 2014-02-25 2017-05-30 Board Of Regents, The University Of Texas System Salts of heterocyclic modulators of HIF activity for treatment of disease

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
EP2385039B1 (en) 2001-04-19 2014-03-12 Eisai R&D Management Co., Ltd. 2-Iminoisoindolinone derivatives as thrombin receptor antagonists
NZ535024A (en) * 2002-03-05 2006-10-27 Ono Pharmaceutical Co 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
NZ535748A (en) * 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
CN100439336C (en) 2003-02-19 2008-12-03 卫材R&D管理有限公司 Methods for producing cyclic benzamidine derivatives
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434034A1 (en) * 1989-12-20 1991-06-26 Bristol-Myers Squibb Company Oxazole derivatives
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
WO1995017393A1 (en) * 1993-12-20 1995-06-29 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
CA2185104A1 (en) 1994-03-10 1995-09-14 Kiyoshi Taniguchi Naphthalene derivatives as prostaglandin 12 agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434034A1 (en) * 1989-12-20 1991-06-26 Bristol-Myers Squibb Company Oxazole derivatives
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
WO1995017393A1 (en) * 1993-12-20 1995-06-29 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole derivatives

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245790B1 (en) 1997-06-02 2001-06-12 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as PGE2 agonists and antagonists
WO1998055468A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds useful as pge2 agonists and antagonists
US8513027B2 (en) 1997-09-25 2013-08-20 Asterand Uk Acquisition Limited Method of identifying an inhibitor of the prostanoid EP4 receptor
WO1999021843A1 (en) * 1997-10-27 1999-05-06 Fujisawa Pharmaceutical Co., Ltd. 4, 5-diaryloxazole compounds
WO1999036419A1 (en) * 1998-01-17 1999-07-22 Bayer Aktiengesellschaft Substituted lactones as modulators of metabotropic glutamate receptors
WO1999045006A1 (en) * 1998-03-02 1999-09-10 Pfizer Inc. Heterocyclic compounds as inhibitors of rotamase enzymes
US6610707B1 (en) 1998-03-02 2003-08-26 Pfizer Inc. Heterocyclic compounds as inhibitors of rotomase enzymes
WO2000016760A3 (en) * 1998-09-23 2000-06-08 Fujisawa Pharmaceutical Co New use of prostaglandin e2 antagonists
WO2000016760A2 (en) * 1998-09-23 2000-03-30 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin e2 antagonists
WO2000018744A1 (en) * 1998-09-25 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
WO2000078350A1 (en) * 1999-06-21 2000-12-28 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
WO2001016132A1 (en) * 1999-08-30 2001-03-08 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds with prostaglandin 12 (pg12) agonistic activity
US6660759B1 (en) 1999-08-30 2003-12-09 Fujisawa Pharmaceutical Co. Ltd. 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9675539B2 (en) 2000-03-31 2017-06-13 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2002085412A1 (en) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Tissue fibrosis inhibitors
KR100468352B1 (en) * 2002-09-24 2005-01-27 한국과학기술연구원 New pyrazolopyrimidine derivatives, process for their preparation and pharmaceutical composition comprising the same
US7622471B2 (en) 2003-02-07 2009-11-24 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives having a pyridazine and pyridine functionality
US7557095B2 (en) 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
US7897629B2 (en) 2006-05-12 2011-03-01 Allergan, Inc. Therapeutic compounds
WO2007134085A3 (en) * 2006-05-12 2008-01-10 Allergan Inc Isothiazolidines useful in the treatment of ocular hypertensive conditions
AU2007249443B2 (en) * 2006-05-12 2012-09-27 Allergan, Inc. Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2010010909A1 (en) 2008-07-23 2010-01-28 東レ株式会社 Therapeutic agent for chronic renal failure
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
US8394844B2 (en) 2008-09-10 2013-03-12 Asahi Glass Company, Limited EP4 agonist
US9034906B2 (en) 2008-09-10 2015-05-19 Asahi Glass Company, Limited EP4 agonist
US8877787B2 (en) 2008-09-10 2014-11-04 Asahi Glass Company, Limited EP4 agonist
US8691857B2 (en) 2008-09-10 2014-04-08 Asahi Glass Company, Ltd. EP4 agonist
WO2011111714A1 (en) * 2010-03-08 2011-09-15 科研製薬株式会社 Novel ep4 agonist
CN102917703A (en) * 2010-03-08 2013-02-06 科研制药株式会社 Novel EP4 agonist
RU2564414C2 (en) * 2010-03-08 2015-09-27 Какен Фармасьютикал Ко., Лтд. New ep4 agonist
JP5734952B2 (en) * 2010-03-08 2015-06-17 科研製薬株式会社 Novel EP4 agonist
US8653118B2 (en) 2010-08-20 2014-02-18 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
AU2011291614B2 (en) * 2010-08-20 2016-05-26 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9085567B2 (en) 2010-08-20 2015-07-21 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2012024559A1 (en) * 2010-08-20 2012-02-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9422273B2 (en) 2010-08-20 2016-08-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9481692B2 (en) 2012-08-24 2016-11-01 Board Of Regents, The University Of Texas System Heterocyclic modulators of HIF activity for treatment of disease
WO2014031933A3 (en) * 2012-08-24 2014-05-22 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US9018380B2 (en) 2012-08-24 2015-04-28 Boar of Regents, The University of Texas System Heterocyclic modulators of HIF activity for treatment of disease
WO2014031936A3 (en) * 2012-08-24 2014-05-22 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014031928A3 (en) * 2012-08-24 2014-05-22 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US10208059B2 (en) 2012-08-24 2019-02-19 Board Of Regents, The University Of Texas System Heterocyclic modulators of HIF activity for treatment of disease
US11001594B2 (en) 2012-08-24 2021-05-11 Board Of Regents, The University Of Texas System Heterocyclic modulators of HIF activity for treatment of disease
US9663504B2 (en) 2014-02-25 2017-05-30 Board Of Regents, The University Of Texas System Salts of heterocyclic modulators of HIF activity for treatment of disease
US10363248B2 (en) 2014-02-25 2019-07-30 Board Of Regents, The University Of Texas System Salts of heterocyclic modulators of HIF activity for treatment of disease
US10888554B2 (en) 2014-02-25 2021-01-12 Board Of Regents, The University Of Texas System Salts of heterocyclic modulators of HIF activity for treatment of disease

Also Published As

Publication number Publication date
AU716304B2 (en) 2000-02-24
US5972965A (en) 1999-10-26
KR19990063582A (en) 1999-07-26
MX9800577A (en) 1998-04-30
ATE224380T1 (en) 2002-10-15
CA2227442A1 (en) 1997-02-06
DE69623785T2 (en) 2003-08-07
EP1213285A3 (en) 2002-07-03
DK0842161T3 (en) 2003-01-27
EP1213285A2 (en) 2002-06-12
EA199800141A1 (en) 1998-08-27
TW401408B (en) 2000-08-11
US6300344B1 (en) 2001-10-09
ES2181902T3 (en) 2003-03-01
HUP9900881A3 (en) 2000-09-28
CN1196726A (en) 1998-10-21
EP0842161A1 (en) 1998-05-20
DE69623785D1 (en) 2002-10-24
AU6469796A (en) 1997-02-18
CN1095839C (en) 2002-12-11
PT842161E (en) 2003-02-28
HUP9900881A2 (en) 1999-08-30
EA002156B1 (en) 2001-12-24
EP0842161B1 (en) 2002-09-18
JPH11509191A (en) 1999-08-17

Similar Documents

Publication Publication Date Title
EP0842161B1 (en) 4,5-diaryl oxazole derivatives
EP0736018B1 (en) 4,5-diaryloxazole derivatives
JP6049791B2 (en) Activator of peroxisome proliferator activated receptor δ
US5863918A (en) Naphthalene derivatives
IL180432A (en) Cetp inhibitors and pharmaceutical compositions comprising the same for treating atherosclerosis
US6660759B1 (en) 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
JP2006512289A (en) Morpholine and tetrohydropyran derivatives and their use as cathepsin inhibitors
JP2001526257A (en) Naphthalene derivative
US6297267B1 (en) 4,5-diaryloxazole compounds
US6384072B1 (en) Benzocycloheptene derivatives
AU746222B2 (en) 4, 5-diaryloxazole compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96197084.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1997 504319

Country of ref document: JP

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN HU JP KR MX US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2227442

Country of ref document: CA

Ref document number: 2227442

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980700438

Country of ref document: KR

Ref document number: PA/a/1998/000577

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 08983139

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1996924137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 199800141

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1996924137

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980700438

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996924137

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019980700438

Country of ref document: KR